Tricyclic carboxamide derivatives as PRMT5 inhibitors
Patent Information
- Application Number
- JP2023530598
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-24
- Filing Date
- 2021-11-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-11-22
AI Technical Summary
Current strategies to target PRMT5 in MTAP-null tumors are limited by the enzyme's essential role in normal tissues, leading to potential side effects, and there is a need for compounds that selectively inhibit PRMT5 in tumor cells while sparing normal cells.
Development of novel compounds, including specific derivatives of formula I, which preferentially target the MTA-bound state of PRMT5 in MTAP-null tumor cells, minimizing inhibition in normal tissues.
These compounds effectively inhibit PRMT5 in tumor cells, addressing the metabolic vulnerability of MTAP-null tumors while reducing adverse effects on normal tissues.
Smart Images

Figure 2022115377000001 
Figure 2022115377000002 
Figure 2022115377000003
Abstract
Description
Technical field
[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 117,937, filed on November 24, 2020. [Background technology]
[0002] Epigenetic regulation of gene expression is an important biological determinant of protein production and cell differentiation, and plays an important etiological role in many human diseases.
[0003] Epigenetic regulation involves genetically modifying genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modifications (e.g., methylation) of DNA and proteins (e.g., histones), which alter the steric relationship between the transcriptionally active and inactive states of chromatin. Control structural transitions. These covalent modifications can be controlled by enzymes such as methyltransferases (eg, PRMT5), many of which are associated with specific genetic changes that can cause human disease. PRMT5 influences diseases such as proliferative, metabolic and hematological disorders.
[0004] Homozygous deletion of tumor suppressor genes is a major driver of cancer and often results in the concomitant loss of passenger genes that are located in close genomic proximity to the tumor suppressor. Deletion of these passenger genes can create specific therapeutically tractable vulnerabilities in tumor cells. Homozygous deletion of the chromosome 9p21 locus, which harbors the well-known tumor suppressor CDKN2A (cyclin-dependent kinase inhibitor 2A), is present in 15% of all tumors and is a key enzyme in the methionine and adenine salvage pathway, passenger It often contains a deletion of the gene MTAP (methylthioadenosine phosphorylase). Deletion of MTAP results in accumulation of its substrate methylthioadenosine (MTA). MTA shares close structural similarity with S-adenosylmethionine (SAM), the methyl donor substrate of the type II methyltransferase PRMT5. The increase in MTA levels promoted by loss of MTAP selectively competes with SAM for binding to PRMT5, placing the methyltransferase in a hypomorphic state susceptible to further PRMT5 inhibition. Multiple genome-scale shRNA dropout screens performed in a panel of large tumor cell lines revealed a strong correlation between MTAP loss and cell line dependence on PRMT5, further elucidating the strength of this metabolic vulnerability. highlighted. However, PRMT5 is a known cellular essential gene, and conditional PRMT5 knockout and siRNA knockdown studies suggest that inhibition of PRMT5 in normal tissues may be associated with significant drawbacks (e.g., pancytocytes hypokinesia, infertility, skeletal muscle loss, cardiac hypertrophy). Therefore, novel strategies are needed to take advantage of this metabolic vulnerability and preferentially target PRMT5 in MTAP-null tumors while sparing PRMT5 in normal tissues (MTAP WT). Targeting PRMT5 with MTA-cooperative small molecule inhibitors can preferentially target the MTA-bound state of PRMT5, which is abundant in MTAP-null tumor cells, while at the same time ensuring that MTAP is intact and MTA levels are low in normal cells. Improve the therapeutic index for cells. [Summary of the invention] [Means to solve the problem]
[0005] In one aspect, the invention provides compounds of formula I [ka] A tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing is provided. In one embodiment, R is tricyclic independently selected from Formula IA. [ka]
[0006] In another embodiment, R can be tricyclic independently selected from Formula IB. [ka] The present invention [ka] can be a single bond or a double bond.
[0007] In one aspect, X 1 ,X 2 and X 6 is X 1 and X 2 can be N in each case, provided that both cannot be N at the same time. In another aspect, X 1 ,X 2 and X 6 can be C. In one embodiment, X 1 is C, it may be substituted with halo. In further embodiments, halo can be Cl. The present invention further provides 3 ,X 4 and X 5 may be C, which may be optionally substituted in each case. In another aspect, X 3 ,X 4 and X 5 may be O in each case optionally substituted. In a further aspect, X 3 ,X 4 and X 5 may be N in each case optionally substituted. In a further aspect, X 3 ,X 4 and X 5 may be substituted and S in each case. The present invention provides that the substituents are independently C 1~3 Alkyl, C 1~3 may be selected from alkyl (OH), providing that alkyl may be substituted with halo.
[0008] In one aspect of the invention, R 3 can be H in each case. In another aspect of the invention, R 3 is in each case C 1~3 Can be alkyl. In a further aspect, R 3 can be methyl.
[0009] The present invention is based on Ar 1 can be a 6-membered, optionally substituted aryl. In another aspect, Ar 1 can be a 6-membered, optionally substituted heteroaryl. In one embodiment, Ar 1 teeth, [ka] It can be. In another embodiment, Ar 1 teeth, [ka] It can be. In a further aspect, Ar 1 teeth, [ka] It can be. In another aspect, Ar 1 teeth, [ka] It can be. In yet another embodiment, Ar 1 teeth, [ka] It can be. In another embodiment, Ar 1 teeth, [ka] It can be. The present invention is based on Ar 1 Substituents are independently C 1~3 Provided that it can be selected from alkyl. In another embodiment, the substituent is -OC 1~3 Can be independently selected from alkyl. In further embodiments, substituents can be independently selected from halo.
[0010] The present invention is based on R 1 can be H in each case. In another aspect, R 1 can be a halo. In a further aspect, R 1 may be substituted with C 1~3 Can be alkyl. Substituents can be selected from halo and -CN. In a further aspect, R 1 may be substituted with -O-C 1~3 Can be alkyl. A substituent can be halo. In a further aspect, R 1 may be substituted with -C(O)OC 1~3 Alkyl(C 1~3 Alkyl can be optionally substituted with halo) and morpholinyl.
[0011] The present invention is based on R 2 but in each case C may be substituted 1~8 Provides that it can be alkyl. C 1~8 Alkyl substituents include halo, hydroxy, amino, -O-C 1~3 Can be selected from alkyl or -CN.
[0012] In a further aspect, R2 may in each case be an optionally substituted 5- or 6-membered ring or heterocycle. 5- or 6-membered ring or heterocyclic substituents include hydroxy, amino, optionally substituted C 1~6 It may be alkyl and the substituents are selected from halo. In a further aspect, R 2 may be substituted with C 1~6 Alkyl-O-C 1~3 It can be alkyl and the substituents are selected from halo. In another aspect, R 2 can be optionally substituted 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl. In another aspect, R 2 is C 1~3 Alkyl-heterocyclyl may be an optionally substituted 3,4-dihydro-2H-pyrano[2,3-c]pyridinyl or pyradazinyl or triazolyl or pyrimidinyl or tetrahydrofuranyl or 1H-pyrrolo[2,3 -b] may be pyridinyl or cyclohexyl. The substituent in each case is C 1~3 Alkyl, -CN or halo, or optionally substituted C 1~6 Alkyl-O-C 1~3 Can be alkyl. In the latter case, the substituents may be selected from halo, optionally substituted phenyl, where the phenyl substituent is halo or C 1~3 Can be selected from alkyl.
[0013] The present invention is based on R 1 may be tricyclic of formula IA, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another aspect, R 1 can be tricyclic of formula IB. In one embodiment, when the compound is tricyclic of formula IA, X 1 and X 2 can both be C. In another aspect, X 1 and X 2 one can be C and the other can be N. In the embodiment below, X 1 is C, it is unsubstituted or substituted with halo. In a further aspect, X 2 can be N.
[0014] The present invention further provides a compound, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R may be tricyclic of formula IA1. [ka]
[0015] In one aspect, X 3 can be unsubstituted or substituted with one or more methyls.
[0016] The present invention further provides a compound, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R may be tricyclic of formula IA2. [ka]
[0017] In one embodiment of the compounds of the invention, R 3 can be H, and in another aspect, R 3 can be methyl.
[0018] The present invention further provides R 2 may be substituted with C 1~8 Provided are compounds that are alkyl, tautomers thereof, stereoisomers thereof, or pharmaceutically acceptable salts of any of the foregoing. In one embodiment, R 2 is optionally substituted methyl, ethyl, isopropyl or cycloC 1~6 Can be alkyl.
[0019] All possible combinations between the aspects and embodiments disclosed above are included in the invention.
[0020] The present invention further provides a compound selected from: a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0021] In one aspect, the compound is selected from: 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3R)-4-Amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8- carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine -8-carboxamide; (3R)-4-Amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3S)-4-Amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3S)-4-Amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine- 8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,8]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-bromo-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; (3R)-4-Amino-N-(2,2-dimethylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; 4-Amino-N-(2,2-dimethylpropyl)-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-3,3-dimethyl-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; 4-Amino-N-(2,2-dimethylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; (3R)-4-Amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-cyclopropyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-7-fluoro-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide ; 4-Amino-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-cyclopropyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3R)-4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-7-chloro-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide ; 4-Amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide ; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide ; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-amino-7-chloro-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-7-chloro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; 4-amino-N-methyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; (3S)-4-Amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; (3R)-4-Amino-N-cyclopropyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3R)-4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3S)-4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; (3R)-4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3R)-4-Amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; Methyl 4-(6-((((4-amino-1,3-dihydrofuro[3,4-c]quinolin-8-yl)carbonyl)(methyl)amino)methyl)-3-pyridinyl)-1-piperazine Carboxylate; (3S)-4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8 -carboxamide; (3R)-4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8 -carboxamide; (3R)-4-Amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3S)-4-Amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8 -carboxamide; 4-amino-N-ethyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-chloro-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c] [1,7]naphthyridine-8-carboxamide; (3S)-4-Amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c] [1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide ; 5-amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 4-Amino-N-((5-(3,6-dihydro-2H-pyran-4-yl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; Methyl 6-((((4-amino-1,3-dihydrofuro[3,4-c]quinolin-8-yl)carbonyl)(methyl)amino)methyl)-3',6'-dihydro[3,4 '-Bipyridine]-1'(2'H)-carboxylate; 5-Oxo-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-5,6-dihydropyrazolo[1,5-c]quinazoline-9-carboxamide ; 4-Amino-1,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8- carboxamide; (3S)-4-Amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8- carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-7-fluoro-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(1,3-dimethoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((8R)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-(tri fluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((8S)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-(tri fluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((8R)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a] pyridin-8-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((8S)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a] pyridin-8-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(4-(3-oxetanyl)benzyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-N-(4-(3-oxetanyl)benzyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(4-morpholinyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-bromo-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-chloro-5-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-7-chloro-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3R)-4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(1-methyl-1H-1,2, 4-triazol-3-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-N-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-7-chloro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][ 1,7]Naphthyridine-8-carboxamide; 4-Amino-7-chloro-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(tetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 6-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[c ][1,7]naphthyridine-2-carboxamide; 6-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-8,9-dihydro-7H-cyclopenta[c] [1,7]Naphthyridine-2-carboxamide; 4-Amino-3-methyl-N-(1-methylcyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8 -carboxamide; 4-Amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-N-ethyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-N-cyclobutyl-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-methoxy-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,7-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclobutyl-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide ; 4-amino-7-chloro-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo [3,4-c]quinoline-8-carboxamide; 4-Amino-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3 -c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4- c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N,3-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-amino-7-fluoro-N,3-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-fluoro-2-pyridinyl)methyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-7-fluoro-N,3-dimethyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((6-cyclopropyl-3-pyridazinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,3,7-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N,1,7-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-3-methyl-N-(2-propanyl)-3H-pyrazolo[3,4-c]quinoline-8- carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-(3-fluoro-4-(trifluoromethyl)benzyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N,1-dimethyl-N-((6-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c ]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((6-(4-(trifluoromethyl)phenyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(4'-(trifluoromethyl)[biphenyl]-4-yl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(6-(4-(trifluoromethyl)phenyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c] Quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(4'-(pentafluoro-lambda~6~-sulfanyl)[biphenyl]-4-yl)ethyl)-1H-pyrazolo[4 ,3-c]quinoline-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-(2-(5-chloro-2-pyridinyl)-2,2-difluoroethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2-c]quinoline-8 -carboxamide; 4-Amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine- 8-carboxamide; 4-Amino-7-fluoro-1,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c ]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1-methyl-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8- carboxamide; 4-Amino-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8- carboxamide; (3R)-4-Amino-N-ethyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-ethyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N-ethyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; (3R)-4-Amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3S)-4-Amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-Amino-N-ethyl-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-ethyl-7-fluoro-1,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-1-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8- carboxamide; 4-Amino-N-ethyl-7-fluoro-1-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[ 4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-methyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N,1-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-hydroxy-4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-3-(hydroxymethyl)-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-(hydroxymethyl)-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-2-cyano-1-cyclopropylethyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-((1S)-2-cyano-1-cyclopropylethyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3, 4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3, 4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3R)-4-Amino-N-ethyl-3-(fluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c] Quinoline-8-carboxamide; (3R)-4-Amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8- carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8 -carboxamide; 4-Amino-N,1-dimethyl-N-((1S)-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8 -carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N,1-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-amino-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; 6-Amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine -2-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine- 8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,8]naphthyridine-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydro-1H-cyclopenta[ c]quinoline-8-carboxamide; 4-Amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-Amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine -8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c][1,8]naphthyridine-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline- 8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline- 8-carboxamide; 4-Amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3, 4-c]quinoline-8-carboxamide; 4-Amino-3-methyl-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3, 4-c]quinoline-8-carboxamide; 4-Amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[ 4,5-c]quinoline-8-carboxamide; 4-Amino-3-methyl-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[ 4,5-c]quinoline-8-carboxamide; 4-Amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine -8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline- 8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c ]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-2,3-dihydro-1H-cyclopenta[ c]quinoline-8-carboxamide; 6-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-8,9-dihydro-7H-cyclopenta[c ][1,8]naphthyridine-2-carboxamide; 6-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[ c][1,8]naphthyridine-2-carboxamide; 6-Amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-8,9-dihydro-7H-cyclopenta[c][1 ,8]Naphthyridine-2-carboxamide; 6-Amino-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-8,9-dihydro- 7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 6-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2-phenanthridinecarboxamide; 6-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2-phenanthridinecarboxamide; 5-amino-N-(2-pyrimidinylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine- 9-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4 ,5-c]quinoline-8-carboxamide; 4-Amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4 ,5-c]quinoline-8-carboxamide; 4-Amino-N-((3-fluoro-2-pyridinyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide ; 4-Amino-N-(2-pyrimidinylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide; 5-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c]quinoline-9 -carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((1S)-1-cyclopropyl-2-methoxyethyl)-N-((6-(4-morpholinyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)thieno[2,3-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(1-methoxy-2-methyl-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(1-methoxy-2-methyl-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline- 8-carboxamide; 4-Amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline- 8-carboxamide; 4-Amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-2,3-dihydro-1H-cyclopenta[ c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-2,3-dihydro-1H-cyclopenta[ c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)-1,3-dihydrofuro[3,4-c][ 1,8]Naphthyridine-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 6-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-7,8,9,10-tetrahydro- 2-phenanthridine carboxamide; 4-Amino-7-chloro-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((5-bromo-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-(3,3-difluorocyclobutyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(1-methyl-1H-1,2,4-triazol-3-yl) ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(1-methyl-1H-1,2,4-triazol-3-yl) ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(3,3-difluorocyclobutyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(2-methylpropyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine -8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide ; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline- 8-carboxamide; 4-Amino-N-((5-bromo-6-methyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((6-chloro-5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 8] Naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((6-chloro-5-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((5-chloro-6-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine- 8-carboxamide; 4-Amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(1-cyclopropyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydrofuro[3,4-c] [1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(1-methylcyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8] Naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8] Naphthyridine-8-carboxamide; 4-Amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8] Naphthyridine-8-carboxamide; 4-Amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8] Naphthyridine-8-carboxamide; 4-Amino-N-ethyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(2,2,2-trifluoroethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][ 1,7]Naphthyridine-8-carboxamide; 4-Amino-N-(3-oxetanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-N,3-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide ; 4-Amino-N,3-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide ; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-ethyl-7-fluoro-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-ethyl-7-fluoro-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; (3R)-4-Amino-N-ethyl-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-Amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-amino-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-3H-pyrazolo[3,4-c]quinoline -8-carboxamide; 4-Amino-N-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-cyclopropyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-N-cyclopropyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-7-chloro-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo [4,3-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-ethyl-N-((1R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-N-ethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-cyclobutyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-cyclobutyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-((S)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1 ,7]Naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 5-Amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-Amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c]quinoline-9-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrido[4,3-c][1,7]naphthyridine-9-carboxamide; 4-Amino-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-3H-pyrazolo[3,4-c] Quinoline-8-carboxamide; 4-amino-N-ethyl-N-(2-(4-(trifluoromethyl)phenyl)-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c][1,7]naphthyridine-9-carboxamide; 4-Amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-ethyl-7-fluoro-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-ethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-((R)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-((S)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-7-fluoro-3-methyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide ; (3R)-4-Amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; 4-Amino-N-((R)-cyclopropyl(6-(trifluoromethyl)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-methyl-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((5-fluoro-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((2,6-difluoro-3-pyridinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-((1R)-1-(5-(difluoromethyl)-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine -8-carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3R)-4-amino-N-((1R)-1-(5-(difluoromethyl)-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline -8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-Amino-N-ethyl-7-fluoro-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-7-fluoro-N-((2-fluoro-6-(trifluoromethyl)-3-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-((R)-cyclopropyl(6-(trifluoromethyl)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; 4-Amino-N,3-dimethyl-N-((1R)-1-(4-(pentafluoroethyl)phenyl)ethyl)-3H-pyrazolo[3,4-c][1,7]naphthyridine-8 -carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(4-(pentafluoroethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(4-(pentafluoroethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-2-pyridinyl)methyl)-1H-pyrazolo[4 ,3-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-7-chloro-N-cyclopropyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-1-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c ]quinoline-8-carboxamide; 4-Amino-7-chloro-N-cyclobutyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-cyclobutyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-fluoro-1-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4 ,3-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-7-fluoro-1-methyl-N-(1,3-oxazol-4-ylmethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-7-fluoro-1-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; 4-Amino-7-fluoro-N-((2-methoxy-6-(trifluoromethyl)-3-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-cyclobutyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8- carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-1-methyl-1H-pyrazolo[4,3-c] Quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N,1-dimethyl-7-(trifluoromethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-cyclopropyl-1-methyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c] Quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-1-methyl-7-(trifluoromethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c] Quinoline-8-carboxamide; 4-Amino-N-((1R)-1-cyclopropylethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-N-((1S)-1-cyclopropylethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-7-fluoro-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-3H-pyrazolo[3 ,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro [3,4-c][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro [3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; (3R)-4-Amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(4-cyanophenyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(4-cyanophenyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; (3R)-4-amino-N-((1R)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-7-chloro-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][ 1,7]Naphthyridine-8-carboxamide; 4-Amino-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][ 1,7]Naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(3,5-difluoro-2-pyridinyl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; (3R)-4-amino-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-methyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; 4-Amino-7-fluoro-N-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1S)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; 4-Amino-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4-c][ 1,7]Naphthyridine-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1S)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(3-methoxy-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4 -c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(3-methoxy-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-N,3-dimethyl-N-((1R)-1-(4-(pentafluoro-lambda~6~-sulfanyl)phenyl)ethyl)-3H-pyrazolo[3,4-c][1 ,7]Naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(4-(pentafluoro-lambda~6~-sulfanyl)phenyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(4-(pentafluoro-lambda~6~-sulfanyl)phenyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-1-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-N-((1R)-1-(5-pyrimidinyl)propyl)-1H-pyrazolo[4, 3-c][1,7]naphthyridine-8-carboxamide; 4-Amino-1-methyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-N-((1S)-1-(5-pyrimidinyl)propyl)-1H-pyrazolo[4, 3-c][1,7]naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N-ethyl-7-fluoro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-1-methyl-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-ethyl-7-fluoro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-1-methyl-1H-pyrazolo[4,3-c]quinoline-8 -carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((1S)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-7-(trifluoromethyl)-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-cyclopropyl-1-methyl-N-((1S)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-7-chloro-N-cyclopropyl-1-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3- c]quinoline-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7] Naphthyridine-8-carboxamide; 4-Amino-N-(3-fluorophenyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,7]naphthyridine-8-carboxamide; 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ][1,8]naphthyridine-8-carboxamide; 5-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,4-dihydro-2H-pyrano[ 3,4-c]quinoline-9-carboxamide; 4-Amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2- c]quinoline-8-carboxamide; 4-Amino-3,3-dimethyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c] Quinoline-8-carboxamide; (3R)-4-Amino-N-((3-fluoro-2-pyridinyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((3-fluoro-2-pyridinyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3S)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3S)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1R,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1R,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1S,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1S,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-((3S)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl )methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1S,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl) -2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((1R)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1R,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1R,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1S,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1S,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1R)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3 -dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((1R)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R,2R)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S,2S)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R,2R)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S,2S)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((5-cyano-2-pyridinyl)methyl)-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; (3R)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl) -1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1-cyanocyclopropyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1-cyanocyclopropyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl )-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl )-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4- c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2R,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2R,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2S,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2S,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2R,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2R,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1 ,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((1S,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((1R,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3- Dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(2-(cis-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(2-(trans-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-(2-(cis-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-(2-(trans-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2R)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2S)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2R)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2S)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1, 3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-((2R)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl) methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl) methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((2R)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl) methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl) methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-N-((5-(trifluoromethyl)-2 -pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-N-((5-(trifluoromethyl)-2 -pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-3-methyl-N-((3R)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2R)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N-((2S)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2R)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3S)-4-Amino-N-((2S)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide; (3R)-4-Amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3S)-4-Amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; (3R)-4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3S)-4-Amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8 -carboxamide; (3R)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; (3S)-4-Amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c ]quinoline-8-carboxamide; 4-amino-N,3,3-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide ; 4-Amino-3,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 4-Amino-N-cyclopropyl-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8- carboxamide; and 4-Amino-N-((1R)-1-(3-cyano-5-(trifluoromethyl)-2-pyridinyl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide.
[0022] In another aspect, the compound may be selected from: (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro [3,4-c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3 -c]quinoline-8-carboxamide; 4-Amino-N,1-dimethyl-N-(4-(pentafluoro-lambda~6~-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; (3R)-4-Amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxamide; 4-Amino-7-fluoro-N-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline -8-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrido[4,3-c][1,7]naphthyridine-9-carboxamide; 4-Amino-N-ethyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-Amino-N-ethyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide ; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-Amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline -8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4 -c]quinoline-8-carboxamide; 4-Amino-N-cyclopropyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8- carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide and 4-Amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide.
[0023] The present invention provides a method for treating cancer, comprising administering to a subject an effective amount of a compound of the present invention, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. A method is further provided comprising: In one aspect, the cancer is selected from ovarian cancer, lung cancer, lymphoid cancer, glioblastoma, colon cancer, melanoma, gastric cancer, pancreatic cancer or bladder cancer.
[0024] The invention comprises a compound of the invention, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions are further provided.
[0025] The present invention provides a method for treating cancer, comprising administering to a subject an effective amount of a compound of the present invention, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. A method is also provided that includes. In one aspect, the cancer can be ovarian cancer, lung cancer, lymphoid cancer, glioblastoma, colon cancer, melanoma, gastric cancer, pancreatic cancer or bladder cancer.
[0026] The invention also provides a compound of the invention, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing for use in a method of treating cancer, the method comprising: , comprising administering to a subject an effective amount of such a compound. In one aspect, the cancer can be ovarian cancer, lung cancer, lymphoid cancer, glioblastoma, colon cancer, melanoma, gastric cancer, pancreatic cancer or bladder cancer.
[0027] The invention also provides the use of a compound of the invention, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in the manufacture of a medicament for treating cancer. In one aspect, the cancer is selected from ovarian cancer, lung cancer, lymphoid cancer, glioblastoma, colon cancer, melanoma, gastric cancer, pancreatic cancer or bladder cancer.
[0028] Other objects, features, and advantages of the invention will be apparent to those skilled in the art from the following description and claims. [Details for carrying out the invention]
[0029] definition As used herein, when any variable occurs more than one time in a chemical formula, its definition at each occurrence is independent of its definition at every other occurrence. If the chemical structure and chemical name conflict, the chemical structure determines the identity of the compound. Compounds of the present disclosure may contain one or more chiral centers and / or double bonds and therefore may exist as stereoisomers such as double bond isomers (i.e. geometric isomers), enantiomers or diastereomers. . Therefore, any chemical structure depicted in relative configuration within all or part of this specification may be stereomerically pure (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure). It encompasses all possible enantiomers and stereoisomers of the exemplified compounds, including (merically pure) forms as well as enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be separated into their enantiomeric or stereoisomeric components using separation techniques or chiral synthesis techniques well known to those skilled in the art.
[0030] Certain compounds of the invention may have asymmetric carbon atoms (optical centers) or double bonds; racemates, enantiomers, diastereomers, geometric isomers and individual isomers are all within the scope of the invention. is intended to be included. Additionally, atropisomers and mixtures thereof, such as those produced by constrained rotation about two aromatic rings or aromatic heterocycles bonded to each other, are intended to be encompassed within the scope of this invention. For example, if the substituent is a phenyl group and is substituted with two groups bonded to the C atoms adjacent to the point bonded to the N atom of the triazole, the rotation of the phenyl may be constrained. In some cases, this rotational barrier is high enough that different atropisomers can be separated and isolated.
[0031] As used herein and unless otherwise indicated, the terms "stereoisomer" or "stereomerically pure" mean one stereoisomer of a compound, i.e., the compound has other stereoisomers. This means that it does not substantially contain the body. For example, a stereomerically pure compound having one chiral center is substantially free of mirror enantiomers in the compound. A stereomerically pure compound that has two chiral centers is substantially free of other diastereomers in the compound. A typical stereomerically pure compound has greater than about 80% by weight of the compound of one stereoisomer and less than about 20% of the other stereoisomer, more preferably about 90% by weight of the compound. % of one stereoisomer and less than about 10% by weight of the compound of the other stereoisomer, even more preferably greater than about 95% of the compound and less than about 5% of the other stereoisomer. and most preferably greater than about 97% by weight of the compound of one stereoisomer and less than about 3% by weight of the compound of the other stereoisomer. If the stereochemistry of a structure or part of a structure is not shown, eg, in bold or dashed lines, that structure or part of a structure should be construed as encompassing all stereoisomers thereof. Bonds drawn with wavy lines indicate that both stereoisomers are included. This wavy line should not be confused with the wavy line drawn perpendicular to the bond, which indicates where the group attaches to the rest of the molecule.
[0032] As known to those skilled in the art, certain compounds of the invention may exist in one or more tautomeric forms. For convenience, references to compounds of a given structural formula include tautomeric forms of the structure represented by the structural formula, since one chemical structure may only be used to represent one tautomeric form. will be understood. Some compounds may exist primarily in one form over another. Also, depending on the compound and the energy required to convert one tautomer to the other, some compounds may exist as a mixture at room temperature, while others may exist as a mixture of one tautomer or the other. Some may be isolated as tautomeric forms. Examples of other tautomers relevant to the compounds of the invention are those with a pyridone group (pyridinyl) in which hydroxypyridine is a tautomer, and compounds with a ketone group with an enol tautomer. Examples of these are shown below. [ka]
[0033] Compounds of the present disclosure include, but are not limited to, compounds of Formula I and all pharmaceutically acceptable forms thereof. Pharmaceutically acceptable forms of the compounds listed herein include pharmaceutically acceptable salts, solvates, crystalline forms (including polymorphs and clathrates), chelates, non-covalent complexes, etc. drugs, prodrugs, and mixtures thereof. In certain embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts. As used herein, the term "compound" refers to the compound itself, as well as its pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof. and mixtures of any of the foregoing. In some embodiments, the term "compound" refers to the compound itself, a pharmaceutically acceptable salt thereof, a tautomer of the compound, a pharmaceutically acceptable salt of a tautomer thereof, and (C 1 ~C 4 ) alkyl esters and other ester prodrugs. In other embodiments, the term "compound" includes the compound itself, a pharmaceutically acceptable salt thereof, a tautomer of the compound, and a pharmaceutically acceptable salt of a tautomer.
[0034] Pharmaceutically acceptable salts of the compounds of this invention include salts with inorganic acids such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with tartaric, acetic, trifluoroacetic acids. , citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, formic acid, propionic acid, glycolic acid, gluconic acid, maleic acid, succinic acid, camphor sulfate, isothionic acid, mucic acid, gentisic acid, isonicotinic acid, saccharic acid , glucuronic acid, furoic acid, glutamic acid, ascorbic acid, anthranilic acid, salicylic acid, phenylacetic acid, mandelic acid, embon (pamoic acid), methanesulfonic acid, ethanesulfonic acid, pantothenic acid, stearic acid, sulfinyl acid, alginic acid, galacturonic acid and acid addition salts formed with arylsulfonic acids, such as benzenesulfonic acid and p-toluenesulfonic acid; alkali metals and alkaline earth metals and N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, megluamine (N-methylglucamine); base addition salts formed with organic bases such as lysine and procaine; and internally formed salts. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection and Use; 2002. Salts with non-pharmaceutically acceptable anions or cations are useful intermediates for the preparation of pharmaceutically acceptable salts and / or for use in non-therapeutic, e.g. in vitro, situations. is within the scope of the present invention.
[0035] The term "solvate" refers to a compound formed by the interaction of a solvent and a compound. Solvates of a compound include all forms of solvates of the compound. In certain embodiments, the solvent is volatile, non-toxic, and / or acceptable for microdose administration to humans. Suitable solvates are pharmaceutically acceptable solvates such as hydrates, including monohydrates and hemihydrates.
[0036] The compounds of the invention may also contain atomic isotopes that are naturally occurring or in unnatural proportions at one or more of the atoms that constitute such compounds. For example, this compound may contain, for example, tritium ( 3 H), iodine-125( 125 I), or carbon-14( 14 C) can be radiolabeled with a radioactive isotope. Radiolabeled compounds are useful as therapeutic or prophylactic agents, research reagents such as assay reagents, and diagnostic agents such as in vivo contrast agents. All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention. For example, when a variable is stated or shown to be H, it is also meant that the variable can be deuterium (D) or tritium (T).
[0037] "Alkyl" refers to a saturated branched or straight chain monovalent hydrocarbon group derived by removing one hydrogen atom from a single carbon atom of a parent alkane. Typical alkyl groups include methyl, ethyl, propyl, such as propan-1-yl and propan-2-yl, butyl, such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl. Examples include, but are not limited to, yl, 2-methyl-propan-2-yl, tert-butyl, and the like. In certain embodiments, alkyl groups contain 1-20 carbon atoms. In some embodiments, the alkyl group contains 1-10 carbon atoms or 1-6 carbon atoms, while in other embodiments the alkyl group contains 1-4 carbon atoms. In still other embodiments, the alkyl group contains 1 or 2 carbon atoms. Branched alkyl groups contain at least 3 carbon atoms, typically 3 to 7, or in some embodiments 3 to 6 carbon atoms. Alkyl groups having 1 to 6 carbon atoms are (C 1 ~C 6 )alkyl group, and an alkyl group having 1 to 4 carbon atoms is (C 1 ~C 4 )Alkyl. This nomenclature can also be used for alkyl groups with different numbers of carbon atoms. "Alkyl" also includes cycloalkyl, groups in which the carbons are arranged in the form of a ring. Cycloalkyl includes, but is not limited to, cyclopropyl, cyclobityl, cyclopentyl and cyclohexyl.
[0038] "Alkenyl" means an unsaturated branched or straight chain having at least one carbon-carbon double bond derived by removal of one hydrogen atom from a single carbon atom of a parent alkene. Refers to the hydrocarbon group of The group can be in either the Z or E configuration (cis or trans) with respect to the double bond. Typical alkenyl groups include, but are not limited to, ethenyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl(allyl); and prop-2-en-2-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, butenyl; -2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, but-1,3-dien-1-yl and but-1,3-dien-2 -il; etc. In certain embodiments, alkenyl groups have 2-20 carbon atoms, and in other embodiments 2-6 carbon atoms. Alkenyl groups having 2 to 6 carbon atoms are (C 2 ~C 6 )Alkenyl group. "Alkenyl" also includes cycloalkenyl. Cycloalkenyl refers to an alkenyl consisting of three or more carbon atoms joined together with at least one carbon-carbon double bond to form a structural ring. Examples include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexanyl.
[0039] "Alkynyl" means an unsaturated branched or straight chain having at least one carbon-carbon triple bond derived by removal of one hydrogen atom from a single carbon atom of a parent alkyne. Refers to hydrocarbons. Typical alkynyl groups include, but are not limited to, ethynyl; propynyl; butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, and the like. In certain embodiments, alkynyl groups have 2-20 carbon atoms, and in other embodiments 2-6 carbon atoms. Alkynyl groups having 2 to 6 carbon atoms are -(C 2 ~C 6 )Alkynyl group
[0040] "Alkoxy" refers to the group -OR, where R represents an alkyl group as defined herein. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, and the like. Typical alkoxy groups contain 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms within the R group. Alkoxy groups containing 1 to 6 carbon atoms are -O-(C 1 ~C 6 )alkyl or -O-(C 1 ~C 6 (alkyl) group. In some embodiments, an alkoxy group can contain 1-4 carbon atoms, -O-(C 1 ~C 4 )alkyl or -O-(C 1 ~C 4 (alkyl) group.
[0041] "Aryl" refers to a monovalent aromatic hydrocarbon group derived by removing one hydrogen atom from a single carbon atom of a parent aromatic ring system. Aryl includes monocyclic carbocyclic aromatic rings, such as benzene. Aryl also includes bicyclic carbocyclic aromatic ring systems in which each ring is aromatic, such as naphthalene. Thus, aryl groups can include fused ring systems in which each ring is a carbocyclic aromatic ring. In certain embodiments, aryl groups contain 6-10 carbon atoms. Such a group is C 6 ~C 10 Sometimes called an aryl group. However, aryl never encompasses or does not overlap with heteroaryl, as otherwise defined below. Thus, when one or more carbocyclic aromatic rings are fused with an aromatic ring containing at least one heteroatom, the resulting ring system is a heteroaryl group, and an aryl group as defined herein do not have.
[0042] "Carbonyl" refers to the group -C(O), and may also be referred to as the -C(=O) group.
[0043] "Carboxy" refers to the group -C(O)OH, sometimes also referred to as -C(=O)OH.
[0044] "Cyano" refers to the group -CN.
[0045] "Cycloalkyl" refers to a saturated cyclic alkyl group derived by removing one hydrogen atom from a single carbon atom of a parent cycloalkane. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, and the like. Cycloalkyl groups may be described by the number of carbon atoms in the ring. For example, a cycloalkyl group having 3 to 8 ring members is (C 3 ~C 8 )cycloalkyl, and a cycloalkyl group having 3 to 7 ring members is (C 3 ~C 7 )cycloalkyl, and a cycloalkyl group having 4 to 7 ring members is (C 4 ~C 7 ) Sometimes referred to as cycloalkyl. In certain embodiments, the cycloalkyl group is (C 3 ~C 10 )cycloalkyl, (C 3 ~C 8 )cycloalkyl, (C 3 ~C 7 )cycloalkyl, (C 3 ~C 6 )cycloalkyl or (C 4 ~C 7 ) cycloalkyl groups, which, using alternative terminology, can be C 3 ~C 10 cycloalkyl, C 3 ~C 8 cycloalkyl, C 3 ~C 7 cycloalkyl, C 3 ~C 6 cycloalkyl or C 4 ~C 7 Sometimes called a cycloalkyl group.
[0046] "Heterocyclyl" refers to a cyclic group containing at least one saturated (partially unsaturated) cyclic ring. Heterocyclyl groups contain at least one heteroatom as a ring member. Typical heteroatoms include O, S and N, which are independently selected. Heterocyclyl groups include monocyclic and bicyclic ring systems. Bicyclic heterocyclyl groups can be fused to a cycloalkyl ring, or can be fused to an aromatic ring, which can be carbocyclic or contain one or more heteroatoms, at least Contains at least one non-aromatic ring with one heteroatom ring member. The point of attachment of a bicyclic heterocyclyl group can be a non-aromatic ring containing at least one heteroatom, or it can be another ring of the heterocyclyl group. For example, a heterocyclyl group derived by removing a hydrogen atom from one of the 9-membered heterocyclic compounds shown below can be attached to the remainder of the 5- or 6-membered molecule. [ka]
[0047] In some embodiments, the heterocyclyl group contains 5-10 ring members, of which 1, 2, 3 or 4 or 1, 2 or 3 are independently selected from O, S or N. It is a heteroatom that is In other embodiments, a heterocyclyl group contains 3 to 7 ring members, of which 1, 2 or 3 heteroatoms are independently selected from O, S or N. In such 3- to 7-membered heterocyclyl groups, if the ring contains only 3 ring members, only one of the ring atoms is a heteroatom; if the ring contains 4 ring members, only one or Contains 2 heteroatoms. In some embodiments, a heterocyclyl group contains 3 or 4 ring members, one of which is a heteroatom selected from O, S or N. In other embodiments, a heterocyclyl group contains 5 to 7 ring members, 1, 2 or 3 of which are heteroatoms independently selected from O, S or N. Typical heterocyclyl groups include epoxide, aziridine, azetidine, imidazolidine, morpholine, piperazine, piperidine, hexahydropyrimidine, 1,4,5,6-tetrahydropyrimidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, benzo Examples include, but are not limited to, groups derived from imidazolone, pyridinone, and the like. A heterocyclyl group can be fully saturated but can contain one or more double bonds. Examples of such heterocyclyl groups include 1,2,3,6-tetrahydropyridinyl, 3,6-dihydro-2H-pyranyl, 3,4-dihydro-2H-pyranyl, 2,5-dihydro-1H -pyrrolyl, 2,3-dihydro-1H-pyrrolyl, 1H-azilinyl, 1,2-dihydroazetenyl, and the like, but are not limited to these. Substituted heterocyclyl includes one or more oxo (=O) or oxide (-O - ) substituents, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, pyridinonyl, benzimidazolonyl, benzo[d]oxazol-2(3H)-onyl , 3,4-dihydroisoquinolin-1(2H)-onyl, indoline-onyl, 1H-imidazo[4,5-c]pyridin-2(3H)-onyl, 7H-purin-8(9H)-onyl, imidazo Also included are lysin-2-onyl, 1H-imidazol-2(3H)-onyl, 1,1-dioxo-1-thiomorpholinyl, and the like.
[0048] The term "comprising" is meant to be open-ended, ie, all-inclusive and non-limiting. This term may be used synonymously herein with "having" or "including". Include is intended to include any indicated or listed component or element, but not to exclude other components or elements.
[0049] "Disease" refers to any disease, disorder, condition, symptom or sign.
[0050] "Halo" or "halogen" refers to a fluoro, chloro, bromo or iodo group.
[0051] "Haloalkyl" refers to an alkyl group in which at least one hydrogen has been replaced with a halogen. Thus, the term "haloalkyl" includes monohaloalkyl (alkyl substituted with one halogen atom) and polyhaloalkyl (alkyl substituted with two or more halogen atoms). Representative "haloalkyl" groups include difluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like. The term "perhaloalkyl," unless otherwise specified, means an alkyl group in which each hydrogen atom has been replaced with a halogen atom. For example, the term "perhaloalkyl" includes, but is not limited to, trifluoromethyl, pentachloroethyl, 1,1,1-trifluoro-2-bromo-2-chloroethyl, and the like.
[0052] "Heteroaryl" refers to a monovalent heteroaromatic group derived by removing one hydrogen atom from a single carbon atom of a parent heteroaromatic ring system. Heteroaryl groups typically contain 5 to 14 ring members, but more typically 1 or more, such as 1, 2, 3 or 4 (or in certain embodiments 1, 2 or 4) ring members. 3), 5- to 10-membered aromatic, monocyclic, bicyclic, and tricyclic rings containing heteroatoms selected from O, S, or N (the remaining ring atoms being carbon) including. In monocyclic heteroaryl groups, the single ring is aromatic and contains at least one heteroatom. In some embodiments, a monocyclic heteroaryl group can contain 5 or 6 ring members, 1, 2, 3 or 4 heteroatoms, 1, 2 or 3 heteroatoms, 1 It may contain one or two heteroatoms or one heteroatom, where the heteroatoms are independently selected from O, S or N. In a bicyclic aromatic ring, both rings are aromatic. For bicyclic heteroaryl groups, at least one of the rings must contain a heteroatom, although it is not necessary for both rings to contain heteroatoms, although it is permissible to do so. For example, the term "heteroaryl" includes a 5- to 7-membered aromatic heterocycle fused to a carbocyclic aromatic ring or fused to another aromatic heterocycle. In a tricyclic aromatic ring, all three of the rings are aromatic and at least one of the rings contains at least one heteroatom. In the case of fused, bicyclic and tricyclic heteroaryl ring systems in which only one of the rings contains one or more heteroatoms, the point of attachment may be a ring containing at least one heteroatom, or Can be a carbocyclic ring. When the total number of S and O atoms in a heteroaryl group exceeds 1, the heteroatoms are not adjacent to each other. In certain embodiments, the total number of S and O atoms in the heteroaryl group is 2 or less. In certain embodiments, the total number of S and O atoms in the aromatic heterocycle is 1 or less. Heteroaryl does not include or overlap with the aryls defined above. Examples of heteroaryl groups include acridine, carbazole, cinnoline, furan, imidazole, indazole, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, isothiazole, 2H-benzo[d][1,2,3 ]Triazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, quinazoline, quinoline, quinolidine, Examples include, but are not limited to, groups derived from quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, and the like. In certain embodiments, a heteroaryl group can be a 5-20 membered heteroaryl, such as a 5-14 membered or a 5-10 membered heteroaryl. In certain embodiments, heteroaryl groups include thiophene, pyrrole, benzothiophene, 2H-benzo[d][1,2,3]triazolebenzofuran, indole, pyridine, quinoline, imidazole, benzimidazole, oxazole, tetrazole, and pyrazine. It can be derived from
[0053] "Pharmaceutically acceptable" refers to something that is generally recognized for use in animals, and more specifically humans.
[0054] "Pharmaceutically acceptable salt" refers to a salt of a compound that is pharmaceutically acceptable and that has the desired pharmacological activity of the parent compound.
[0055] "Pharmaceutically acceptable excipient" refers to a wide range of ingredients that can be combined with a compound or salt of the invention to prepare a pharmaceutical composition or formulation. Excipients typically include diluents, colorants, vehicles, anti-adhesives, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, adsorbents, preservatives, etc. Examples include, but are not limited to, agents.
[0056] "Stereoisomer" refers to isomers that differ in the arrangement of their constituent atoms in space. Optically active stereoisomers that are mirror images of each other are termed "enantiomers," and optically active stereoisomers that are not mirror images of each other are termed "diastereomers."
[0057] "Subject" includes mammals and humans. The terms "human" and "subject" are used interchangeably herein.
[0058] "Therapeutically Effective Amount" means an amount that, when administered to a subject to treat a disease or at least one clinical symptom of the disease or disorder, is sufficient to affect such treatment of the disease, disorder or condition. Refers to the amount of a compound. As one of ordinary skill in the art will appreciate, this amount is typically not limited to a single dose, but rather multiple doses over a substantial period of time as required to produce a therapeutic or prophylactic response in a subject. may include. Accordingly, a "therapeutically effective amount" is not limited to the amount in a single capsule or tablet, but can include multiple capsules or tablets at a dose prescribed by a qualified physician or health care provider. A "therapeutically effective amount" refers to the compound, disease, disorder and / or symptoms of the disease or disorder, the severity of the disease, disorder and / or symptoms of the disease or disorder, the age of the subject being treated and / or the age of the subject being treated. May vary depending on weight. Appropriate amounts in any given instance may be readily apparent to those skilled in the art or may be capable of being determined by routine experimentation.
[0059] "Treating" or "treatment" of any disease or disorder means ceasing or ameliorating the disease, disorder, or at least one clinical symptom of the disease or disorder; reducing the risk of contracting at least one of the symptoms, reducing the onset of the disease, disorder or at least one clinical symptom of the disease or disorder, or reducing the onset of at least one of the disease, disorder or clinical manifestation of the disease or disorder Refers to reducing risk. "Treat" or "treatment" refers to inhibiting a disease or disorder physically (e.g., stabilizing recognizable symptoms), physiologically (e.g., stabilizing physical parameters), or both, or refers to the inhibition of at least one physical parameter that may be unrecognizable. Furthermore, "treating" or "treatment" refers to preventing the disease or disorder, or at least the onset of symptoms thereof, in a subject who may be exposed to or susceptible to the disease or disorder. refers to delaying symptoms even if the patient is not yet experiencing or exhibiting symptoms.
[0060] In some embodiments, a compound can be in a salt form. Such salts may be anhydrous or associated with water as hydrates. In some embodiments, the compound can be in neutral form as a base or an acid.
[0061] A compound according to any one of the Examples or a pharmaceutically acceptable salt thereof, a tautomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, a stereoisomer of any of the foregoing or a stereoisomer thereof; Also provided are pharmaceutical compositions comprising the mixture and at least one pharmaceutically acceptable excipient, carrier or diluent. In some such embodiments, a compound according to any one of the embodiments or a pharmaceutically acceptable salt thereof, a tautomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, Either stereoisomer or mixture thereof is present in an amount effective to treat PRMT5-dependent cancers. In some embodiments, the pharmaceutical composition is formulated for oral delivery, while in other embodiments, the pharmaceutical composition is formulated for intravenous delivery. In some embodiments, the pharmaceutical composition is formulated for once-daily oral administration of QD, and some such formulations have an effective amount of active ingredient ranging from 1 mg to 100 mg, 5 mg to 80 mg. , tablets ranging from 10mg to 50mg or 15 to 30mg.
[0062] In some embodiments, the subject is a mammal. In some such embodiments, the mammal is a rodent. In other embodiments, the mammal is a dog. In still other embodiments, the subject is a primate, and in some such embodiments, the subject is a human.
[0063] Pharmaceutical compositions or formulations for administration of the compounds of this invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art. All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Generally, pharmaceutical compositions may be prepared by homogenizing and comminuting the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation. In this pharmaceutical composition, the active subject compound is included in an amount sufficient to produce the desired effect in response to the disease process or condition.
[0064] The compounds of the invention may be administered orally, mucosally (including sublingually, bucally, rectally, nasally or vaginally), parenterally (including subcutaneously, intramuscularly, by bolus injection, intraarterially or intravenously), transdermally or topically. It can be administered by administration. In some embodiments, the compounds of the invention are administered mucosally (including sublingually, bucally, rectally, nasally or vaginally), parenterally (including subcutaneously, intramuscularly, by bolus injection, intraarterially or intravenously), Administered by transdermal or topical administration. In other embodiments, the compounds of the invention are administered by oral administration. In yet other embodiments, the compounds of the invention are not administered by oral administration.
[0065] A compound of the present invention, a pharmaceutically acceptable salt thereof, a tautomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, a stereoisomer of any of the foregoing or a mixture thereof can be used in many forms. It can be used in treating conditions.
[0066] The compounds and compositions described herein are generally useful for inhibiting PRMT5. In some embodiments, the method of treating a subject in need of treatment comprises administering to the subject an effective amount of a compound described herein (e.g., a compound of Formula I or a pharmaceutically acceptable salt thereof). Methods of treating PRMT5-mediated disorders are provided. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, the subject is suffering from a PRMT5-mediated disorder (eg, cancer, eg, lymphoma, breast cancer, or pancreatic cancer). In other embodiments, the subject is susceptible to a PRMT5-mediated disorder (eg, cancer, eg, lymphoma, breast cancer, or pancreatic cancer).
[0067] As used herein, the term "PRMT5-mediated disorder" refers to any disease, disorder or other condition known to be affected by PRMT5. Accordingly, in some aspects, the present disclosure relates to treating or reducing the severity of one or more diseases that PRMT5 is known to affect.
[0068] In some embodiments, a method of inhibiting PRMT5 activity in a subject in need thereof, comprising: an effective amount of a compound described herein (e.g., a compound of Formula I or a pharmaceutically acceptable salt thereof) ) or a pharmaceutical composition thereof is provided herein.
[0069] In a further aspect, compounds contemplated by the invention are useful in treating proliferative disorders such as cancer. In certain embodiments, the compounds described herein are useful in treating lymphoma. In some embodiments, the lymphoma is mantle cell lymphoma (MCL). In some embodiments, the lymphoma is acute myeloid lymphoma (AML). In some embodiments, the cancer compounds described herein are useful for treating pancreatic cancer. In some embodiments, the cancer compounds described herein are useful in treating multiple myeloma (MM). In further embodiments, the cancer compounds described herein are useful in treating breast cancer. Breast cancer may be estrogen receptor negative (ER-), or breast cancer may be progesterone receptor negative (PR-). In further embodiments, the breast cancer may be HER2 negative. In some embodiments, the breast cancer is estrogen receptor negative, progesterone receptor negative, and HER2 negative, also referred to herein as "triple negative breast cancer."
[0070] In further embodiments, the breast cancer is lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), inflammatory breast cancer, Paget's disease of the nipple, phyllodes tumor, angiosarcoma, Adenoid cystic carcinoma, low-grade adenosquamous carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, tubular carcinoma, metaplastic carcinoma, micropapillary carcinoma, mixed carcinoma or another breast cancer (triple negative, HER positive, estrogen receptor positive, progesterone receptor positive, HER and estrogen receptor positive, HER and progesterone receptor positive, estrogen and progesterone receptor positive, and HER and estrogen and progesterone receptor positive).
[0071] In one embodiment, compounds of the invention are useful in treating pancreatic cancer.
[0072] In another embodiment, the compounds of the invention are useful in the treatment of NSCLC (non-small cell lung cancer). In one embodiment, the NSCLC may be squamous NSCLC. In another embodiment, the NSCLC may be an adenocarcinoma.
[0073] In further embodiments, the cancer can be GBM. In further embodiments, the cancer can be mesothelioma. In one aspect, the cancer can be bladder cancer. In another aspect, the cancer can be esophageal cancer. In further embodiments, the cancer can be melanoma. In one aspect, the cancer can be DLBCL, HNSCC or cholangiomas.
[0074] In some embodiments, one or more compounds described herein are useful in treating any PRMT5-mediated or PRMT5-responsive proliferative cell disorder, such as a cancer that is PRMT5-responsive.
[0075] In one aspect, cancers lacking p53 (eg, p53 null cancers) are less sensitive to PRMT5 inhibition than p53-positive cancers. Therefore, a PRMT5-responsive cancer may be a p53-positive cancer. The term "p53 positive" refers to cancers that do not lack p53 expression and / or activity. In some embodiments, one or more compounds described herein are useful in treating p53-positive cancers. In some embodiments, higher amounts of one or more compounds described herein may be required to treat p53-negative cancers (eg, p53-null cancers) than p53-positive cancers.
[0076] In some embodiments, the present disclosure provides methods for identifying subjects with cancer that are susceptible to treatment with PRMT5 inhibitors. In some embodiments, the method comprises: obtaining a sample from a subject; detecting the presence or absence of p53; and determining that if p53 is present in the sample, the subject has a cancer that is susceptible to treatment with a PRMT5 inhibitor. Including identifying the object. Accordingly, in some embodiments, subjects with p53-positive cancers are identified as subjects for treatment with a PRMT5 inhibitor. In some embodiments, the method further comprises administering to the subject a composition comprising a PRMT5 inhibitor.
[0077] In some embodiments, aspects of the present disclosure relate to methods for identifying a subject with a cancer that is insensitive (or less susceptible) to treatment with a PRMT5 inhibitor. In some embodiments, the method includes obtaining a sample from a subject; detecting the presence or absence of p53; and if p53 is absent from the sample (e.g., if the cancer is a p53-null cancer), the method comprises: obtaining a sample from a subject; including identifying a subject as having a cancer that is not sensitive to treatment (eg, a cancer that is less sensitive than a p53 positive cancer). In some embodiments, a p53-negative cancer (e.g., a p53-null cancer) is treated with a PRMT5 inhibitor, but a higher amount of PRMT5 inhibitor is required to treat a p53-negative cancer than a p53-positive cancer. obtain. However, in some embodiments, a subject with a p53-negative cancer (eg, a p53-null cancer) is treated with a therapeutic agent that is not a PRMT5 inhibitor.
[0078] "Sample" means any biological sample derived from a subject, including, but not limited to, cells, tissue samples, body fluids (including, but not limited to, mucus, blood, plasma, serum, urine, saliva, and semen), cancer cells; and cancer tissue, but are not limited to these. Detection of the presence or absence of p53 in a sample may be performed using any suitable method for detecting p53 nucleic acid or protein, such as nucleic acid sequencing (e.g., DNA or RNA sequencing), quantitative PCR, Western blotting, or the like. Any combination can be used.
[0079] In some embodiments, one or more of the compounds described herein may be used to treat other types of cancer, including but not limited to acoustic neuroma, adenocarcinoma, adrenal cancer, anal cancer, angiosarcoma (e.g. , lymphangiosarcoma, intralymphatic sarcoma, intravascular sarcoma), appendiceal cancer, benign monoclonal gammopathy, biliary tract cancer (e.g., cholangiocarcinoma), bladder cancer, brain cancer (e.g., meningioma; tumors (e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchial carcinoma, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, colon Rectal cancer (e.g. colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial cancer, ependymoma, internal sarcoma (e.g. Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g. uterine cancer, uterine sarcoma), esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma, Ewing's sarcoma, ocular cancer (e.g., intraocular melanoma, retinoblastoma), familial hypereosinophilia, gallbladder cancer, gastric cancer (e.g. , gastric adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g. head and neck squamous cell carcinoma), oral cavity cancer (e.g. oral squamous cell carcinoma (OSCC), throat cancer (e.g. pharynx cancer) (laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer), hematopoietic cancer (e.g., leukemia such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B cell AML, T cell AML), chronic myeloid leukemia (CML) (e.g., B cell CML, T cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal margin marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma (e.g., "Waldenström macroglobulinemia"), hair cell Leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL, e.g. precursor T lymphoblastic lymphoma / leukemia, peripheral sexual T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathic type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); a combination of one or more of the above leukemias / lymphomas; and multiple myeloma (MM)); heavy chain diseases (e.g. alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, renal cancer (e.g. nephroblastoma, also known as Wilms tumor, renal cell cancer), liver cancer (e.g., hepatocellular carcinoma (HCC), malignant liver cancer), lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma), leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma, myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis). myeloid metaplasia (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), and chronic neutrophilic leukemia (CNL). ), hypereosinophilic syndrome (HES)), neuroblastoma, neurofibroma (e.g. type 1 or type 2 neurofibromatosis (NF), schwannomatosis), neuroendocrine cancer (e.g. gastrointestinal and pancreatic neuroendocrine tumors (GEP-NET), carcinoid tumors), osteosarcomas, ovarian cancers (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, penile cancer (e.g., Paget of the penis and scrotum). disease), pinealoma, primitive neuroectodermal tumor (PNT), prostate cancer (e.g., prostatic adenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer (e.g., squamous cell carcinoma (SCC) , keratoacanthocytoma (KA), melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g., appendiceal cancer), soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant Peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous gland carcinoma, sweat gland carcinoma, synovial tumor, testicular cancer (e.g. seminoma, testicular embryonal carcinoma), thyroid cancer (e.g. It is understood that the present invention may be useful in the treatment of cancers of the vulva (including papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma), urethral cancer, vaginal cancer, and vulvar cancer (eg, Paget's disease of the vulva).
[0080] In some embodiments, a method of treating cancer in a subject comprises administering to the subject a composition comprising a PRMT5 inhibitor, wherein treatment with the PRMT5 inhibitor reduces tumor growth of the cancer by more than about 25%, by about 50% %, more than about 75%, more than about 90% (eg, 25% to 50%, 50% to 75%, 75% to 90%, or 90% to 100%). In some embodiments, the method of treating cancer in a subject comprises administering to the subject a composition comprising a PRMT5 inhibitor, wherein the methyl mark of the cancer is greater than about 50%, greater than about 75%, about 80% % (for example, 50% to 75%, 50% to 80%, 80% to 90%, 80% to 100%, or 90% to 100%). Methyl marks refer to protein methylation, e.g. histone methylation (e.g. methylation of one or more lysines and / or arginines of a histone protein) or DNA methylation (e.g. epigenetic DNA methylation, e.g. methyl CpG site). In some embodiments, the methyl mark level of a cell is a measure of the extent to which histones are methylated (eg, at one or more specific lysine and / or arginine positions) in the cell.
[0081] Some methods of the invention involve the administration of a compound of the invention and an additional therapeutic agent (ie, a therapeutic agent other than the compound of the invention). Accordingly, compounds of the invention can be used in combination with at least one other therapeutic agent. Examples of further therapeutic agents include antibiotics, anti-emetics, anti-depressants, anti-fungals, anti-inflammatory agents, anti-neoplastic agents, anti-viral agents, cytotoxic and other anti-cancer agents, immunomodulators, alpha- These include, but are not limited to, interferons, β-interferons, alkylating agents, hormones and cytokines. In one embodiment, the invention encompasses the administration of additional therapeutic agents used to treat subjects with chronic heart failure or hypertension.
[0082] As described above, some methods of the invention involve administration of a compound of the invention and an additional therapeutic agent (ie, a therapeutic agent other than the compound of the invention). In some embodiments, the invention provides additional therapeutic agents used to treat a subject, acceptable salts thereof, tautomers thereof, pharmaceutically acceptable salts of tautomers, Includes the administration of any of the foregoing stereoisomers, or mixtures thereof, and additional therapeutic agents used to treat the subject with, for example, inhibitors of funny currents. In some embodiments, methods of use may include two or more additional therapeutic agents.
[0083] The invention will be further illustrated with reference to the following examples. These examples are intended to illustrate, but in no way limit, the claimed invention.
Example
[0084] Unless otherwise noted, all materials were obtained from commercial sources and used without further purification.
[0085] The following abbreviations are used to refer to various reagents and solvents:
[0086]
table 1
[0087] [Table 2]
[0088] [Table 3]
[0089] General synthesis scheme [ka] [ka] [ka] Method A: Compound I is prepared in Et in a solvent such as DMF or DMAc. 3 It can be prepared from the reaction of acid IA with a secondary amine IB-1 in the presence of a base such as N or DIPEA, an activating reagent such as HATU or PyBrOP. When using racemic amines or acids in Method A, chiral SFC can be used to separate stereoisomers, where stereochemistry was arbitrarily assigned to each isomer. Method B: Compound I is prepared in Et in a solvent such as THF or dioxane or DCM or DCE. 3 It can be prepared from the reaction of an acid chloride IC with a secondary amine IB in the presence of N or a base such as DIPEA or pyridine. Alternatively, compound I can be prepared from the reaction of acid chloride IC and secondary amine IB in the presence of DMAP in pyridine. When using racemic amines or acids in Method B, chiral SFC can be used to separate stereoisomers, where stereochemistry was arbitrarily assigned to each isomer. Method C: Compound I can be prepared by a small-scale, one-pot, two-step protocol as illustrated in General Scheme Method C. The primary amine 1D can be combined with the aldehyde 1E in the solvent specified by the method to obtain the secondary amine (Int-1) as a crude product after formation and reduction of the imine. The secondary amine (Int-1) was reacted with acid IA and specific coupling reagents to give product I after HPLC purification.
[0090] Analytical U / HPLC The following equipment was used for analytical UHPLC: Waters Acquity system with Acquity BEH C18 (1.7 μm, 2.1x50 mm) with linear gradient of binary solvent system using 0.5 mL / min flow rate and DAD at ambient temperature, combined with MS detection SQD I. Use linear slope (H 2 O / CH 3 CN / HCO 2 H(95 / 5 / 0.1%~0 / 100 / 0.1%)). Agilent Infinity I / II-TOF6230B / CLND Antek 8060 with Acquity BEH C18 (1.7μm, 2.1x50mm) with a linear gradient of binary solvent system using a flow rate of 0.75mL / min, combined with DAD. Use linear slope (H 2 O / MeOH / HCO 2 H(95 / 5 / 0.1%~0 / 100 / 0.1%)).
[0091] Preparative HPLC For preparative HPLC, the following equipment was used: linear gradient of a binary solvent system using a flow rate of 4-7 mL / min and UV detection at 254 nm, combined with MS detection on a Shimadzu LCMS-2020. Shimadzu Nexera X2 with Merck Chromolith SpeedROD RP-18E (5μm, 10x100mm). Use linear slope (H 2 O / MeOH / HCO 2 H(95 / 5 / 0.1%~0 / 100 / 0.1%)).
[0092] intermediate Intermediate 1: 6-(2,2,2-trifluoroethoxy)pyridazine-3-carbaldehyde [ka]
[0093] Step 1. A microwave vial was charged with 3-chloro-6-methylpyridazine (1.00 g, 7.78 mmol), potassium carbonate (2.150 g, 15.56 mmol), and 1,4-dioxane (14.0 mL). 2,2,2-trifluoroethanol (2.334 g, 1.704 mL, 23.34 mmol) was added to the resulting suspension and the mixture was heated to 140° C. in the microwave for 14 hours. After cooling to 23 °C, the reaction mixture was converted to CH 2 Cl 2 (30mL), H 2 O (20 mL) and saturated NH 4 Transfer to a separatory funnel with aqueous Cl (30 mL), separate the layers, and remove the aqueous layer with CH 2 Cl 2 (2x20mL). The combined organic layer was diluted with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated to dryness. The resulting crude residue was purified by flash chromatography (0-100% 3:1 EtOAc:EtOH in heptane) to give 3-methyl-6-(2,2,2-trifluoroethoxy)pyridazine (662 mg, 3.45 mmol). , yield 44.3%) as a pale yellow solid. m / z(ESI):193.2(M+H) + .
[0094] Step 2. In a vial, add 3-methyl-6-(2,2,2-trifluoroethoxy)pyridazine (662 mg, 3.45 mmol), selenium dioxide (612 mg, 5.51 mmol), and 1,4-dioxane (13.8 mL). filled with. The resulting mixture was flushed with nitrogen for 10 minutes, after which the vial was heated to 110°C. After 1.5 hours, the reaction mixture was cooled to 23° C., filtered through a 1 cm pad of celite (30 mL 3:1 EtOAc:EtOH eluent), and concentrated to dryness. The resulting crude residue was purified by flash chromatography (0-50% 3:1 EtOAc:EtOH in heptane) to give 6-(2,2,2-trifluoroethoxy)pyridazine-3-carbaldehyde (1,154.7 mg, 0.751 mmol, yield 21.8%) was obtained as a pale yellow solid. m / z(ESI):207.1(M+H) + .
[0095] Intermediate 2: 2-Methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)propan-1-amine. [ka]
[0096] Acetic acid (1.11 g, 18.48 mmol) was added at room temperature. The mixture was stirred at room temperature for 30 minutes and then treated with sodium triacetoxyborohydride (5.49g, 25.9mmol, Aldrich). The mixture was stirred at room temperature for 1 h, then saturated Na 2 C.O. 3 Neutralized with aqueous solution. The layers were separated and the aqueous layer was extracted with DCM. The combined organic phase was 2 S.O. 4 and concentrated in vacuo. The crude material was purified by silica gel chromatography (0-100% EtOAc / EtOH in heptane (3 / 1)) to give 2-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)propane. -1-amine (2, 2.81 g, 70% yield) was obtained as a brown oil. m / z(ESI):233.0(M+H) + . 1 HNMR(400MHz,chloroform-d)δ ppm 8.81(s,1H),7.88(dd,J=8.1,2.1Hz,1H),7.50(d,J=8.1Hz,1H),3.98(s,2H), 2.46(d,J=6.6Hz,2H),1.73-1.84(m,2H),0.94(d,J=6.6Hz,6H). 19 FNMR(376MHz,chloroform-d)δ ppm -62.26(s,3F).
[0097] The secondary amines of Table 1 were prepared in a similar manner as described for Intermediate 2.
[0098] [Table 4]
[0099] [Table 5]
[0100] [Table 6]
[0101] [Table 7]
[0102] [Table 8]
[0103] [Table 9]
[0104] [Table 10]
[0105] [Table 11]
[0106] Intermediate 97: N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine -8-amine [ka]
[0107] 5-(trifluoromethyl)picolinaldehyde (534 mg, 3.05 mmol, Chemshuttle) and 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-amine (430 mg, To a stirred mixture of 3.11 mmol, Enamine) in DCM (8 mL) was added triethylamine (315 mg, 0.437 mL, 3.11 mmol, Sigma-Aldrich Corporation) followed after 5 minutes by glacial acetic acid (224 mg, 0.216 mL, 3.73 mmol). , Sigma-Aldrich Corporation). After stirring the resulting mixture at room temperature for 15 minutes, sodium triacetoxyborohydride (857 mg, 4.05 mmol, Sigma-Aldrich Corporation) was added as a solid in one portion. The resulting mixture was stirred at room temperature for 25 minutes. The crude mixture was loaded directly onto a silica gel precolumn (25 g) and subjected to combi-flash column chromatography using a 24 g ISCO gold column eluting with MeOH (containing 0.5% ammonium hydroxide) / DCM (1-20%), followed by combiflash column chromatography with toluene. After azeotroping, N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine -8-amine (350 mg, 1.177 mmol, 37.8% yield) was obtained as a colorless oil. m / z(ESI):298.2(M+H) + . 1 HNMR (400MHz, chloroform-d) δ8.78(d,J=1.05Hz,1H),7.81-7.89(m,2H),7.50(d,J=8.15Hz,1H),4.09-4.29(m,4H) ),3.97-4.06(m,2H),2.12-2.33(m,2H),1.83-2.04(m,2H). 19 FNMR(376MHz,chloroform-d)δ-62.34(s,3F).
[0108] The secondary amines in Table 2 were prepared in a similar manner as described for Intermediate 97. 106-109 were derived from commercially available chiral amines.
[0109] [Table 12]
[0110] [Table 13]
[0111] Intermediate 110: (R)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1-amine. [ka]
[0112] Step 1. (5-(trifluoromethyl)pyridin-2-yl)methanamine hydrochloride (115 g, 541 mmol) and 1-(pyrimidin-2-yl)ethan-1-one (76 g, 622 mmol) in DCM (3.5 Potassium acetate (63.7 g, 649 mmol) was added to the stirring solution in L). The mixture was stirred at room temperature for 30 minutes and then treated with sodium triacetoxyborohydride (149g, 703mmol). After stirring for 1.5 hours, the reaction mixture was diluted with water (2L), treated with 1N HCl (2L), and extracted with DCM (1L). The layers were separated. The aqueous layer was treated with 10% sodium hydroxide to adjust the pH to 12 and extracted with DCM (3x2L). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated. The crude material was purified by silica gel chromatography (2% MeOH in DCM) to give 1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1- The amine (101.97 g, 344 mmol, 63% yield) was obtained as a brown oil. m / z(ESI):283.0(M+H) + . 1 HNMR (400MHz, chloroform-d): δ ppm 8.81(dt,J=2.2,1.0Hz,1H),8.74(d,J=4.9Hz,2H),7.88(dd,J=8.2,2.3Hz,1H) ,7.54(d,J=8.2Hz,1H),7.20(t,J=4.9Hz,1H),4.10(q,J=6.8Hz,1H),3.94(d,J=2.9Hz,2H),1.53 (d,J=6.8Hz,3H).
[0113] Step 2. Dissolve racemic secondary amine 110 (44 g) in 200 mL of MeOH and use a Chiralpak AD-H column (250x30 mm, 5 μ) with mobile phase of 90% liquid CO 2 and subjected to chiral SFC using 10% EtOH, 0.5% DEA, flow rate 100 mL / min. The first eluting peak was (S)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethan-1-amine (111, 18 g, > 99% ee), and the second eluting peak was (R)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1- Amine (112, 19g, >99% ee).
[0114] The racemic amines of Table 3 were prepared in a similar manner as described above for amine 110. Racemic amines were subjected to chiral SFC to yield enantiomerically pure amines (>99% ee).
[0115] [Table 14]
[0116] Intermediate 125: (R)-N-((6-methoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethane-1-amine. [ka]
[0117] Step 1. 6-methoxy-pyridazine-3-carbaldehyde (0.49 g, 3.54 mmol, Princeton BioMolecular Research, Inc.) and 1-(pyrimidin-2-yl)ethane-1-amine dihydrochloride (0.73 g, 3.72 mmol) , Enamine), 1,2-dichloroethane (30 mL), and acetic acid (0.22 mL, 3.90 mmol) was stirred at room temperature for 10 minutes, then sodium triacetoxyborohydride (1.013 g, 4.78 mmol) was added. added. The mixture was stirred at room temperature for 30 min, then saturated Na 2 C.O. 3 Neutralized with aqueous solution. The crude was extracted with DCM. organic phase with Na 2 S.O. 4 and concentrated in vacuo. The residue was purified by silica gel chromatography (30-100% EtOAc / EtOH in heptane (3 / 1)) to give N-((6-methoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl) Ethan-1-amine (125, 0.84 g, 96% yield) was obtained as an orange oil. m / z(ESI):246(M+H) + .
[0118] Step 2. Racemic amine 125 was added to 70% liquid CO using a flow rate of 150 mL / min. 2 and 30% MeOH (containing 0.2% TEA) as the mobile phase and subjected to chiral SFC using a Chiral Technologies IC column (250x30 mm, 5 μm). The first eluting peak was (R)-N-((6-methoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethane-1-amine (126, 369 mg, >99% ee) Met. The second eluting peak was (S)-N-((6-methoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine (127, 374 mg, >99% ee) Met.
[0119] The racemic amines of Table 4 were prepared in a similar manner as described above for amine 125. Racemic amines were subjected to chiral SFC to yield enantiomerically pure amines (>99% ee).
[0120] [Table 15]
[0121] The secondary amines in Table 5 were prepared in a similar manner as described for amine 125 and derived from commercially available enantiomerically pure reagents.
[0122] [Table 16]
[0123] Intermediate 153: N-(1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)cyclopropanamine [ka]
[0124] Step 1.1-(5-(trifluoromethyl)pyridin-2-yl)ethan-1-one (0.71 g, 3.75 mmol, Enamine), 1,2-dichloroethane (20 mL) and cyclopropanamine (0.257 g, 4.50 mmol) Titanium(IV) isopropoxide (1.280 g, 1.334 mL, 4.50 mmol, Aldrich) was added to the mixture of 100 mg, Acros). The mixture was stirred at room temperature overnight, then MeOH (2 mL) was added followed by sodium borohydride (0.142 g, 3.75 mmol, Aldrich). The mixture was stirred for 30 minutes until LCMS showed product. Saturate the mixture with Na 2 C.O. 3 It was basified with aqueous solution and extracted with EtOAc. organic phase with Na 2 S.O. 4 Dry on top, filter and concentrate in vacuo. The residue was purified by silica gel chromatography: 0-100% EtOAc in heptane. The racemic product (153, 631 mg, 73% yield) was obtained as a pale yellow oil. m / z(ESI):231(M+H) +
[0125] Step 2. Oil, 90% liquid CO 2 and purified by Prep SFC using a 2x Chiralpak IG column (250x21 mm, 5 μm) with a mobile phase of 10% heptane EtOH (15:85, v:v) using a flow rate of 70 mL / min. The first eluting peak was assigned (S)-N-(1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)cyclopropanamine (154, 198 mg, 97.72% ee). The second eluting peak was assigned (R)-N-(1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)cyclopropanamine (155, 188 mg, 98.9% ee). Absolute stereochemistry was assigned arbitrarily.
[0126] The secondary amines in Table 6 were prepared in a similar manner as described for amine 153.
[0127] [Table 17]
[0128] [Table 18]
[0129] Intermediate 171: 1-(2-fluoro-6-(trifluoromethyl)pyridin-3-yl)-N-methylmethanamine [ka]
[0130] Step 1. In a resealable vial, combine 3-bromo-2-fluoro-6-(trifluoromethyl)pyridine (0.600 g, 2.385 mmol) in 1,4-dioxane (5.96 mL) and water (1.988 mL). block) and potassium vinyltrifluoroborate (0.639 g, 4.77 mmol, Oakwood Products, Inc.). Potassium carbonate (1.319 g, 9.54 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture. The reaction mixture was flushed with argon (gas) for 5 min, then [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.044 g, 0.060 mmol, Sigma-Aldrich Corporation) was added to the reaction mixture. Ta. The vial was sealed and the entire reaction mixture was then stirred and heated at 80° C. for 16 hours. The reaction mixture was diluted with EtOAc, filtered through a pad of celite, and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column eluting with a gradient of 0-15% EtOAc in heptane to give 2-fluoro-6-(trifluoromethyl)-3. -vinylpyridine (0.206 g, 1.078 mmol, 45.2% yield) was obtained as a pale yellow oil. 1 HNMR(400MHz,chloroform-d)δ ppm 8.05(t,J=8.4Hz,1H),7.59(dd,J=7.7,1.3Hz,1H),6.83(dd,J=17.8,11.3Hz,1H), 6.05(d,J=17.8Hz,1H),5.67(d,J=11.3Hz,1H).m / z(ESI):192.3(M+H) + .
[0131] Step 2. In a 100 mL round bottom flask, add 2-fluoro-6-(trifluoromethyl)-3-vinylpyridine (1.176 g, 6.15 mmol) in acetone (25.6 mL) / water (5.13 mL) (5:1). did. To this mixture were added potassium osmate (vi) dihydrate (0.227 g, 0.615 mmol, Acros Organics) and 4-methylmorpholine n-oxide (2.52 g, 21.54 mmol, Sigma-Aldrich Corporation). The entire reaction mixture was purified with inert (N 2 ) atmosphere at room temperature for 45 minutes. The reaction mixture was quenched by the addition of solid sodium sulfite (700 mg) and the mixture was stirred for 15 minutes. The reaction mixture was partially concentrated in vacuo (to remove acetone). The mixture was diluted with EtOAc and brine. The layers were separated and the aqueous layer was extracted with EtOAc. Combine organics and MgSO 4 dried, filtered and concentrated in vacuo. The crude residue was used in the next step of the synthesis without further purification.
[0132] The crude diol was diluted with THF (25 mL) and then sodium periodate (meth) (3.95 g, 18.46 mmol, Sigma-Aldrich Corporation) and water (3 mL) were added to the mixture. The resulting reaction mixture was inert (N 2 ) Stirred under atmosphere for 2.5 hours. The reaction mixture was diluted with a mixture of EtOAc / heptane (1:1) (36 mL). The mixture was stirred in a sonicator for 1 minute. The mixture was filtered and the filtrate was collected. NaHCO mixture 3 Diluted with saturated aqueous solution (36 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3x). The combined organic extracts were washed with aqueous brine (twice), then MgSO 4 Dry on top, filter and concentrate in vacuo. This material was used in the next step of the synthesis without further purification to prevent degradation. 1 HNMR (400MHz, chloroform-d) δ ppm 10.29-10.51(m,1H),8.44-8.66(m,1H),7.67-7.88(m,1H).
[0133] Step 3. In an oven-dried 100 mL round bottom flask, add 2-fluoro-6-(trifluoromethyl)nicotinaldehyde (0.200 g, 1.036 mmol), titanium(IV) isopropoxide (0.368 g, 0.379 mL, 1.295 mmol) A 2.0 M solution of methylamine in tetrahydrofuran (1.036 mL, 2.071 mmol, Sigma-Aldrich Corporation) in dichloromethane (2.59 mL) was added. The reaction mixture was stirred at room temperature overnight. Methanol (2.59 mL) was then added, the mixture was cooled to 0° C., and sodium borohydride (0.047 g, 1.243 mmol, Sigma-Aldrich) was slowly added to the reaction mixture. The entire reaction mixture was stirred at room temperature for 16 hours, then the reaction mixture was concentrated in vacuo. The crude material was absorbed onto a silica gel plug and CH 2 Cl 2 Purified by chromatography on a Redi-Sep packed silica gel column (40 g) eluting with a gradient of 0-25% MeOH in medium. This gave 1-(2-fluoro-6-(trifluoromethyl)pyridin-3-yl)-N-methylmethanamine (0.052 g, 0.250 mmol, 24.12% yield) as a tan oil. 1 HNMR(400MHz,DMSO-d 6 )δ ppm 8.24(t,J=8.3Hz,1H),7.78-7.93(m,1H),3.76(s,2H),3.29(brs,1H),2.21-2.41(m,3H).m / z (ESI):209.2(M+H) +
[0134] Intermediate 172: N-(oxazol-4-ylmethyl)cyclobutanamine [ka]
[0135] Cyclobutylamine (176 mg, 0.21 mL, 2.47 mmol) and 1,3-oxazole-4-carbaldehyde (240 mg, 2.47 mmol) were dissolved in dichloromethane (5 mL), and acetic acid ice (29.7 mg, 0.029 mL, 0.494 mmol) was added. Added. The mixture was stirred at room temperature for 30 minutes, then methanol (5.00 mL) was added and the solution was cooled to 0°C. Sodium borohydride (112 mg, 3.00 mmol) was added in portions and the mixture was slowly warmed to room temperature. After 16 h, the volatiles were removed in vacuo, the crude product was absorbed onto silica gel, and the mixture was purified via column chromatography (0-20% MeOH / DCM in 8 min) to give N-(oxazole- 4-ylmethyl)cyclobutanamine (206 mg, 1.35 mmol, 54.7% yield) was obtained as a colorless oil. m / z(ESI):153.3(M+H) + .
[0136] The secondary amines in Table 7 were prepared in a similar manner as described for amine 172.
[0137] [Table 19]
[0138] Intermediate 176: 2-((methylamino)methyl)-5-(pentafluoro-l6-sulfanyl)phenol [ka]
[0139] Step 1. To a solution of 3-(pentafluoro-l6-sulfanyl)phenol (2.5 g, 11.36 mmol, Aurum Pharmatech) in trifluoroacetic acid (20 mL) was added hexamethylenetetramine (HMTA) (2.229 g, 15.90 mmol, Combi-Blocks Inc). .) and stirred at 80°C for 4 hours. Water (40 mL) was added to the reaction mixture and the reaction was stirred for an additional 30 minutes at room temperature. The reaction mixture was extracted with EtOAc (2x40mL). Saturate the organic extract with NaHCO 3 Wash with aqueous solution, water and brine, Na 2 S.O. 4 dried with. The solution was filtered and concentrated in vacuo to give the crude material as a colorless oil. The crude product was absorbed onto a silica gel plug and purified by chromatography on a Redi-Sep packed silica gel column (40 g) eluting with a gradient of 0-50% EtOAc in heptane to give 2-hydroxy-4-(pentafluoro-l6 -sulfanyl)benzaldehyde (1.176 g, 4.74 mmol, 41.7% yield) was obtained as a colorless oil. m / z(ESI):248.9(M+H) + . 1 H NMR(400MHz, CDCl 3 )δ 11.06(s,1H),10.00(s,1H),7.71(dd,J=8.2,0.8Hz,1H),7.40-7.45(m,2H). 19 F NMR(376MHz,DMSO-d 6 )δ ppm 57.10(s),56.70(s)
[0140] Step 2. A solution of 2-hydroxy-4-(pentafluoro-l6-sulfanyl)benzaldehyde (300 mg, 1.209 mmol) in dichloromethane (5 mL) is treated with a methylamine solution (2.0 M in tetrahydrofuran, 1.813 mL, 3.63 mmol, Sigma Aldrich). and stirred at room temperature for 3 hours. The resulting mixture was concentrated to dryness to obtain (E)-2-((methylimino)methyl)-5-(pentafluoro-l6-sulfanyl)phenol as a yellow solid. The above material was dissolved in dichloromethane (5 mL) / methanol (2 mL) and treated with sodium borohydride (45.7 mg, 1.209 mmol, Sigma Aldrich) at room temperature and stirred for 30 minutes. The reaction mixture was diluted with brine and extracted with EtOAc. The organic extract was washed with saturated aqueous NaCl solution and 2 S.O. 4 dried on top. The solution was filtered and concentrated in vacuo to give the crude material as a yellow oil. The crude product was absorbed onto a plug of silica gel, 0%-100% EtOAc in heptane, then 10% MeOH (2M NH 3 Purification by chromatography on a Redi-Sep prepacked silica gel column (24 g) eluting with a gradient of 2-((methylamino)methyl)-5-(pentafluoro-l6-sulfanyl)phenol (142 mg, 0.539 mmol) , yield 44.6%). m / z(ESI):264.0(M+H) + . 1 H NMR(400MHz,DMSO-d 6 )δ 7.30(d,J=8.4Hz,1H),7.15-7.23(m,1H),7.11(d,J=2.3Hz,1H),6.29(brs,1H),4.14(s,1H),3.84 (s,2H),2.30(s,3H).
[0141] Intermediate 177: (R)-1-(5-(difluoromethyl)pyridin-2-yl)-N-ethylethan-1-amine [ka]
[0142] Step 1. In an oven-dried 100 mL round bottom flask, add (R)-(+)-2-methyl-2-propanesulfinamide (0.310 g, 2.56 mmol, AK Scientific, Inc.) in dichloromethane (5.12 mL). was added. To this mixture was added copper(ii) sulfate (0.816 g, 5.12 mmol, Sigma-Aldrich Corporation) followed by 5-(difluoromethyl)-2-pyridinecarboxaldehyde (0.402 g, 2.56 mmol, Enamine). did. The resulting reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was filtered through a pad of celite and the filter cake was washed with DCM. The filtrate was collected and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column (80 g), eluting with a gradient of 0-30% EtOAc:EtOH in heptane (3:1) to give (R ,E)-N-((5-(difluoromethyl)pyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (0.660 g, 2.54 mmol, 99% yield) was obtained as a pale yellow solid. Ta. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.97(s,1H),8.54(s,1H),8.19-8.25(m,2H),7.25(t,J=55.0Hz,1H),1.23(s,9H).m / z(ESI ):261.0(M+H) + .
[0143] Step 2. In an oven-dried 100 mL two-neck round bottom flask, add (R,E)-2-methyl-N-((5-(difluoromethyl)pyridin-2-yl)methylene in tetrahydrofuran (10.78 mL). ) Propane-2-sulfinamide (0.600 g, 2.31 mmol) was added. The reaction mixture was cooled to −78° C. and then methylmagnesium chloride (3.0M in THF) (1.294 mL, 3.88 mmol, Oakwood Chemicals) was added dropwise to the reaction mixture. After 10 minutes, saturated NH 4 The reaction was quenched by the addition of aqueous Cl (5.8 mL) and extracted with EtOAc (3x25 mL). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a silica gel column eluting with a gradient of 0-80% EtOAc in heptane to yield both diastereomers. Peak 1 was converted to N-((R)-1-(5-(difluoromethyl)pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (0.361 g, 1.306 mmol, yield) as a pale yellow solid. rate of 60.6%) and was arbitrarily assigned. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.68-8.74(m,1H),8.02(d,J=8.5Hz,1H),7.70(d,J=8.2Hz,1H),7.14(t,J=55.3Hz,1H),5.83( d,J=7.9Hz,1H),4.51(quin,J=7.1Hz,1H),1.44(d,J=6.9Hz,3H),1.14(s,9H).m / z(ESI):277.1( M+H) + .Peak 2 was identified as N-((S)-1-(5-(difluoromethyl)pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (0.232 g, 0.840 mmol, yield) as a white solid. rate of 38.9%) and was arbitrarily assigned. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.71(s,1H),8.02(d,J=8.5Hz,1H),7.70(d,J=8.2Hz,1H),7.14(t,J=55.4Hz,1H),5.83(d, J=7.7Hz,1H),4.51(quin,J=7.1Hz,1H),1.44(d,J=6.9Hz,3H),1.14(s,9H).m / z(ESI):277.1(M+ H) + .
[0144] Step 3. In a 100 mL round bottom flask, add (S)-N-((R)-1-(5-(difluoromethyl)pyridin-2-yl)ethyl)-2-methyl in 1,4-dioxane (8.81 mL). Propane-2-sulfinamide (0.365 g, 1.321 mmol) and hydrogen chloride solution, 4.0 M dioxane solution (0.413 mL, 1.651 mmol, Sigma-Aldrich Corporation) were added. The resulting reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated in vacuo. The crude residue was carried on to the next step of the synthesis without further purification. m / z(ESI):173.0(M+H) + .
[0145] Step 4. In a 50 mL round bottom flask, add (R)-1-(5-(difluoromethyl)pyridin-2-yl)ethane-1-amine hydrochloride (0.276 g, 1.323 mmol) in methanol (6.61 mL) and Acetaldehyde (0.117g, 0.148mL, 2.65mmol, Acros Organics) was added. The reaction mixture was cooled to 0° C. and then titanium(IV) isopropoxide (0.470 g, 0.485 mL, 1.654 mmol, Sigma-Aldrich) was added. The resulting mixture was stirred at room temperature for 5 minutes. Sodium borohydride (0.300 g, 7.94 mmol, Sigma-Aldrich) was then added slowly to the reaction mixture. An additional aliquot of acetaldehyde (0.117g, 0.148mL, 2.65mmol, Acros Organics) was added to the reaction mixture and stirred for an additional 10 minutes. Saturate the reaction mixture with NaHCO 3 (0.5 mL) aqueous solution and stirred for 5 min, which was then combined with MgSO 4 and filtered through a Celite pad. The filtrate was collected and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and CH 2 Cl 2 Purification by chromatography eluting with a gradient of 0-30% MeOH in medium yields (R)-1-(5-(difluoromethyl)pyridin-2-yl)-N-ethylethan-1-amine (0.200 g, 0.999 mmol, (yield 76%) was obtained as an off-white solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.72-8.80(m,1H),8.00-8.07(m,1H),7.60-7.69(m,1H),7.15(t,J=55.3Hz,1H),7.14(brt,J=55.4Hz ,1H),4.13-4.17(m,1H),2.56-2.67(m,1H),2.41-2.49(m,1H),1.04-1.10(m,3H),0.82-0.92(m,3H).m / z(ESI):201.1(M+H) + .
[0146] The secondary amines in Table 8 were prepared in a similar manner as described for amine 177. Secondary amines 178 and 179 were replaced with commercially available chiral primary amines, (R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethanamine hydrochloride (CAS#1948236-91-6) and Each was synthesized starting from step 4 from (R)-1-(5-(trifluoromethyl)pyridin-2-yl)ethane-1-amine hydrochloride (CAS#1956437-55-0).
[0147] [Table 20]
[0148] Intermediate 181: 1-(3,5-difluoropyridin-2-yl)-N-methylethane-1-amine [ka]
[0149] Step 1. In a 100 mL round bottom flask, add 1-(3,5-difluoropyridin-2-yl)ethanamine hydrochloride (0.250 g, 1.285 mmol, Combi-Blocks Inc.) in 1,2-dichloroethane (6.42 mL). and di-tert-butyl dicarbonate (0.421 g, 0.447 mL, 1.927 mmol, Oakwood Products, Inc.). Triethylamine (0.520 g, 0.722 mL, 5.14 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture and the whole mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (5 mL) and saturated aqueous NaHCO 3 (5 mL). The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified with a gradient of 0-25% EtOAc in heptane to give tert-butyl (1-(3,5-difluoropyridin-2-yl)ethyl)carbamate (0.300 g, 1.162 mmol, yield 90%) was obtained as an off-white solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.46(d,J=1.9Hz,1H),7.87(t,J=9.6Hz,1H),7.21(brd,J=7.5Hz,1H),4.81-4.98(m,1H),1.34( brd,J=5.9Hz,9H),1.31-1.33(m,3H).m / z(ESI):259.1(M+H) + .
[0150] Step 2. To a 100 mL round bottom flask was added tert-butyl (1-(3,5-difluoropyridin-2-yl)ethyl)carbamate (0.300 g, 1.162 mmol) in tetrahydrofuran (5.81 mL). The mixture was cooled to 0° C. and then sodium hydride (60% dispersion in mineral oil) (0.058 g, 1.452 mmol, Oakwood Products, Inc.) was added to the reaction mixture. The resulting mixture was stirred at 0° C. for 20 minutes, then iodomethane (0.198 g, 0.198 mL, 1.394 mmol, Sigma-Aldrich Corporation) was added dropwise to the mixture. The reaction mixture was stirred for an additional 20 minutes and the temperature was maintained at 0° C., then the mixture was stirred at room temperature overnight. The reaction mixture was quenched with MeOH and concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified by chromatography on a Redi-Sep prepacked silica gel column (40 g) eluting with a gradient of 0-30% EtOAc in heptane to give tert-butyl (1-(3,5-difluoro) Pyridin-2-yl)ethyl)(methyl)carbamate (0.287 g, 1.054 mmol, 91% yield) was obtained as a pale yellow oil. 1 H NMR(400MHz,chloroform-d)δ ppm 8.31(d,J=2.3Hz,1H),7.18(ddd,J=9.4,8.3,2.4Hz,1H),5.63(brs,1H),2.75(brs, 3H),1.53-1.57(m,3H),1.47(s,9H).m / z(ESI):295.3(M+Na) + .
[0151] The residue was dissolved in dichloromethane (5.81 mL) and treated with trifluoroacetic acid (1.324 g, 0.866 mL, 11.62 mmol, Sigma-Aldrich Corporation). The reaction mixture was stirred at room temperature for 1 hour, at which time it was concentrated in vacuo. The residue was diluted with DCM, then saturated NaHCO 3 Treated with aqueous solution. The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. This gave 1-(3,5-difluoropyridin-2-yl)-N-methylethane-1-amine (0.109 g, 0.633 mmol, 54.5% yield) as a pale yellow oil. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.50(d,J=2.3Hz,1H),7.87(ddd,J=10.0,9.2,2.3Hz,1H),3.98(qd,J=6.7,1.4Hz,1H),3.25-3.34(m ,1H),2.14(s,3H),1.26-1.30(m,3H).m / z(ESI):173.2(M+H) + .
[0152] The secondary amines of Table 9 were prepared in a similar manner to steps 1-2 described for amine 181. The chiral primary amine used in Step 1 was synthesized in the same manner as in Steps 1 to 3 of Example 177 above.
[0153] [Table 21]
[0154] Intermediate 185: 1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-N-methylmethanamine [ka]
[0155] In an oven-dried 100 mL round bottom flask were added 3-fluoro-5-(trifluoromethyl)picolinaldehyde (0.300 g, 0.300 mL, 1.554 mmol, Combi-Blocks Inc.) and 2,2,2-trifluoroethanol ( A solution of 2.0 M methylamine in tetrahydrofuran (1.554 mL, 3.11 mmol, Sigma-Aldrich Corporation) in 4.09 mL) was added. The reaction mixture was stirred at room temperature for 4 hours. Then, after cooling the mixture to 0° C., sodium borohydride (0.071 g, 1.864 mmol, Sigma-Aldrich) was slowly added to the reaction mixture. The entire reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column eluting with a gradient of 0-20% MeOH in DCM to give 1-(3-fluoro-5-(trifluoromethyl). )pyridin-2-yl)-N-methylmethanamine (0.190 g, 0.913 mmol, 58.8% yield) was obtained as a yellow oil. m / z(ESI):209.2(M+H) + .
[0156] The secondary amines in Table 10 were prepared in a similar manner as described for amine 185.
[0157] [Table 22]
[0158] Intermediate 188: N-methyl-1-(6-(1-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methanamine [ka]
[0159] Step 1. In a 100 mL round bottom flask, add 1-(6-bromopyridazin-3-yl)-N-methylmethanamine (0.320 g, 1.584 mmol) and di-tert- in 1,2-dichloroethane (7.92 mL). Butyl dicarbonate (0.518g, 0.552mL, 2.376mmol, Oakwood Products, Inc.) was added. Triethylamine (0.641 g, 0.890 mL, 6.33 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture and the entire mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (5 mL) diluted with aqueous solution. The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified with a gradient of 0-60% EtOAc in heptane to yield tert-butyl((6-bromopyridazin-3-yl)methyl)(methyl)carbamate (0.400 g, 1.324 mmol, (Yield: 84%) was obtained as a pale yellow oil. 1 H NMR(400MHz,chloroform-d)δ ppm 7.65(brd,J=8.8Hz,1H),7.30-7.51(m,1H),4.71(s,2H),2.94(brs,3H),1.49(brs, 9H).m / z(ESI):302.0(M+H) + .
[0160] Step 2. In a resealable vial, add tert-butyl((6-bromopyridazin-3-yl)methyl)(methyl)carbamate (0.200 g, 0.662 mmol), 4-(4,4,5,5-tetra Methyl-1,3,2-dioxaborolan-2-yl)-1-(trifluoromethyl)-1h-pyrazole (0.347g, 0.347mL, 1.324mmol, Enamine) and tribasic potassium phosphate (0.421g, 1.986 mmol, Sigma-Aldrich Corporation) was added into a mixture of toluene (2.98 mL) / water (0.331 mL). The reaction mixture was flushed with argon (gas) for 5 minutes, then tricyclohexylphosphine (0.074 g, 0.265 mmol, Strem Chemicals, Inc.) followed by palladium(II) acetate (0.030 g, 0.132 mmol, Sigma-Aldrich Corporation). was added to the reaction mixture and the vial was sealed. The reaction mixture was stirred and heated at 90° C. for 16 h, at which point it was cooled to room temperature, then diluted with EtOAc and filtered through a pad of celite. The organic filtrate was collected and then concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified by chromatography on a packed silica gel column eluting with a gradient of 0-45% EtOAc in heptane to yield tert-butylmethyl ((6-(1-(trifluoromethyl)-1H- Pyrazol-4-yl)pyridazin-3-yl)methyl)carbamate (0.078 g, 0.218 mmol, 33.0% yield) was obtained as a tan oil.
[0161] Step 3. In a 50 mL round bottom flask, add tert-butylmethyl ((6-(1-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl) in 1,2-dichloroethane (1.6 mL). Carbamate (0.060 g, 0.168 mmol) and trifluoroacetic acid (0.191 g, 0.191 mL, 1.679 mmol, Apollo Scientific Ltd.) were added. The whole mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo. The crude product was used in the next step of the synthesis without further purification. m / z(ESI):258.2(M+H) + .
[0162] The secondary amines in Table 11 were prepared in a similar manner as described for amine 188.
[0163] [Table 23]
[0164] Intermediate 191: (R)-N-methyl-1-(6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)ethane-1-amine [ka]
[0165] Step 1. In an oven-dried 100 mL round bottom flask, add (R)-(+)-2-methyl-2-propanesulfinamide (1.220 g, 10.07 mmol, AK Scientific, Inc.) in dichloromethane (20.13 mL). was added. To this mixture was added copper(ii) sulfate (3.21 g, 20.13 mmol, Sigma-Aldrich Corporation) followed by 6-bromopyridazine-3-carbaldehyde (1.882 g, 10.07 mmol, PharmaBlock Sciences). The resulting reaction mixture was stirred at room temperature for 24 hours, at which point it was filtered through a pad of celite and the filter cake was washed with 1:1 EtOAc:heptane. The filtrate was collected and concentrated in vacuo. The crude material was triturated with EtOAc and heptane. The solid was collected and dried in a vacuum oven for an additional 2 hours. This produced (R,E)-N-((6-bromopyridazin-3-yl)methylene)-2-methylpropane-2-sulfinamide (1.667 g, 5.74 mmol, yield 57.1%) as a yellowish brown solid. obtained as. 1 H NMR(400MHz,chloroform-d)δ ppm 9.00(s,1H),8.04(brd,J=8.8Hz,1H),7.80(brd,J=8.8Hz,1H),1.32(s,9H).m / z(ESI):314.0(M+Na) + .
[0166] Step 2. In an oven-dried 150 mL three-neck round-bottom flask equipped with an internal temperature probe, add (R,E)-N-((6-bromopyridazin-3-yl)methylene)-2 in tetrahydrofuran (28.7 mL). -Methylpropane-2-sulfinamide (1.667g, 5.74mmol) was added. The reaction mixture was cooled to −78° C., then methylmagnesium chloride (3.45 mL, 10.34 mmol, Oakwood) was added dropwise to the reaction mixture. (Note: The addition of the Grignard reagent was added slowly enough that the temperature of the reaction mixture did not warm above -70°C.) After the addition, the entire reaction mixture was stirred for an additional 20 min while maintaining the temperature at -78°C. Stirred. Then saturated NH 4 The reaction was quenched at −70° C. while adding aqueous Cl (30 mL). The mixture was warmed to room temperature and extracted with EtOAc (3x100mL). The combined organic extracts were washed with brine, then MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and passed through an Intertim (15 micron) silica gel column (120 grams) with a gradient of 0-100% EtOAc in heptane, then 0-50% EtOAc in heptane:EtOH (3:1). The mixture of both diastereomers was purified by chromatography eluting with a gradient of (R)-N-((R)-1-(6-bromopyridazin-3-yl)ethyl)-2-methylpropane-2- Sulfinamide (0.657 g, 2.146 mmol, 37.3% yield) as a tan solid and (R)-N-((S)-1-(6-bromopyridazin-3-yl)ethyl)-2-methyl Propane-2-sulfinamide (0.067 g, 0.219 mmol, 3.81% yield) was obtained as a tan solid. The stereochemistry of the major isomers was assigned similarly to Kuduk, et al. Tet. Lett. 2004, 45(35), 6641. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 7.90-8.08(m,1H),7.76-7.85(m,1H),5.96(d,J=8.4Hz,1H),4.61-4.71(m,1H),1.50(d,J=6.9Hz ,3H),1.14(s,9H).m / z(ESI):306.1(M+H) +
[0167] In a 50 mL round bottom flask, (R)-N-((R)-1-(6-bromopyridazin-3-yl)ethyl)-2-methylpropane-2-sulfine in 1,4-dioxane (10.61 mL). Amide (0.650 g, 2.123 mmol) and hydrogen chloride solution, 4.0 M dioxane solution (0.663 mL, 2.65 mmol, Sigma-Aldrich Corporation) were added. The entire reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the residue was diluted with heptane and DCM (10:1) and then stirred by sonication for 1 min. The precipitate was collected by filtration and the solids were then washed with heptane (3 times). This gave (R)-1-(6-bromopyridazin-3-yl)ethane-1-amine hydrochloride as a black crude mixture, which was taken to the next step of the synthesis without further purification. . m / z(ESI):202.1(M+H) +
[0168] Step 3. In a 100 mL round bottom flask, add (R)-1-(6-bromopyridazin-3-yl)ethane-1-amine hydrochloride (0.500 g, 2.096 mmol) and dichloroethane (10.48 mL). -tert-butyl dicarbonate (0.686 g, 0.730 mL, 3.14 mmol, Oakwood Products, Inc.) was added. Triethylamine (1.061 g, 1.473 mL, 10.48 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture and the entire mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (5 mL) diluted with aqueous solution. The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified with a gradient of 0-80% EtOAc in heptane to give tert-butyl(R)-(1-(6-bromopyridazin-3-yl)ethyl)carbamate (0.182 g , 0.602 mmol, yield 28.7%) was obtained as a tan solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 7.90(d,J=8.8Hz,1H),7.71(d,J=9.0Hz,1H),7.44-7.66(m,1H),4.78-4.94(m,1H),1.38(brd,J =8.8Hz,12H).m / z(ESI):302.0(M+H) + .
[0169] Step 4. To a 100 mL round bottom flask was added tert-butyl (R)-(1-(6-bromopyridazin-3-yl)ethyl)carbamate (0.170 g, 0.563 mmol) in tetrahydrofuran (5.63 mL). The mixture was cooled to 0° C. and then sodium hydride (60% dispersion in mineral oil) (0.028 g, 0.703 mmol, TCI America) was added to the reaction mixture. The resulting mixture was stirred at 0° C. for 20 minutes, then iodomethane (0.096 g, 0.042 mL, 0.675 mmol, Sigma-Aldrich Corporation) was added dropwise to the mixture. The reaction mixture was stirred for an additional 20 minutes and the temperature was maintained at 0° C., then the mixture was stirred at room temperature overnight. The reaction mixture was quenched with MeOH and concentrated in vacuo. The crude material was absorbed onto a silica gel plug and purified by chromatography on a Redi-Sep packed silica gel column (40 g) eluting with a gradient of 0-25% EtOAc in heptane to give tert-butyl(R)-(1-(6 -bromopyridazin-3-yl)ethyl)(methyl)carbamate (0.170 g, 0.538 mmol, 96% yield) was obtained as a pale yellow oil. 1 H NMR(400MHz,chloroform-d)δ ppm 8.31(d,J=2.3Hz,1H),7.18(ddd,J=9.4,8.3,2.4Hz,1H),5.63(brs,1H),2.75(brs, 3H),1.53-1.57(m,3H),1.47(s,9H).m / z(ESI):216.1(M-Boc+H) +
[0170] Step 5. In a resealable vial, add tert-butyl (R)-(1-(6-bromopyridazin-3-yl)ethyl)(methyl)carbamate (0.160 g, 0.506 mmol), b-[4-( Trifluoromethyl)phenyl]-boronic acid (0.288 g, 1.518 mmol, AA block) and potassium carbonate (0.210 g, 1.518 mmol, Oakwood Chemicals) in 1,2-dimethoxyethane (2.300 mL) / water (0.230 mL). Filled with. The reaction mixture was flushed with argon for 5 minutes. Then, Pd(PPh 3 ) 4 (0.117g, 0.101mmol, Sigma-Aldrich) was added to the reaction mixture. The vial was sealed and the reaction mixture was then stirred and heated at 90° C. for 16 hours. The reaction mixture was diluted with EtOAc and brine solution. The layers were separated and the aqueous layer was extracted with EtOAc (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column (40 g) eluting with a gradient of 0-100% EtOAc in heptane to give tert-butyl (R)-methyl (1- (6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)ethyl)carbamate (0.155 g, 0.406 mmol, 80% yield) was obtained as a pale yellow solid. 1 H NMR(400MHz,chloroform-d)δ ppm 8.16-8.47(m,1H),7.77-7.96(m,3H),7.49-7.72(m,2H),5.07(s,1H),1.51(s,3H) ),1.28(s,12H).m / z(ESI):382.1(M+H) +
[0171] Step 6. In a 50 mL round bottom flask, add tert-butyl(R)-methyl(1-(6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)ethyl) in 1,2-dichloroethane (3.67 mL). Carbamate (0.140 g, 0.367 mmol) and trifluoroacetic acid (0.419 g, 0.419 mL, 3.67 mmol, Apollo Scientific Ltd.) were added. The whole mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo. The crude residue was carried on to the next step of the synthesis without further purification. m / z(ESI):282.2(M+H) +
[0172] The secondary amines (192-193) in Table 12 were prepared starting from step 3 using a commercially available chiral amine, (R)-1-(4-bromophenyl)ethylamine (CAS number 45791-36-4). , prepared in a similar manner as described for amine 191.
[0173] [Table 24]
[0174] Intermediate 194: 1-(6-cyclopropylpyridazin-3-yl)-N-methylmethanamine [ka]
[0175] Step 1. 1-(6-bromopyridazin-3-yl)-N-methylmethanamine (16, 176.6 mg, 0.874 mmol) and diisopropylethylamine (226 mg, 305 μL, 1.748 mmol, Sigma-Aldrich Corporation) in dichloromethane (4370 μL) and anhydrous Boc (210 mg, 0.961 mmol, Sigma-Aldrich Corporation) was added. The reaction was stirred at room temperature for 18 hours. The mixture was then partitioned between DCM and water and the layers were separated. Wash the organic layer with brine and MgSO 4 and concentrated. The crude product was then purified by medium pressure chromatography (silica, 10-100% EtOAc:heptane) to yield tert-butyl((6-bromopyridazin-3-yl)methyl)(methyl)carbamate (204 mg, 0.675 mmol, A yield of 77%) was obtained. m / z(ESI):302.0,304.2(M+H) + . 1 H NMR(400MHz,chloroform-d)δ ppm 7.65(brd,J=7.9Hz,1H),7.44(brd,J=7.1Hz,1H),4.71(s,2H),2.93(brs,3H),1.48 (brd,J=5.4Hz,9H)
[0176] Step 2. A mixture of tert-butyl((6-bromopyridazin-3-yl)methyl)(methyl)carbamate (204.6mg, 0.677mmol), cyclopropylboronic acid (291mg, 3.39mmol) and toluene (2888μL) was heated with Ar and then potassium tribasic phosphate (431 mg, 2.031 mmol, Alfa Aesar) and water (321 μL) were added and the mixture was stirred at room temperature for 10 minutes. Tricyclohexylphosphine (38.0 mg, 0.135 mmol, Strem Chemicals, Inc.) and palladium(II) acetate (15.20 mg, 0.068 mmol, Strem Chemicals, Inc.) were then added. The mixture was stirred in a sealed vial at 90° C. for 2 hours, then it was filtered through celite and concentrated in vacuo. The crude material was purified by chromatography through a silica gel column eluting with 0-60% 3:1 EtOAc:EtOH in heptane and purified with tert-butyl((6-cyclopropylpyridazin-3-yl)methyl)(methyl)carbamate ( 90.4 mg, 0.343 mmol, yield 50.7%) was obtained. m / z(ESI):264.2(M+H) + . 1 H NMR(400MHz,chloroform-d)δ ppm 7.39(brd,J=7.5Hz,1H),7.17-7.27(m,1H),4.69(s,2H),2.91(brs,3H),2.11-2.22( m,1H),1.49(brs,9H),1.09-1.24(m,4H)
[0177] Step 3. To a solution of tert-butyl((6-cyclopropylpyridazin-3-yl)methyl)(methyl)carbamate (90.4 mg, 0.343 mmol) in dichloromethane (1248 μL) was added a 4.0 M solution of hydrogen chloride in dioxane (687 μL, 2.75 mmol (Sigma-Aldrich Corporation) was added. The solution became a suspension, so MeOH was added to make the suspension a solution again. The mixture was stirred at room temperature for 4 hours until LCMS showed product. The mixture was concentrated in vacuo. The product 1-(6-cyclopropylpyridazin-3-yl)-N-methylmethanamine hydrochloride (74.8 mg, 0.375 mmol, 109% yield) was obtained as a light brown solid and used directly in further experiments. m / z(ESI):164.2(M+H) + .
[0178] Intermediate 195: 2-(5-chloropyridin-2-yl)-2,2-difluoro-N-methylethane-1-amine [ka]
[0179] Step 1.2-(5-chloropyridin-2-yl)-2,2-difluoroethane-1-amine dihydrochloride (307 mg, 1.16 mmol, 1.0 eq., Enamine) and triethylamine (351 mg, 483 μL, 3.47 mmol, 3.0 eq., To a stirred, ice-cold solution of Aldrich) in DCM (3.85 mL) was added di-tert-butyl dicarbonate (252 mg, 1.16 mmol, 1 eq., Aldrich). The resulting mixture was stirred at 0° C. for 15 minutes, then for 1.5 hours to room temperature until complete. The crude mixture was directly loaded onto a silica gel column and subjected to medium pressure column chromatography eluting with EtOAc / heptane (15 min, 0 to 100%), yielding tert-butyl (2-(5-chloropyridin-2-yl)- 2,2-difluoroethyl)carbamate (310 mg, 1.06 mmol, yield 92%) was obtained. m / z(ESI):293.1(M+H) + .
[0180] Step 2. Add hydrogen to a stirred ice-cold solution of tert-butyl (2-(5-chloropyridin-2-yl)-2,2-difluoroethyl)carbamate (300 mg, 1.03 mmol, 1.0 equiv.) in THF (5.0 mL). Sodium chloride (60% dispersion) (36.9 mg, 1.54 mmol, 1.5 eq.) was added under nitrogen atmosphere. After stirring the resulting mixture at 0° C. for 15 minutes, methyl iodide (145 mg, 64.1 μL, 1.03 mmol, 1.0 equiv.) was added via syringe. The resulting mixture was stirred at 0° C. for 15 minutes and then at ambient temperature for 16 hours. The reaction mixture was cooled in an ice bath and then quenched with MeOH. The volatiles were removed in vacuo and the residue was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give tert-butyl(2-(5-chloropyridin-2-yl)-2,2 -difluoroethyl)(methyl)carbamate (210 mg, 0.685 mmol, yield 66.8%) was obtained. This material was then dissolved in TFA (4.0 mL) and stirred for 25 minutes until completion. The reaction mixture was then concentrated under reduced pressure on a rotary evaporator to obtain the crude TFA salt. This salt was then dissolved in MeOH, loaded onto an SCX column, eluted with 0-2M ammonia in MeOH, and co-precipitated to yield 2-(5-chloropyridin-2-yl)-2,2-difluoro- N-methylethane-1-amine (127 mg, 0.615 mmol, yield 60.0%) was obtained. m / z(ESI):207.1(M+H) + .
[0181] Intermediate 196: (R)-1-(pyrimidin-2-yl)-N-((6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)ethane-1-amine. [ka]
[0182] Step 1. Add 150 mL of 1-(pyrimidin-2-yl)ethane-1-amine dihydrochloride (2.79 g, 14.23 mmol, Enamine) in a 1:1 mixture of methanol (21.56 mL) / dichloromethane (21.56 mL). into a round bottom flask. The reaction mixture was cooled to 0° C., then n,n'-diisopropylethylamine (3.51 g, 4.74 mL, 27.2 mmol, Sigma-Aldrich Corporation) was added to the reaction mixture and stirred for 10 minutes. 3-Formyl-6-hydroxypyridazine (1.60 g, 12.93 mmol, Aurum Pharmatech LLC) and acetic acid (0.77 g, 0.74 mL, 12.93 mmol, Sigma-Aldrich Corporation) were then added to the mixture, followed by acetic acid (0.77 g , 0.74 mL, 12.93 mmol, Sigma-Aldrich Corporation) was added. The reaction mixture was allowed to warm to room temperature over 15 minutes, then sodium triacetoxyborohydride (6.85 g, 32.3 mmol, Sigma-Aldrich Corporation) was added and the entire mixture was heated to inert (N 2 ) Stirred under atmosphere for 16 hours. Another aliquot of sodium triacetoxyborohydride (6.85 g, 32.3 mmol, Sigma-Aldrich Corporation) was added to the reaction mixture and stirred for an additional 16 hours. The reaction mixture was filtered through a pad of celite and the filter cake was then rinsed with 1:1 MeOH:DCM (3 times). The filtrate was collected and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and CH 2 Cl 2 Purification by chromatography on a Redi-Sep prepacked silica gel column (120 g) eluting with a gradient of 0-35% MeOH in medium yields 6-(((1-(pyrimidin-2-yl)ethyl)amino)methyl)pyridazine-3 -ol (1.11 g, 4.84 mmol, 37.4% yield) was obtained as a pale yellow solid. m / z(ESI):232.1(M+H) + . 1 H NMR (400MHz, methanol-d4) δ ppm 8.78(d,J=5.0Hz,2H),7.54(d,J=9.6Hz,1H),7.38(t,J=4.9Hz,1H),6.92(d ,J=9.6Hz,1H),4.07(q,J=6.8Hz,1H),3.72(d,J=2.3Hz,2H),1.98(s,1H),1.48(d,J=6.9Hz,3H ).
[0183] Step 2. 6-(((1-(pyrimidin-2-yl)ethyl)amino)methyl)pyridazin-3-ol (1.11 g, 4.80 mmol) and triethylamine (1.45 g, 2.02 mL, 14.40 mmol, Sigma-Aldrich Corporation) was added to a 150 mL round bottom flask. Di-tert-butyl dicarbonate (1.57 g, 1.67 mL, 7.20 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture. The entire reaction mixture was stirred and heated at 70° C. for 2 hours. Saturate the reaction mixture with NaHCO 3 and the mixture was diluted with DCM. The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column (120 g), eluting with a gradient of 0-80% EtOAc:EtOH in heptane (3:1) to obtain tert- Butyl ((6-hydroxypyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (1.043 g, 3.15 mmol, 65.6% yield) was obtained as a white solid. m / z(ESI):332.1(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 12.77(s,1H),8.75(d,J=4.8Hz,2H),7.37(t,J=4.8Hz,2H),6.85(d,J=9.6Hz ,1H),4.88-5.05(m,1H),4.42(brs,2H),1.54(d,J=7.3Hz,3H),1.15-1.34(m,9H).
[0184] Step 3. Racemic tert-butyl((6-hydroxypyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (1.043g) using a Chiral Technologies AD column (250x30mm, 5mm) and mobile phase 80% liquid CO with 0.2% TEA. 2 and 20% EtOH, purified by preparative SFC using a flow rate of 150 mL / min. The first eluting peak was tert-butyl (R)-((6-hydroxypyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (430 mg, >99% ee). Ta. The second eluting peak was tert-butyl(S)-((6-hydroxypyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (455 mg, 98.8% ee) . Peak assignments were determined by SFC with an AD column using 10% EtOH containing 0.2% TEA. Peak 1 is the more active enantiomer.
[0185] Step 4. In a 50 mL round bottom flask, add tert-butyl(R)-((6-hydroxypyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl) in N,N-dimethylformamide (5.23 mL). ) Carbamate (0.20 g, 0.62 mmol) and cesium carbonate (0.25 g, 0.78 mmol, Sigma-Aldrich Corporation) were added. 2,2,2-trifluoroethyl triflate (0.18 g, 0.78 mmol, Combi-Blocks Inc.) was then added to the reaction mixture over 5 minutes. The resulting reaction mixture was stirred at room temperature overnight, then concentrated in vacuo. The crude material was absorbed onto a silica gel plug and CH 2 Cl 2 Purified by chromatography through a Redi-Sep prepacked silica gel column (40 g) eluting with a gradient of 0 to 60% MeOH in tert-butyl(R)-(1-(pyrimidin-2-yl)ethyl)( (6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)carbamate (0.20 g, 0.48 mmol, 77% yield) was obtained as a pale yellow solid. m / z(ESI):414.1(M+H) + .
[0186] Step 5. In a 50 mL round bottom flask, add tert-butyl(R)-(1-(pyrimidin-2-yl)ethyl)((6-(2,2,2-trifluoroethoxy)pyridazine-) in dichloromethane (1.25 mL). 3-yl)methyl)carbamate (0.10 g, 0.25 mmol) and trifluoroacetic acid (1.00 g, 0.65 mL, 8.81 mmol, Sigma-Aldrich Corporation) were added. The resulting reaction mixture was stirred at room temperature for 1 hour. Concentrate the crude (R)-1-(pyrimidin-2-yl)-N-((6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)methyl)ethan-1-amine in vacuo. and was carried on to the next step of the synthesis without further purification. m / z(ESI):314.0(M+H) + .
[0187] Intermediate 197: (R)-N-((6-cyclopropylpyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethane-1-amine [ka]
[0188] Step 1. (R)-N-((6-bromopyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine (133, 0.8 g, 2.72 mmol) and DIPEA (0.703 g, 0.950 mL, 5.44 mmol, Aldrich) was stirred in dichloromethane (13.60 mL), then di-tert-butyl dicarbonate (0.653 g, 0.695 mL, 2.99 mmol, Oakwood Products, Inc.) was added. The reaction was then stirred at room temperature for 4 hours. Additionally 0.5 equivalents of Boc 2 After adding O and stirring overnight, the mixture was partitioned between 100 mL of DCM and water. The layers were separated. Wash the organic layer with brine and remove Na 2 S.O. 4 and concentrated. The crude product was purified by flash chromatography (silica, 10-100% EtOAc:heptane) to give tert-butyl(R)-((6-bromopyridazin-3-yl)methyl)(1-(pyrimidin-2-yl) )ethyl)carbamate (1.16 g, 2.94 mmol, yield 108%) was obtained. m / z(ESI):394,396(M+H) + .
[0189] Step 2. tert-butyl (R)-((6-bromopyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (0.2g, 0.507mmol), cyclopropylboronic acid (0.218 g, 2.54 mmol, Combi-Blocks), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(ii) dichloromethane complex (0.041 g, 0.051 mmol, Oakwood Products, Inc.), silver oxide (i ) (0.223 g, 0.964 mmol, Sigma-Aldrich Corporation), potassium carbonate (0.210 g, 1.522 mmol, Acros), and 1,4-dioxane (5 mL) were purged with Ar and then heated at 80 °C for 4.5 min in a sealed vial. Stir for hours. The mixture was then filtered through celite and concentrated in vacuo. The crude material was purified by chromatography on a silica gel column eluting with 0-100% 3 / 1 EtOAc / EtOH in heptane. Off-white tert-butyl (R)-((6-cyclopropylpyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (149.2 mg, 0.42 mmol, 83% yield) Obtained as a colored solid and used in next step. m / z(ESI):356.3(M+H) +
[0190] Step 3. tert-butyl (R)-((6-cyclopropylpyridazin-3-yl)methyl)(1-(pyrimidin-2-yl)ethyl)carbamate (0.14 g, 0.394 mmol) in dichloromethane (4 mL) To the medium solution was added 4.0 M HCl in dioxane (0.788 mL, 3.15 mmol, Aldrich). MeOH was added to bring the suspension back into solution. The mixture was stirred at room temperature overnight, then concentrated in vacuo to give (R)-N-((6-cyclopropylpyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethane-1 -amine (155 mg, 0.425 mmol, 108% yield) was obtained as an orange solid. m / z(ESI):256(M+H) +
[0191] Intermediate 198: 1-Cyclopropyl-N-((6-morpholinopyridazin-3-yl)methyl)methanamine [ka]
[0192] Step 1. 1-(6-bromopyridazin-3-yl)-N-(cyclopropylmethyl)methanamine (18, 0.84 g, 3.47 mmol) and DIPEA (0.897 g, 1.21 mL, 6.94 mmol, Aldrich) were dissolved in dichloromethane (17.4 mL). ) and then di-tert-butyl dicarbonate (1.21 g, 1.29 mL, 5.55 mmol, Oakwood Products, Inc.) was added. The reaction was stirred at room temperature overnight. The mixture was then partitioned between 200 mL of DCM and water. The layers were separated. organic layer with Na 2 S.O. 4 dried over and concentrated to give crude tert-butyl((6-bromopyridazin-3-yl)methyl)(cyclopropylmethyl)carbamate (1.31 g, 3.83 mmol, A yield of 110%) was obtained. This material was successfully used in the next reaction. m / z(ESI):342,344(M+H) +1 H NMR(400MHz,DMSO-d6)δ ppm 7.11(brd,J=8.6Hz,1H),6.76(d,J=9.0Hz,1H),4.02(s,1H),3.96(s,1H),2.40 -2.46(m,1H),0.54-0.73(m,10H),0.25-0.29(m,2H),0.18(brs,1H),-0.36(brd,J=7.3Hz,1H),-0.61(brs ,1H)
[0193] Step 2. RuPhos Palladacycle G1 (298mg, 0.365mmol, Strem), RuPhos (170mg, 0.365mmol, Strem), morpholine (256μL, 255mg, 2.92mmol, Aldrich), cesium carbonate (1.55g, 4.75mmol, Aldrich) and tert -Butyl((6-bromopyridazin-3-yl)methyl)(cyclopropylmethyl)carbamate (500 mg, 1.46 mmol) was combined in THF and heated at 85° C. for 2.5 hours. The reaction mixture was then diluted with EtOAc and filtered through a pad of diatomaceous earth. The residue was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give tert-butyl(cyclopropylmethyl)((6-morpholinopyridazin-3-yl)methyl)carbamate (430 mg, 1.234 mmol, yield 84%) was obtained. m / z(ESI):349.1(M+H) +1 H NMR(400MHz,chloroform-d)δ ppm 7.29-7.41(m,1H),6.88(d,J=9.4Hz,1H),4.68(s,2H),3.78-3.86(m,4H),3.55- 3.63(m,4H),3.03-3.20(m,2H),1.46(brs,9H),0.87-1.00(m,1H),0.37-0.43(m,2H),0.17(brs,2H).
[0194] Step 3. Tert-butyl(cyclopropylmethyl)((6-morpholinopyridazin-3-yl)methyl)carbamate was dissolved in TFA (12.5 mL) and stirred for 15 minutes to completion. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in MeOH, eluted through an SCX column with 0-2M ammonia in MeOH, and concentrated to give 1-cyclopropyl-N-((6-morpholinopyridazin-3-yl) Methyl)methanamine (198, 90.0 mg, 0.362 mmol, yield 24.8%) was obtained. m / z(ESI):249.2(M+H) +
[0195] Intermediate 199: Methyl 4-(6-((methylamino)methyl)pyridin-3-yl)pipe 159 Radin-1-carboxylate [ka]
[0196] Intermediate 199 was prepared in a similar manner as described above for amine 198. m / z(ESI):265.2(M+H) +
[0197] Intermediate 200: (S)-1-cyclopropyl-2-methoxy-N-((6-morpholinopyridazin-3-yl)methyl)ethane-1-amine [ka]
[0198] Step 1. In a 100 mL round bottom flask, add N-((6-bromopyridazin-3-yl)methyl)-1-cyclopropyl-2-methoxyethane-1-amine (0.075 g) in 1,2-dichloroethane (1.30 mL). , 0.26 mmol) and triethylamine (0.080 g, 0.11 mL, 0.79 mmol, Sigma-Aldrich Corporation) were added. Di-tert-butyl dicarbonate (0.086 g, 0.091 mL, 0.390 mmol, Sigma-Aldrich Corporation) was then added to the reaction mixture. The entire reaction mixture was stirred and heated at 70° C. for 2 hours. Saturate the reaction mixture with NaHCO 3 and the mixture was diluted with DCM. The layers were separated and the aqueous layer was extracted with DCM (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep packed silica gel column (12 g), eluting with a gradient of 0-30% EtOAc:EtOH in heptane (3:1) to give racemic tert. -Butyl((6-bromopyridazin-3-yl)methyl)(1-cyclopropyl-2-methoxyethyl)carbamate (0.085 g, 0.220 mmol, 84% yield) was obtained as a tan solid. m / z(ESI):386.0(M+H) + .
[0199] Step 2. Place the racemic sample in 90% liquid CO containing 0.2% TEA. 2 and purified by preparative SFC using a Chiral Technologies IG column (250x21mm, 5mm) with 10% iPrOH and a flow rate of 80 mL / min to have peak 1 of 390 mg with an ee of 98% and peak 1 with an ee of 98%. Generated 380 mg of peak 2. Absolute stereochemistry was arbitrarily assigned for these isomers, and the more intense peak 2 was considered below as the (S)-isomer.
[0200] Step 3. tert-butyl (S)-((6-bromopyridazin-3-yl)methyl)(1-cyclopropyl-2-methoxyethyl)carbamate (peak 2, 170 mg, 0.440 mmol), RuPhos (51.0 mg, 0.110mmol, Aldrich), RuPhos PreCat G1 (90.0mg, 0.110mmol, Strem), cesium carbonate (470mg, 1.40mmol, Aldrich), and morpholine (0.077mL, 0.88mmol, Spectrum) in degassed THF (2.9mL). The mixture was combined inside and completed by heating at 85°C for 2 hours. The reaction was then cooled, diluted with EtOAc, and filtered through a pad of diatomaceous earth. The filtrate was then concentrated and the residue was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane to 30-100% (3:1 EtOAc:EtOH:heptane) to remove the impure tert-butyl(S)- (1-Cyclopropyl-2-methoxyethyl)((6-morpholinopyridazin-3-yl)methyl)carbamate was obtained.
[0201] Step 4. This material was dissolved in TFA (10 mL) and stirred for 10 minutes. The reaction mixture is then concentrated and the residue is then eluted through an SCX column eluting with 0-2M ammonia in MeOH and concentrated to give (S)-1-cyclopropyl-2-methoxy-N-((6 -morpholinopyridazin-3-yl)methyl)ethan-1-amine (110 mg, 0.37 mmol, yield 83%) was obtained. m / z(ESI):293.1(M+H) + .
[0202] Intermediate 201: N-((6-ethoxypyridazin-3-yl)methyl)-2-methylpropan-1-amine [ka]
[0203] Step 1. N-((6-bromopyridazin-3-yl)methyl)-2-methylpropan-1-amine (17, 0.950 g, 3.89 mmol) and DIPEA (1.01 g, 1.36 mL, 7.78 mmol, Aldrich) was stirred in dichloromethane (19.5 mL), then di-tert-butyl dicarbonate (1.36 g, 1.45 mL, 6.23 mmol, Oakwood Products, Inc.) was added. The reaction was then stirred at room temperature overnight. The mixture was then partitioned between 200 mL of DCM and water. The layers were separated. Organic layer with MgSO 4 dried over and concentrated to give crude tert-butyl((6-bromopyridazin-3-yl)methyl)(isobutyl)carbamate (1.89 g, 5.49 mmol, yield 141) contaminated with ~30% with anhydrous Boc byproduct. %) was obtained. This material was used directly in the next reaction. m / z(ESI):344,346(M+H) +
[0204] Step 2. In a resealable screw-cap test tube (Tube A), add tBuBrettPhos (170 mg, 0.350 mmol, 0.150 equiv.), cesium carbonate (1.10 g, 3.30 mmol, 1.40 equiv.) and tert-butyl ((6-bromopyridazine) -3-yl)methyl)(isobutyl)carbamate (800mg, 2.3mmol, 1.0eq) was charged. Tube A was evacuated and filled with argon (3x), then ethanol (1000 μL, 17.0 mmol, 7.50 eq.) was added to tube A via syringe. At the same time, tBuBrettPhos Pd G3 (300 mg, 0.350 mmol, 0.150 equiv.) was charged into a resealable screw-cap test tube (tube B) equipped with a Teflon-coated magnetic stir bar. Tube B was then evacuated and filled with argon (3x) and 1,4-dioxane (12.0 mL) was added to tube B via syringe. The reaction mixture in tube B was stirred at room temperature for about 1 minute to form a homogeneous solution. The precatalyst solution from tube B was transferred to tube A via syringe. The resulting reaction mixture in tube A was stirred at room temperature for 20 hours. The crude product was diluted with ethyl acetate and concentrated in vacuo using a rotary evaporator. The crude product residue was purified by flash column chromatography with medium pressure chromatography (silica, 0-100% EtOAc:heptane) to yield ((6-ethoxypyridazin-3-yl)methyl)(isobutyl)carbamate. m / z(ESI):310.1(M+H) +
[0205] Step 3. This material was then dissolved in TFA (10 mL) and stirred for 15 minutes until completion. The reaction mixture was then concentrated under reduced pressure and the residue was dissolved in MeOH and eluted through an SCX column eluting with 0-2M ammonia in MeOH, giving the N-( (6-Ethoxypyridazin-3-yl)methyl)-2-methylpropan-1-amine was obtained which was successfully used in the next reaction. 100 mg was obtained on the first pass through the SCX column where traces of TFA were present. m / z(ESI):210.1(M+H) +1 H NMR(400MHz,chloroform-d)δ ppm 7.41-7.52(m,1H),6.92(d,J=9.0Hz,1H),4.57(q,J=7.1Hz,2H),4.00(s,2H) ,2.43-2.51(m,2H),1.74-1.89(m,2H),1.45(t,J=7.1Hz,3H),0.93(d,J=6.5Hz,6H)
[0206] Intermediate 202: 1-(5-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)-N-methylmethanamine [ka]
[0207] Step 1. 1-(5-bromopyridin-2-yl)-N-methylmethanamine (0.950 g, 4.72 mmol, 34) and DIPEA (1.22 g, 1.65 mL, 9.45 mmol, Aldrich) in dichloromethane (23.6 mL). Stir and add di-tert-butyl dicarbonate (1.65 g, 1.76 mL, 7.56 mmol, Oakwood Products, Inc.). The reaction was then stirred at room temperature overnight until completion. The mixture was then partitioned between 200 mL DCM and 50 mL water. The layers were separated. Organic layer with MgSO 4 Dry over and concentrate to give crude tert-butyl ((5-bromopyridin-2-yl)methyl)(methyl)carbamate (1.42 g, 4.71 mmol, 100% yield). m / z(ESI):301.2,303.1(M+H) + .
[0208] Step 2.2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (837 mg, 3.98 mmol, Combi-Blocks), tricyclohexyl Phosphine (112 mg, 0.398 mmol, Strem), tert-butyl((5-bromopyridin-2-yl)methyl)(methyl)carbamate (0.600 g, 1.99 mmol, from step 1) and Pd 2 (dba) 3 (182 mg, 0.199 mmol, Acros) was slurried in dioxane (7.00 mL) and then sparged with argon. Potassium carbonate (1.30M solution) (4.14mL, 5.38mmol, Aldrich) was then added and the reaction mixture was heated to 90°C for 1 hour. The reaction was cooled and then concentrated to reduced volume. The residue was then dissolved in water (30 mL) and extracted with dichloromethane (2x80 mL). The combined organic layers were dried over magnesium sulfate and concentrated. The crude product was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give tert-butyl ((5-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl) Methyl)(methyl)carbamate (372 mg, 1.22 mmol, yield 61.3%) was obtained.
[0209] Step 3. This material was then dissolved in 7 mL of TFA and stirred for 10 minutes to obtain complete deprotection. The reaction mixture was then concentrated and the resulting TFA salt was converted to 1-(5-( 3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl)-N-methylmethanamine (90.0 mg, 440 mmol, yield 22.1%) was obtained. m / z(ESI):205.2(M+H) + .
[0210] Intermediate 203: 6-((methylamino)methyl)-3’,6’-dihydro-[3,4’-bipyridine]-1’(2’H)-carboxylate [ka]
[0211] Step 1. Diisopropylamine (185 mg, 0.261 mL, 1.83 mmol, Aldrich) was dissolved in THF (7.00 mL) and cooled to -78°C. Then n-butyllithium (2.50M in hexanes) (0.732 mL, 1.83 mmol, Aldrich) was added dropwise at -78°C and stirred for 25 minutes. The mixture was lifted from the dry ice bath for 15 minutes and then re-soaked. Methyl 4-oxopiperidine-1-carboxylate (250 mg, 1.59 mmol, Combi-Blocks) was then dissolved in THF (4.00 mL) and slowly added to the LDA solution at -78°C and stirred for 45 minutes. N-phenyl-bis(trifluoromethanesulfonimide) (625 mg, 1.75 mmol, Combi-Blocks) dissolved in THF (5.00 mL) was added slowly and the reaction mixture was stirred overnight while warming to room temperature. The reaction mixture was quenched with water (20 mL) and the mixture was extracted with hexane (3x50 mL). The combined organic layers were washed with brine and dried over magnesium sulfate. The crude product was purified by medium pressure chromatography (silica, 0-40% ethyl acetate:hexanes) to yield methyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxy Lato (249 mg, 0.861 mmol, yield 54.1%) was obtained. m / z(ESI):290.1(M+H) + .
[0212] Step 2. Methyl 4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate (230 mg, 0.795 mmol), bis(pinacolato)diboron (242 mg, 0.954 mmol, Aldrich ), 1,1'-bis(diphenylphosphino)ferrocene-palladium dichloride (64.9 mg, 0.080 mmol, Strem Chemicals, Inc.), and potassium acetate (312 mg, 3.18 mmol, Aldrich) in dioxane (2.65 mL). added to the flask. This mixture was heated at 80°C overnight. The reaction mixture was cooled, filtered and washed with ethyl acetate. The filtrate was concentrated and purified by medium pressure chromatography (silica, 0-60% EtOAc:heptane) to yield methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl). -3,6-dihydropyridine-1(2H)-carboxylate (130 mg, 0.487 mmol, yield 61.2%) was obtained. m / z(ESI):268.2(M+H) + .
[0213] Step 3. Methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (133 mg, 0.498 mmol, from step 2), tricyclohexylphosphine (27.9 mg, 0.100 mmol, Strem), tert-butyl((5-bromopyridin-2-yl)methyl)(methyl)carbamate (0.150 g, 0.498 mmol, Boc-34, intermediate (see step 1 for body 202) and Pd 2 (dba) 3 (45.6 mg, 0.050 mmol, Acros) was slurried in dioxane (1.74 mL) and flushed with argon. Potassium carbonate (1.30M solution) (1.03mL, 1.35mmol, Aldrich) was added and the reaction mixture was heated to 90°C for 1 hour. The reaction was cooled and concentrated to reduced volume. This residue was dissolved in water (15 mL) and extracted with dichloromethane (2x40 mL). The combined organic layers were dried over magnesium sulfate and concentrated. The crude product was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give methyl 6-(((tert-butoxycarbonyl)(methyl)amino)methyl)-3',6'-dihydro-[ 3,4'-bipyridine]-1'(2'H)-carboxylate (93.0 mg, 0.257 mmol, yield 51.7%) was obtained. The material was dissolved in TFA and stirred for 10 minutes for Boc deprotection. The mixture was concentrated to obtain the TFA salt of the desired product. The free base is then eluted through an SCX column eluting with 0-2M ammonia in methanol and concentrated to yield methyl 6-((methylamino)methyl)-3',6'-dihydro-[3,4'- Bipyridine]-1'(2'H)-carboxylate (63.0 mg, 0.241 mmol, yield 48.4%) was obtained. m / z(ESI):262.2(M+H) + .
[0214] Intermediate 204: (R)-N-ethyl-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethane-1-amine [ka]
[0215] Step 1. In a 100 mL two-neck round bottom flask, add (R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethan-1-amine (0.50 g, 2.41 mmol, AP) in dichloromethane (12 mL). Bioscience) and pyridine (0.27 g, 0.27 mL, 3.38 mmol, Sigma-Aldrich Corporation) were added. The reaction mixture was cooled to −78° C. and then acetic anhydride (0.30 g, 0.27 mL, 2.90 mmol, Sigma-Aldrich Corporation) was added dropwise to the reaction mixture over 2 minutes under an inert (N2) atmosphere. The ice bath was removed and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was cooled to 0° C., then the reaction mixture was quenched with 1N HCl (2.4 mL). The mixture was diluted with heptane (20 mL) and washed with 1N HCl (6 mL x 2), then saturated NaHCO 3 (12 mL) aqueous solution and brine (12 mL). Collect organics and then MgSO 4 dried, filtered and concentrated in vacuo to give (R)-N-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)acetamide (0.43 g, 1.73 mmol, yield 72 %) as a white solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.48(brd,J=7.3Hz,1H),7.53-7.66(m,3H),5.13(quin,J=7.2Hz,1H),1.86(s,3H),1.35(d,J=7.1 Hz,3H).m / z(ESI):250.0(M+H) + .
[0216] Step 2. To a 150 mL round bottom flask was added (R)-N-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)acetamide (0.42 g, 1.69 mmol) in tetrahydrofuran (9 mL). A 2.0 M lithium aluminum hydride solution in tetrahydrofuran (2.1 mL, 4.21 mmol, Sigma-Aldrich Corporation) was then slowly added to the reaction mixture over 2 minutes. The resulting reaction mixture was stirred at room temperature for 1 hour, then the mixture was stirred and heated at 55° C. for 5 hours. The reaction mixture was diluted with heptane (15 mL) and cooled to 0°C. Water (0.4 mL) was then added to the mixture and stirred for 1 minute. Then, 15% NaOH (0.4 mL) aqueous solution was added to the mixture and stirred for 1 minute. Water (3x1.2 mL) was then added to the mixture and the resulting mixture was warmed to room temperature over 15 minutes. MgSO 4was added to the mixture and stirred for an additional 15 minutes. The entire reaction mixture was filtered through a pad of Celite, then the filtrate was collected and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography on a Redi-Sep prepacked silica gel column (40 g), eluting with a gradient of 0-60% EtOAc:EtOH in heptane (3:1) to give (R )-N-ethyl-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethan-1-amine (0.081 g, 0.344 mmol, 20.43% yield) was obtained as a pale yellow oil. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 7.76(t,J=7.7Hz,1H),7.53-7.61(m,2H),4.07(q,J=6.6Hz,1H),2.26-2.40(m,2H),2.08-2.17(m ,1H),1.26(d,J=6.7Hz,3H),0.98(t,J=7.1Hz,3H).m / z(ESI):236.1(M+H) + .
[0217] Intermediate 205: (R)-N-ethyl-1-(4-(trifluoromethyl)phenyl)ethane-1-amine [ka]
[0218] Intermediate 205 was prepared in a similar manner as described for intermediate 204. m / z(ESI):218.1(M+H) +
[0219] Intermediate 206: Preparation of (S)-N-(cyclopropyl(5-(trifluoromethyl)pyridin-2-yl)methyl)ethanamine [ka]
[0220] Step 1. In an oven-dried 100 mL round bottom flask, add (R)-(+)-2-methyl-2-propanesulfinamide (0.50 g, 4.13 mmol, AK Scientific, Inc.) in dichloromethane (8.25 mL). was added. To this mixture was added copper(ii) sulfate (1.32 g, 8.25 mmol, Sigma-Aldrich Corporation) followed by 5-(trifluoromethyl)picolinaldehyde (0.75 g, 4.13 mmol, J&W Pharmlab). The resulting reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was filtered through a pad of celite and the filter cake was washed well with DCM. The filtrate was collected and concentrated in vacuo. The crude product was purified by flash chromatography (silica, 0-20% EtOAc:EtOH in heptane (3:1)) to give (R,E)-2-methyl-N-((5-(trifluoromethyl) Pyridin-2-yl)methylene)propane-2-sulfinamide (1.105 g, 3.97 mmol, 96% yield) was obtained as an off-white solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 9.15-9.19(m,1H),8.56(s,1H),8.42(dd,J=8.2,2.3Hz,1H),8.28(d,J=8.2Hz,1H),1.23(s,9H ).m / z(ESI):279.0(M+H) + .
[0221] Step 2. In an oven-dried 100 mL two-necked round bottom flask, add (R,E)-2-methyl-N-((5-(trifluoromethyl)pyridin-2-yl) in tetrahydrofuran (7.19 mL). Methylene)propane-2-sulfinamide (0.40g, 1.44mmol) was added. The reaction mixture was cooled to −78° C. and then a 0.5 M solution of cyclopropylmagnesium bromide in THF (5.17 mL, 2.59 mmol, Sigma-Aldrich Corporation) was added dropwise to the reaction mixture. After 10 minutes, saturated NH 4 Cl (5.8 mL) was extracted with EtOAc (3x25 mL). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude product was purified by flash chromatography (silica, 0-60% EtOAc:DCM) to yield both diastereomers, with peak 1 as a pale yellow oil (R)-sulfinamine (0.176 g, 0.55 mmol, Yield: 38%). 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.91(s,1H),8.24(dd,J=8.4,2.3Hz,1H),7.79(d,J=8.4Hz,1H),5.82(d,J=7.5Hz,1H),3.81( t,J=8.0Hz,1H),1.12-1.24(m,10H),0.36-0.62(m,4H).m / z(ESI):321.1(M+H) + .Peak 2 was (S)-sulfinamine (0.099g, 0.309mmol, yield 22%), a white solid. 1 H NMR(400MHz,DMSO-d 6 )δ ppm 8.89(s,1H),8.24(dd,J=8.4,2.3Hz,1H),7.75(d,J=8.4Hz,1H),5.64(d,J=6.3Hz,1H),3.74( dd,J=9.0,6.5Hz,1H),1.25-1.32(m,1H),1.10(s,9H),0.59-0.64(m,1H),0.42-0.51(m,3H).m / z( ESI):321.1(M+H) + Absolute stereochemistry was assigned to the sulfinimine intermediate and the purchased enantiopure amine based on similarity to literature examples (Tetrahedron Letters, S.D. Kuduk et al, 45 (2004) 6641-6643).
[0222] Step 3. In a 50 mL round bottom flask, add (S)-sulfinamide (0.16 g, 0.48 mmol, peak 2) and 4.0 M dioxane solution (0.15 mL, 0.61 mmol, Sigma-Aldrich Corporation) in 1,4-dioxane (2.42 mL). ) was added. The resulting reaction mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated in vacuo and the crude product was carried on to the next step of the synthesis without further purification. m / z(ESI):217.0(M+H) + .
[0223] Step 4. In a 50 mL round bottom flask, (S)-cyclopropyl(5-(trifluoromethyl)pyridin-2-yl)methanamine hydrochloride (0.12 g, 0.48 mmol) and acetaldehyde (0.03 g, 0.03 mL, 0.61 mmol, Sigma-Aldrich Corporation) was added. Titanium (IV) isopropoxide (0.17 g, 0.18 mL, 0.60 mmol, Aldrich) was then added to the reaction mixture and stirred at room temperature for 16 hours. The mixture was cooled to 0 °C, then methanol (0.16 g, 0.2 mL, 4.83 mmol, Sigma-Aldrich Corporation) was added to the mixture, followed by sodium borohydride (0.02 g, 0.48 mmol, Aldrich). , and the resulting reaction mixture was stirred for 2 hours. The reaction mixture was concentrated in vacuo. The crude product was purified by flash chromatography (silica, 0-35% MeOH:DCM) to give (S)-N-(cyclopropyl(5-(trifluoromethyl)pyridin-2-yl)methyl)ethanamine (0.040 g , 0.164 mmol, yield 33.9%) was obtained as a tan solid. m / z(ESI):245.1(M+H) + .
[0224] The primary and secondary amines in Table 13 were prepared in a manner similar to that described for Intermediate 206.
[0225] [Table 25]
[0226] Intermediate 211: N-methyl-1-(5-(trifluoromethyl)pyridin-2-yl)propan-1-amine [ka]
[0227] Step 1. Add N-methoxy-N-methyl-5-(trifluoromethyl)picolinamide (0.29 g, 1.21 mmol, J&W Pharmlab) in tetrahydrofuran (6.1 mL) to an oven-dried two-necked 100 mL round bottom flask. did. The reaction mixture was cooled to −78° C. and then a 2.0 M ethylmagnesium chloride solution in THF (1.83 mL, 3.65 mmol, Sigma-Aldrich Corporation) was added dropwise to the reaction mixture. The resulting reaction mixture was stirred at -78 °C for 15 min, then the mixture was diluted with saturated NH 4 Quenched with aqueous Cl (6 mL). The mixture was allowed to warm to room temperature. The reaction mixture was then diluted with EtOAc (30 mL) and the aqueous layer was extracted with EtOAc (3x). Combined organic extracts with MgSO 4 dried, filtered and concentrated in vacuo. The crude product was used without further purification. m / z(ESI):204.0(M+H) + .
[0228] Step 2. In a 50 mL round bottom flask, add 1-(5-(trifluoromethyl)pyridin-2-yl)propan-1-one (0.10 g, 0.49 mmol) and tetrahydrofuran (0.37 mL, 0.74 mmol) in methanol (2.5 mL). A 2.0 M solution of methylamine in mmol (Sigma-Aldrich Corporation) was added. Titanium (IV) isopropoxide (0.18 g, 0.18 mL, 0.62 mmol, Sigma-Aldrich) was then added to the reaction mixture. The resulting reaction mixture was stirred at room temperature for 30 minutes under an inert atmosphere. The mixture was then cooled to 0° C. and sodium borohydride (0.09 g, 2.46 mmol, Sigma-Aldrich) was slowly added to the reaction mixture. The mixture was stirred at room temperature for 1 hour. Saturate the reaction mixture with NaHCO 3 (0.5 mL) aqueous solution and the resulting mixture was stirred for 10 minutes. The mixture was then diluted with MeOH (2 mL) and filtered through a pad of celite. The filtrate was concentrated in vacuo. This gave N-methyl-1-(5-(trifluoromethyl)pyridin-2-yl)propan-1-amine as a pale yellow solid. The mixture was carried on to the next step of the synthesis without further purification. m / z(ESI):219.1(M+H) + .
[0229] The secondary amines of Table 14 were prepared in a similar manner as described for Intermediate 211.
[0230] [Table 26]
[0231] Intermediate 214: (R)-N-((6-ethoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethane-1-amine [ka]
[0232] Step 1. (R)-N-((6-bromopyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine (133, 0.840 g, 3.47 mmol) and DIPEA (0.897 g, 1.21 mL, 6.94 mmol, Aldrich) was stirred in dichloromethane (17.4 mL) and di-tert-butyl dicarbonate (1.21 g, 1.29 mL, 5.55 mmol, Oakwood Products, Inc.) was added. The reaction was then stirred at room temperature overnight until completion. The mixture was partitioned between 200 mL of DCM and water. The layers were separated. organic layer with Na 2 S.O. 4 and concentrated. The crude product was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptene) to give tert-butyl(R)-((6-bromopyridazin-3-yl)methyl)(1-(pyrimidine-2- yl)ethyl)carbamate (1.61 g, 4.70 mmol, yield 136%) was obtained. m / z(ESI):394.1,396.1(M+H) + .
[0233] Step 2. t-Butyl BrettPhos (55.0 mg, 0.110 mmol, Aldrich) was mixed in dioxane (1.0 mL). In a separate flask, t-butyl BrettPhosPd G3 (98.0 mg, 0.110 mmol, Aldrich), ethanol (0.300 mL, 5.70 mmol, Aldrich), (R)-((6-bromopyridazin-3-yl)methyl)( 1-(Pyrimidin-2-yl)ethyl)carbamate (300 mg, 0.76 mmol) and cesium carbonate (350 mg, 1.10 mmol, Aldrich) were slurried in dioxane (2.50 mL). The t-butyl BrettPhos mixture was added to the second flask. The slurry was then stirred overnight to completion. The mixture was concentrated under reduced pressure and the residue was purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give tert-butyl(R)-((6-ethoxypyridazin-3-yl)methyl)(1 -(pyrimidin-2-yl)ethyl)carbamate (231 mg, 0.643 mmol, yield 84.0%) was obtained. m / z(ESI):360.0(M+H) + This material was dissolved in TFA (10 mL) and stirred for 15 minutes to completion. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in MeOH, eluted through an SCX column eluting with 0-2M ammonia in MeOH, and concentrated to give (R)-N-((6-ethoxy Pyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine (214, 166 mg, 0.640 mmol, yield 84%) was obtained. m / z(ESI):260.0(M+H) + .
[0234] Intermediate 215: 4-amino-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid. [ka]
[0235] Step 1. To a stirred solution of 4-oxotetrahydrofuran-3-carbonitrile (0.500 g, 4.50 mmol) in dichloromethane (5.00 mL) was added DIPEA (0.943 mL, 5.40 mmol) and the reaction mixture was cooled to -78°C. Trifluoromethanesulfonic anhydride (0.760 mL, 4.50 mmol) was then added dropwise at −78° C. for 1 min, and the reaction mixture was stirred at the same temperature for 15 min. After completion of the reaction, the reaction mixture is diluted with water, the organic layer is separated, washed with brine (2x10 mL), dried over sodium sulfate, and concentrated to give the crude 4-cyano-2,5-dihydrofuran-3 -yl trifluoromethanesulfonate (1.05 g, 4.32 mmol, 96% yield) was obtained, which was used in the next step without further purification.
[0236] Step 2. In a 150 mL round bottom flask, methyl 4-amino-3-bromobenzoate (4 g, 17.39 mmol, Combi-Blocks Inc.) and bis(pinacolato)diboron (8.83 g, 34.8 mmol, Frontier Scientific, Inc.) was added. Potassium acetate (5.12 g, 52.2 mmol, Sigma-Aldrich Corporation) was then added to the solution and the mixture was degassed by bubbling argon for 5 min. [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(ii) complex with dichloromethane (1.420 g, 1.739 mmol, Strem Chemicals, Inc.) was then added. The reaction was stirred at 100°C. After 18 hours, the reaction was cooled and the solids were filtered under vacuum and washed with DCM. The mother liquor was then concentrated to obtain a semi-solid residue. DCM was added and the solid that formed was collected by vacuum filtration. The mother liquor was concentrated again and the process was repeated. The desired methyl 4-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.6 g, 9.38 mmol, 54.0% yield) as a gray solid. isolated. m / z(ESI):196.1(M+H) + (boronic acid). 1 H NMR(400MHz,chloroform-d)δ ppm 8.33(d,J=2.1Hz,1H),7.90(dd,J=8.6,2.2Hz,1H),6.57(d,J=8.5Hz,1H),5.20 (brs,2H),3.87(s,3H),1.37(s,12H).
[0237] Step 3. To a stirred solution of 4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (10 g, 41.1 mmol) in 1,4-dioxane (200 mL) and water (20.00 mL) was added methyl 4 under a nitrogen purge. -Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (9.12g, 32.9mmol), K 2 C.O. 3 (17.05g, 123mmol) and Pd(PPh 3 ) 4 (4.75g, 4.11mmol) was added. The reaction mixture was then heated at 80°C for 16 hours. The reaction mixture was concentrated, then diluted with ethyl acetate (50 mL) and water (50 mL) and stirred at room temperature for 30 minutes. The solid formed was then filtered, washed with ethyl acetate (50 mL) and 2% MeOH in DCM (50 mL), then dried under vacuum to give methyl 4-amino-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxylate (6.6 g, 27.0 mmol, 65.7% yield) was obtained as a gray solid. m / z(ESI):245.3(M+H) + . 1 H NMR(400MHz,TFA-d)δ ppm 8.59-8.67(2H,m),7.97(1H,d,J=9.3Hz),5.94(2H,t,J=3.5Hz),5.65(2H,t, J=3.4Hz),4.24(3H,s).Note: For some heterocycles, Pd(PPh 3 ) 4 Pd(dppf)Cl instead of 2 It was used.
[0238] Step 4. To a stirred solution of methyl 4-amino-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (30 g, 123 mmol) in water (300 mL):tetrahydrofuran (300 mL):methanol (300 mL) , LiOH (11.77g, 491mmol) was added and the reaction mixture was heated at 75°C for 3 hours. The reaction mixture was concentrated and acidified with 1.5N HCl to pH 6.0. The resulting solid was filtered, washed with methanol (300 mL), and dried to give 4-amino-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid (28 g, 122 mmol, yield 99 %) as an off-white solid. m / z(ESI):231.2(M+H) + . 1 H NMR(400MHz,DMSO-d)δ ppm 12.83(1H,s),7.88-8.30(2H,m),7.59(1H,d,J=8.8Hz),7.02(2H,s),5.40(2H, t,J=3.5Hz),5.03(2H,t,J=3.6Hz).
[0239] The acids in Table 15 were prepared in a similar manner as described for Intermediate 215.
[0240] [Table 27]
[0241] [Table 28]
[0242] [Table 29]
[0243] [Table 30]
[0244] Intermediate 245: 6-amino-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxylic acid. [ka]
[0245] Step 1. DCM ( The mixture was cooled to −78° C. and trifluoromethanesulfonic anhydride (7.03 mL, 7.03 mmol, Sigma-Aldrich Corporation) was added. After the addition was complete, the mixture was stirred at −78° C. for 5 minutes, then the dry ice bath was removed and stirred at room temperature. After 15 minutes, the mixture was concentrated to give quantitative methyl 2-(((trifluoromethyl)sulfonyl)oxy)cyclopent-1-ene-1-carboxylate. Obtained as a pale yellow solid and used as is. m / z(ESI):275(M+H) + .
[0246] Step 2. Methyl 2-(((trifluoromethyl)sulfonyl)oxy)cyclopent-1-ene-1-carboxylate (1.982g, 7.23mmol), (2-amino-5-(methoxycarbonyl)pyridine-3- yl)boronic acid (1.70 g, 8.67 mmol), potassium phosphate, tribasic (3.78 g, 21.69 mmol, Acros) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(ii), dichloromethane (0.177 g, 0.217 mmol, Strem Chemicals, Inc.) in 1,4-dioxane / water (10 / 0.60 mL) was heated at 80 °C for 1 h, at which time it was brought to room temperature and diluted with EtOAc. did. A precipitate was formed corresponding to the desired product. The precipitate was filtered and washed with EtOAc to give a diluted solution containing quantitatively methyl 6-oxo-6,7,8,9-tetrahydro-5H-cyclopenta[c][1,8]naphthyridine-2-carboxylate. Obtained as a gray solid. yield. m / z(ESI):245(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 11.93-12.58(m,1H),8.96(d,J=2.1Hz,1H),8.33(d,J=2.1Hz,1H),3.89(s,3H) ,3.13(brt,J=7.6Hz,2H),2.78(brt,J=7.3Hz,2H),2.08-2.18(m,2H).
[0247] Process 3.POCl 3 Methyl 6-oxo-6,7,8,9-tetrahydro-5H-cyclopenta[c][1,8]naphthyridine-2-carboxylate (1.76 g, 7.21 mmol, Aldrich) in (24.68 g, 15 mL, 161 mmol, Aldrich) ) The mixture was heated to reflux for 30 minutes. Once the reaction is complete, carefully cool the saturated NaHCO 3 was added to basify the reaction. After stirring for 15 min, the mixture was extracted with EtOAc and the combined organics were concentrated to quantitatively yield methyl 6-chloro-8,9-dihydro-7H-cyclopenta[c][1,8] as a yellow solid. Naphthyridine-2-carboxylate was obtained. yield. m / z(ESI):263(M+H) + .
[0248] Step 4. To a suspension of methyl 6-chloro-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxylate (1.89 g, 7.19 mmol) in DMSO (15 mL) was added DIPEA. (2.79g, 3.77mL, 21.58mmol, Aldrich) was added followed by (2,4-dimethoxyphenyl)methanamine (1.564g, 1.405mL, 9.35mmol, Aldrich). The resulting mixture was heated at 90°C overnight. The reaction was then cooled to room temperature, diluted with water, and saturated NH 4 Washed with Cl and extracted with EtOAc. The combined organic matter is Na 2 S.O. 4 , filtered and concentrated to give methyl 6-((2,4-dimethoxybenzyl)amino)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxylate ( 2.18 g, 5.54 mmol, 77% yield) was obtained as a yellow solid and used as is. m / z(ESI):394(M+H) + .
[0249] Step 5 Methyl 6-((2,4-dimethoxybenzyl)amino)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxylate (2.18 g, 5.54 mmol) in THF / To the solution in MeOH (10 / 10 mL) was added NaOH (10 mL, 10.00 mmol) and the resulting solution was heated at 70° C. for 2 hours, at which point it was brought to room temperature and acidified with 10 mL of 1M HCl. A pale yellow precipitate is formed which is filtered off and azeotropically dried with toluene to yield 6-((2,4-dimethoxybenzyl)amino)-8,9-dihydro-7H-cyclopenta[c][1, 8] Naphthyridine-2-carboxylic hydrochloride (1.44 g, 3.46 mmol, yield 62.5%) was obtained as a yellow solid. m / z(ESI):380.2(M+H) + .
[0250] The acids in Table 16 were prepared in a similar manner as described for Intermediate 245.
[0251] [Table 31]
[0252] [Table 32]
[0253] [Table 33]
[0254] Intermediate 259: 4-Amino-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid [ka]
[0255] Step 1. A suspension of sodium hydride (11.10 g, 278 mmol 0.5 eq., 60% in mineral oil) in anhydrous tetrahydrofuran (250 mL) was added with N 2Methyl glycolate (42.4 mL, 555 mmol, 1.0 eq.) was added at room temperature under atmosphere. To the reaction mixture was slowly added (E)-but-2-enenitrile (54.5 mL, 666 mmol, 1.2 eq.) at 65° C. and stirred at the same temperature for 2 hours. The reaction mixture was cooled, quenched with 2N NaOH solution (250 mL), and extracted with diethyl ether (500 mL). The aqueous layer was acidified with concentrated HCl to adjust the pH to ~1 and extracted with dichloromethane (2x500 mL). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica gel (230-400 mesh) using 10% ethyl acetate as eluent to give 2-methyl-4-oxotetrahydrofuran-3-carbonitrile (22 g, 176 mmol, yield 32 %) as a brown solid. m / z (ESI, negative): 124.3[M-1].1H NMR (400MHz, chloroform-d): δ ppm 4.40-4.27(m,2H),4.26-4.19(m,1H),3.24-2.99( m,1H),1.61(dd,J=18.6,6.2Hz,3H).
[0256] Step 2. To a stirred solution of 2-methyl-4-oxotetrahydrofuran-3-carbonitrile (25.0 g, 200 mmol, 1.0 eq.) in dichloromethane (500 mL) was added DIPEA (69.8 mL, 400 mmol, 2.0 eq.) and trifluoromethanesulfonic anhydride ( 47.1 mL, 280 mmol, 1.4 eq) was added at -78°C and stirred for 15 minutes at the same temperature. The reaction mixture was quenched by slow addition of water (250 mL) and after reaching room temperature was extracted with dichloromethane (2x500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was stirred in diethyl ether and filtered. The mother liquor was concentrated under reduced pressure to give 4-cyano-5-methyl-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (35.0 g, crude) as a light brown adduct. The crude material was used in the next step without further purification. m / z:257.1 [no ionization]
[0257] Step 3. To a stirred solution of 4-cyano-5-methyl-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (35 g, 136 mmol, 1.0 eq.) in 1,4-dioxane (1400 mL) and water (70.0 mL), Methyl 4-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (37.7 g, 136 mmol, 1.0 eq.) and potassium phosphate ( 87g, 408mmol, 3.0eq) was added. The reaction mixture was degassed with nitrogen for 15 min, then PdCl 2 (dppf)-DCM adduct (9.96 g, 13.61 mmol, 0.1 eq.) was added and the reaction mixture was heated at 90° C. for 16 h. The reaction mass was concentrated under reduced pressure to obtain the crude product. The crude residue was purified by column chromatography on silica gel (60-120 mesh) using 50% ethyl acetate and hexane as eluent to give methyl 4-amino-3-methyl-1,3-dihydrofuro[3,4- c]quinoline-8-carboxylate (25 g, 97 mmol, 71% yield) was obtained as a brown solid. m / z:259.2(M+H) +1 H NMR(400MHz,DMSO-d 6 ):δ 8.11(d,J=2.0Hz,1H),8.00(dd,J=8.8,2.0Hz,1H),7.58(d,J=8.8Hz,1H),6.87(s,2H),4.11( q,J=5.3Hz,1H),3.87(s,2H),3.17(d,J=5.3Hz,3H),1.41(d,J=5.9Hz,3H).
[0258] Step 4. Methyl 4-amino-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (26.0 g, 101 mmol, 1.0 equiv.) in tetrahydrofuran (130 mL), methanol (78 mL) and To a stirred solution in water (52 mL) was added lithium hydroxide (9.64 g, 403 mmol, 4.0 eq.) and stirred at 75° C. for 4 hours. LCMS showed the reaction to be complete. The reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in water (100 mL) and filtered to remove insoluble particles. The aqueous layer was acidified with concentrated HCl (pH 6-6.5). The precipitated solid was filtered, washed with water and dried under vacuum to give 4-amino-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid (17.5 g, 71.6 mmol, yield 71%) was obtained as an off-white solid. m / z:245.1(M+H) +1 H NMR(TFA,400MHz):δ(ppm) 8.68(t,J=6.2Hz,2H),8.01(dd,J=9.1,4.2Hz,1H),6.15(s,1H),5.94(m,2H) ),1.86(t,J=5.4Hz,3H)
[0259] Step 5. Chiral SFC separation: 44.5 g of racemic 4-amino-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid was separated by chiral SFC to obtain 14 g of each isomer. Ta. Stereochemistry is assigned arbitrarily.
[0260] Separation information:
[0261] [Table 34]
[0262] The racemic acids in Table 17 were prepared in a manner similar to that described for Intermediate 259.
[0263] [Table 35]
[0264] Intermediate 268: 4-amino-3-((benzyloxy)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid [ka]
[0265] Step 1. To a stirred solution of diethyl(cyanomethyl)phosphonate (130 g, 732 mmol, 1.1 eq.) in tetrahydrofuran (2000 mL) was added potassium tert-butoxide (1M solution in THF; 732 mL, 732 mmol, 1.1 eq.) at -78 °C. , stirred for 30 minutes. To the reaction mixture was added 2-(benzyloxy)acetaldehyde (100 g, 666 mmol, 1.0 eq) at -78°C and left at room temperature for 1 hour. After completion, the reaction mixture is saturated with NH 4 Quenched with Cl solution (1500 mL) and extracted with ethyl acetate (2x3000 mL). The combined organic layers were washed with an aqueous brine solution (1000 mL) and diluted with anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate under vacuum. The crude residue was purified by column chromatography on silica gel (60-120 mesh) using 15% ethyl acetate with petroleum ether as eluent to give 4-(benzyloxy)but-2-enenitrile (100.6 g, yield 87%) was obtained as a colorless oil. m / z:174.1(M+H) + . 1 H NMR (chloroform-d, 400MHz): δ (ppm) proton NMR showed a mixture of isomers. 7.47-7.32(m,5H),6.80-6.62(m,1H),5.77-5.72(m,1H),4.59(d,J=2.8Hz,2H),4.18-4.16(m,2H).
[0266] Step 2. To a stirred solution of potassium tert-butoxide (1M solution in THF; 289.0 mL, 289 mmol, 1.0 eq.) in tetrahydrofuran (260 mL) was added methyl 2-hydroxy acetate (22.03 mL, 289 mmol, 1.0 eq.) at room temperature. , heated to 50 °C under nitrogen atmosphere. To this was added 4-(benzyloxy)but-2-enenitrile (50.0 g, 289 mmol, 1.0 eq.) and stirred at the same temperature for 4 hours. The reaction temperature was raised to 70°C and stirred for 16 hours. After completion, the reaction mixture was cooled to 0° C. and quenched with ice water (500 mL). The resulting solution was washed with diethyl ether (2x200 mL), then acidified with concentrated HCl (to a pH of about 1-2), and then extracted with DCM (2x500 mL). The combined organic layer was diluted with anhydrous Na 2 S.O. 4 dried, filtered and concentrated under vacuum. The crude residue was purified by column chromatography on silica gel (60-120 mesh) using 26% ethyl acetate with petroleum ether as eluent to give 2-((benzyloxy)methyl)-4-oxotetrahydrofuran-3- Carbonitrile (9.2 g, 14% yield) was obtained as a colorless oil. LCMS (ESI, positive) m / z:232.0 (M+H) + . 1 H NMR(400MHz,chloroform-d)δ 7.41-7.28(m,5H),4.83-4.60(m,2H),4.52(dd,J=11.8,6.6Hz,1H),4.33(dd,J=17.0, 9.0Hz,1H),4.11-3.89(m,2H),3.82-3.68(m,2H).
[0267] Step 3. To a stirred solution of 2-((benzyloxy)methyl)-4-oxotetrahydrofuran-3-carbonitrile (5.8 g, 25.08 mmol, 1.0 eq.) in dichloromethane (116 mL) was added N 2Triflic anhydride (6.75 mL, 40.1 mmol, 1.6 eq.) and DIPEA (8.76 mL, 50.2 mmol, 2.0 eq.) were added at −78° C. under atmosphere and stirred for 10 minutes. The reaction mixture was quenched with water (50 mL) and extracted with dichloromethane (2x200 mL). The combined organic layers were washed with an aqueous brine solution (100 mL) and diluted with anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate under reduced pressure. The crude residue was washed with diethyl ether (200 mL) and filtered. The organic layer was concentrated under reduced pressure to obtain 5-((benzyloxy)methyl)-4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (7.65 g) as a light brown liquid. It was used as it was in the next step.
[0268] Step 4. 5-((benzyloxy)methyl)-4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (7.65 g, 20.93 mmol, 1.0 eq.) in 1,4-dioxane (232 mL) and water ( 11.60 mL) of methyl 4-amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (5.8 g, 20.93 mmol, 1.0 eq.) , potassium carbonate (8.68g, 62.8mmol, 3.0eq) was added at room temperature. Reaction mixture N 2 Purge with gas for 15 min, then Pd(PPh 3 ) 4 (1.209g, 1.046mmol, 0.05eq) was added. The reaction mixture was heated at 80°C for 16 hours. After completion, the reaction mixture was concentrated under reduced pressure and the crude residue was purified by column chromatography on silica gel (60-120 mesh) using 80% ethyl acetate with petroleum ether as eluent to give 4-amino-3- ((Benzyloxy)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (4.4 g, 58% yield) was obtained as an off-white solid. m / z:365.2(M+H) + . 1 H NMR(400MHz,DMSO-d 6 )δ 8.12(d,J=2.0Hz,1H),8.01(dd,J=8.9,2.0Hz,1H),7.59(d,J=8.8Hz,1H),7.34-7.20(m,5H),6.91 (brs,2H),5.49(dq,J=5.6,3.6,2.7Hz,1H),5.44-5.32(m,2H),4.56-4.44(m,2H),3.90-3.73(m,5H).Ester 268 was treated with LiOH in THF and the lithium salt of 268 was used crude in the amide coupling reaction.
[0269] Intermediate 269: Lithium 4-amino-1-methyl-7-(trifluoromethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxylate hydroxide [ka]
[0270] Process 1.K 3 P.O. 4 ·H 2 O (1.08g, 4.70mmol, Sigma-Aldrich Corporation), X-Phos (0.08g, 0.16mmol, Sigma-Aldrich Corporation), (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1 ,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(ii) methanesulfonate (0.14 mg, 0.16 mmol, Sigma-Aldrich Corporation), 1-methyl-5-(4 ,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole-4-carbonitrile (1.10 g, 4.70 mmol, Enamine) and methyl 4-amino-5-bromo- 2-(Trifluoromethyl)benzoate (0.700 g, 2.349 mmol, Combi Blocks) was suspended in a degassed mixture of water (1.0 mL) and 1,4-dioxane (5.0 mL) at 60 °C overnight and then Stirred at 90°C for 18 hours. The volatiles were removed in vacuo and the crude product was purified by silica column chromatography (0~5%MeOH / DCM+0.5%NH 3 / MeOH) to produce methyl 4-amino-1-methyl-7-(trifluoromethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (0.63 g, 1.94 mmol, yield 83 %) was obtained as a slightly brownish solid. m / z(ESI):324.8(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 8.71-8.76(m,1H),8.33-8.37(m,1H),7.87-7.92(m,1H),7.54-7.61(m,2H),4.41-4.46 (m,3H),3.92(s,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -58.06.
[0271] Step 2. Methyl 4-amino-1-methyl-7-(trifluoromethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (0.62 g, 1.90 mmol) and lithium hydroxide (0.91 g , 3.79 mmol, Sigma-Aldrich Corporation) in methanol (3.0 mL), H 2 It was suspended in O (3.0 mL) and THF (3.0 mL) and stirred at 50°C for 2 hours. The volatiles of the crude mixture were removed in vacuo and the tan solid was coevaporated twice with DCM followed by toluene to yield lithium 4-amino-1-methyl-7-(trifluoromethyl)- 1H-pyrazolo[4,3-c]quinoline-8-carboxylate hydroxide (585 mg, 1.720 mmol, 91% yield) was obtained, which was used in the subsequent step without further purification. m / z(ESI):310.9(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 8.33(s,1H),8.27(s,1H),7.68(s,1H),7.03(brs,2H),4.38(s,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -57.47.
[0272] Intermediate 270: Lithium 4-amino-7-chloro-3-methyl-3H-pyrazolo[3,4-c]quinoline-8-carboxylate hydroxide [ka]
[0273] Step 1.1H-pyrazole-5-carbonitrile, 4-bromo-1-methyl-(273 mg, 1.47 mmol), methyl 4-amino-2-chloro-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzoate (457 mg, 1.47 mmol), phosphoric acid, tripotassium salt, monohydrate (1.35 g, 5.87 mmol, Sigma-Aldrich Corporation) and Pd(amphos)Cl 2 (72.7 mg, 0.10 mmol) was suspended in degassed water (1.0 mL) and 1,4-dioxane (4.00 mL) and stirred at 90° C. overnight, resulting in the formation of a yellow solid. The mixture was cooled to room temperature, the precipitate was filtered, washed with DCM, MeOH and acetone, then water (10 mL) was added. 92 mg of the solid was dried and the organic washings were absorbed onto silica gel, 0-20% MeOH + 0.5% NH in MeOH / DCM. 3 Purification via column chromatography using ) was obtained as an orange solid. m / z(ESI):291.000(M+H) + .1H NMR(400MHz,DMSO-d6)δ ppm 8.52-8.63(m,2H),7.60(s,1H),7.25(s,2H),4.35(s,3H),3.89(s,3H).
[0274] Step 2. Methyl 4-amino-7-chloro-3-methyl-3H-pyrazolo[3,4-c]quinoline-8-carboxylate (164 mg, 0.56 mmol) in water (0.5 mL) and methanol (0.5 mL). and tetrahydrofuran (0.5 mL), then lithium hydroxide hydrate (47.3 mg, 1.13 mmol, Sigma-Aldrich Corporation) was added and the reaction was stirred at 50° C. for 90 minutes. The volatiles were removed in vacuo to give lithium 4-amino-7-chloro-3-methyl-3H-pyrazolo[3,4-c]quinoline-8-carboxylate hydroxide (170 mg, 0.56 mmol, yield 98 %) as a yellow solid. m / z(ESI):277.0(M+H) + .
[0275] Intermediate 271: Lithium 4-amino-7-fluoro-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxylate [ka]
[0276] Step 1. In a 100 mL round bottom flask, add 5-bromo-1H-pyrazole-4-carbonitrile (1 g, 5.81 mmol, Enamine), cesium carbonate (3.79 g, 11.63 mmol, Sigma- Aldrich Corporation) and 2,2,2-trifluoroethyl triflate (1.687 g, 1.054 mL, 7.27 mmol, Combi-Blocks Inc.) were added. The reaction mixture was stirred at 35°C for 20 hours. Once complete as judged by LC-MS, the reaction was filtered and concentrated in vacuo to give the crude product. This was used directly in the next step without further purification. m / z(ESI):253.9(M+H) +
[0277] Step 2. In a 25 mL pressure vial, add methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2- Dioxaborolan-2-yl)benzoate (534 mg, 1.810 mmol), 5-bromo-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carbonitrile (418 mg, 1.646 mmol), anhydrous potassium carbonate (1137 mg, 8.23 mmol, Acros Organics) and tetrakis(triphenylphosphine)palladium (190 mg, 0.165 mmol, Strem) were added. solution in N 2 The mixture was degassed for 10 minutes and heated at 90°C for 18 hours. Once complete as judged by LC-MS, the reaction mixture was cooled to room temperature and 5 ml of water was added. The product was filtered and the precipitate was washed twice with 5 ml of water and 3 times with 5 ml of DCM. The crude product was isolated as a solid and used directly in the next step without further purification. m / z(ESI):343.0(M+H) +
[0278] Step 3. In a 20 ml pressure vial, add methyl 4-amino-7-fluoro-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (544 mg, 1.589 mmol) and lithium hydroxide were added and the monohydrate (133 mg, 3.18 mmol, Sigma-Aldrich Corporation) in tetrahydrofuran (1766 μL), methanol (1766 μL) and water (1766 μL) was stirred at 50° C. for 12 hours. Once complete by LCMS, the reaction mixture was cooled to room temperature, evaporated to dryness and used as such for the next step. m / z(ESI):329.1(M+H) +
[0279] Intermediate 272: 4-Amino-3-(fluoromethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic hydrochloride [ka]
[0280] Step 1. Methyl 4-amino-3-((benzyloxy)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (3.40 g, 9.33 mmol, 1.0 eq., intermediate 206- methyl ester) was dissolved in tetrahydrofuran (46.7 mL) and triethylamine (4.16 mL, 29.9 mmol, 3.2 eq., Aldrich) and phthalic anhydride (2.76 g, 18.7 mmol, 2.0 eq., Aldrich) were added. The reaction mixture was heated at reflux for 4 days. The reaction was then concentrated to dryness and then dissolved in water (100 mL) and DCM (150 mL). The layers were separated and the aqueous layer was extracted with DCM (1x200mL). Combined organic layers with MgSO 4 The crude product is purified by medium pressure chromatography (silica, 0-100% EtOAc:heptane) to give methyl 3-((benzyloxy)methyl)-4-(1,3-dioxo Isoindolin-2-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (3.22 g, 6.51 mmol, 69.8% yield) was obtained. m / z(ESI):495.1(M+H) + .
[0281] Step 2. Methyl 3-((benzyloxy)methyl)-4-(1,3-dioxoisoindolin-2-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate ( 4.22 g, 8.53 mmol, 1.0 eq.) was dissolved in dichloromethane (114 mL) and cooled to -78 °C, then boron trichloride (1.0 M in DCM) (21.3 mL, 21.3 mmol, 2.5 eq., Aldrich) was added. and the resulting mixture was stirred in a dry ice bath for 1.5 hours to completion. The slurry was recooled to −78° C. and methanol (3.5 mL) was slowly added to quench the reaction mixture. The slurry was removed from the dry ice bath and slowly warmed. The mixture was diluted with water (150 mL) and extracted with EtOAc (2x250 mL). Combine the combined organic layers, wash with brine (1x100mL), and MgSO 4 dried with. The filtrate was concentrated and then triturated with EtOAc / hexane to give the desired methyl 4-(1,3-dioxoisoindolin-2-yl)-3-(hydroxymethyl)-1,3-dihydrofuro[3, 4-c]quinoline-8-carboxylate (2.83 g, 7.00 mmol, yield 82%) was obtained. m / z(ESI):405.1(M+H) + .
[0282] Step 3. Methyl 4-(1,3-dioxoisoindolin-2-yl)-3-(hydroxymethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (998 mg, 2.47 mmol, 1.0 eq.) was dissolved in DCE (24.7 mL) and DAST (1.31 mL, 9.87 mmol, 4.0 eq., Aldrich) was slowly added. The resulting mixture was stirred for 1.5 hours until completion. Pour the reaction mixture into 40 mL of saturated NaHCO 3 The reaction was quenched by slowly adding . This mixture was extracted with EtOAc (2x100mL). The combined organic layers were washed with brine (1x45ml) and MgSO 4 dried with. The crude product was triturated with EtOAc, the precipitate was filtered and washed to give methyl 4-(1,3-dioxoisoindolin-2-yl)-3-(fluoromethyl)-1,3-dihydrofuro[3 ,4-c]quinoline-8-carboxylate (690 mg, 1.70 mmol, yield 68.8%) was obtained. m / z(ESI):406.9(M+H) + .
[0283] Step 4. Lithium hydroxide monohydrate (273 mg, 6.50 mmol, 4.0 eq., Sigma-Aldrich Corporation) was dissolved in methyl 4-(1,3-dioxoisoindolin-2-yl)-3-(fluoromethyl). Suspension of -1,3-dihydrofuro[3,4-c]quinoline-8-carboxylate (660 mg, 1.62 mmol, 1.0 eq) in MeOH (8.5 mL), THF (8.5 mL) and water (8.5 mL) added to. The mixture was heated to 70°C for 19 hours, then cooled to room temperature. The organic solvent was removed in vacuo and the resulting aqueous solution was brought to pH 6 with 5N HCl solution. The resulting suspension was filtered and air-dried to give 4-amino-3-(fluoromethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic hydrochloride (490 mg, 1.64 mmol). , yield 101%). m / z(ESI):263.1(M+H) + .
[0284] Example Example 300: 4-Amino-N-(cyclopropylmethyl)-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-1,3-dihydrofuro[3,4-c]quinoline-8 -Carboxamide [ka]
[0285] 1-Cyclopropyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine (2, 0.050g, 0.217mmol), 4-amino-1,3-dihydrofuro[3,4-c ]Quinoline-8-carboxylic acid (165, 0.057g, 0.250mmol), N,N-dimethylacetamide (2mL), HATU (0.099g, 0.261mmol, Combi-Blocks) and diisopropylethylamine (0.112g, 0.151mL, 0.869 mmol, Aldrich) was stirred at room temperature overnight. The mixture was filtered and the crude material was purified by reverse-phase preparative HPLC (10-70% MeCN in water with 0.1% TFA) to yield 4-amino-N-(cyclopropylmethyl)-N-[[5-(tri- Fluoromethyl)-2-pyridyl]methyl]-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide 2,2,2-trifluoroacetate (105 mg, 0.189 mmol, 87% yield) Obtained as a white solid. m / z(ESI):443(M+H) + . 1 H NMR (400MHz, methanol-d4) δ ppm 8.88(brs,1H),8.04-8.16(m,1H),7.89-7.99(m,2H),7.46-7.88(m,2H),5.34-5.60(m ,2H),4.86-5.25(m,4H),3.33-3.60(m,2H),0.93-1.18(m,1H),0.37-0.57(m,2H),0.00-0.31(m,2H). 19 F NMR(377MHz, methanol-d4)δ ppm -63.87(s,3F),-77.15(s,3F).
[0286] The compounds in Table 18 were prepared in a similar manner to Example 300 above using the amide coupling reagents indicated in the table.
[0287] [Table 36]
[0288] [Table 37]
[0289] [Table 38]
[0290] [Table 39]
[0291] [Table 40]
[0292] [Table 41]
[0293] [Table 42]
[0294] [Table 43]
[0295] [Table 44]
[0296] [Table 45]
[0297] [Table 46]
[0298] [Table 47]
[0299] [Table 48]
[0300] [Table 49]
[0301] [Table 50]
[0302] [Table 51]
[0303] [Table 52]
[0304] [Table 53]
[0305] [Table 54]
[0306] [Table 55]
[0307] [Table 56]
[0308] [Table 57]
[0309] [Table 58]
[0310] [Table 59]
[0311] [Table 60]
[0312] [Table 61]
[0313] [Table 62]
[0314] [Table 63]
[0315] [Table 64]
[0316] [Table 65]
[0317] [Table 66]
[0318] [Table 67]
[0319] [Table 68]
[0320] [Table 69]
[0321] [Table 70]
[0322] [Table 71]
[0323] [Table 72]
[0324] [Table 73]
[0325] [Table 74]
[0326] [Table 75]
[0327] [Table 76]
[0328] [Table 77]
[0329] [Table 78]
[0330] [Table 79]
[0331] [Table 80]
[0332] [Table 81]
[0333] [Table 82]
[0334] [Table 83]
[0335] [Table 84]
[0336] [Table 85]
[0337] [Table 86]
[0338] [Table 87]
[0339] [Table 88]
[0340] [Table 89]
[0341] [Table 90]
[0342] [Table 91]
[0343] [Table 92]
[0344] [Table 93]
[0345] [Table 94]
[0346] [Table 95]
[0347] [Table 96]
[0348] [Table 97]
[0349] [Table 98]
[0350] [Table 99]
[0351] [Table 100]
[0352] [Table 101]
[0353] [Table 102]
[0354] Examples 577 and 578: 4-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[3,4-c ]Quinoline-8-carboxamide [ka]
[0355] Step 1. 4-Amino-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid (215, 131 mg, 0.569 mmol), 6-(((1-fluoropropan-2-yl)amino)methyl) N -Ethyl-N-isopropylpropan-2-amine (201 mg, 0.271 mL, 1.553 mmol, Aldrich) was added. The resulting mixture was briefly sonicated and stirred at room temperature for 1 hour. The crude mixture was loaded directly onto a silica gel precolumn (25 g) and subjected to Combiflash column chromatography on a 12 g ISCO gold column eluting with MeOH / DCM (15 min from 0% to 18%) (2x) to obtain the desired product. Got 2 portions. The less pure fraction was dissolved in DMSO / methanol / TFA and preparative reversed-phase HPLC (Gemini™ Prep C18 10 μm column; Phenomenex; water containing 0.1% TFA, where both solvents were 24 min by 15 min). 4-Amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3- 140 mg of dihydrofuro[3,4-c]quinoline-8-carboxamide 2,2,2-trifluoroacetate were obtained as a white solid. m / z(ESI):406.2(M+H) + . 1 H NMR (methanol-d4,400MHz)δ 8.89(s,1H),8.0-8.3(m,1H),7.4-7.9(m,4H),6.1-6.1(m,1H),5.4-5.6(m, 2H),5.1-5.3(m,2H),4.97(s,2H),4.2-4.6(m,3H),1.1-1.5(m,3H). 19 F NMR(methanol-d4,376MHz)δ-221.55(brs,1F).
[0356] Step 2. Transfer the racemate to the mobile phase with 75% liquid CO 2 and purified by preparative SFC using a Chiral Technologies OJ column (250x21 mm, 5 mm) containing 25% MeOH and 0.2% TEA at a flow rate of 80 mL / min. More potent (IC in HCT116 MTAP null cell viability assay) 50 Assign the enantiomer to (R)- (measured by 50 (determined by ) was assigned the enantiomer (S)-. The first eluting peak is (R)-4-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide (577, 54.0 mg, 0.133 mmol, yield 25.7%). The second eluting peak is (S)-4-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[ 3,4-c]quinoline-8-carboxamide (578, 56.1 mg, 0.138 mmol, yield 26.7%). m / z(ESI):406.2(M+H) + . 1 H NMR(DMSO-d6,500MHz)δ 8.99(d,1H,J=1.8Hz),8.26(brs,1H),7.56(brs,4H),6.67(brs,2H),5.34(brs,2H), 5.01(brs,2H),4.7-4.9(m,2H),4.2-4.7(m,3H),3.1-3.3(m,1H),1.15(brs,3H).
[0357] The compounds in Table 19 were prepared in a similar manner as described for 577 and 578 utilizing the coupling agents indicated.
[0358] [Table 103]
[0359] [Table 104]
[0360] [Table 105]
[0361] [Table 106]
[0362] [Table 107]
[0363] [Table 108]
[0364] [Table 109]
[0365] Example 606: (R)-4-Amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-1,3-dihydrofuro[3 ,4-c][1,7]naphthyridine-8-carboxamide. [ka]
[0366] Step 1. (R)-6-((((1-(pyrimidin-2-yl)ethyl)amino)methyl)nicotinonitrile (121,0.118g,0.495mmol), 4-((4-methoxybenzyl) amino)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxylic hydrochloride (251, 0.160g, 0.413mmol) and 1,1'-dimethyltriethylamine (0.533g, 0.721 mL, 4.13 mmol, Sigma-Aldrich Corporation) in DMF (5 mL) was added bromotripyrrolidinophosphonium hexafluorophosphate (0.192 g, 0.413 mmol, Sigma-Aldrich Corporation) and the resulting mixture was Heated for 1 h at °C. The reaction was brought to room temperature and treated with water and saturated NaHCO 3 and extracted with EtOAc (3x). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated. The crude residue was diluted in toluene (3 mL) and concentrated (3x). The residue was then chromatographed on silica gel using 0-50% 3:1 EtOAc / EtOH in heptane to give (R)-N-((5-cyanopyridin-2-yl)methyl)-4-((4- methoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide (0.112g, 0.196mmol, Yield: 47.4%) was obtained as a pale yellow solid. m / z(ESI):573.2(M+H) + .
[0367] Step 2. (R)-N-((5-cyanopyridin-2-yl)methyl)-4-((4-methoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)- A solution of 1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide (0.112 g, 0.196 mmol, 47.4% yield) in DCM (2 mL) was added with TFA (22.20 g, 15 mL, 195 mmol (Aldrich) was added and the resulting mixture was stirred at 70° C. for 24 hours. Reactant 10%Na 2 C.O. 3 and extracted with DCM. The combined organic layers were concentrated and chromatographed on silica gel using 0-50% 3:1 EtOAc / EtOH in heptane and repurified by HPLC to give (R)-4-amino-N-((5-cyanopyridine- 2-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide as an off-white solid (606, 0.070g, 0.155mmol, yield 78.9%). m / z(ESI):453.2(M+H) + .1H NMR(400MHz,DMSO-d6)δ ppm 8.58-8.93(m,4H),8.24(dd,J=8.3,2.1Hz,1H),7.80(s,1H),7.31-7.54(m,2H) ,6.97-7.12(m,2H),5.78-5.88(m,1H),5.18-5.44(m,2H),4.96-5.09(m,3H),4.55(d,J=17.2Hz,1H),1.54 -1.72(m,3H).
[0368] Example 607: 6-Amino-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine -2-carboxamide. [ka]
[0369] Step 1. 2-Methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)propan-1-amine (2, 0.101g, 0.435mmol), 6-((2,4-dimethoxybenzyl) Amino)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxylic hydrochloride (245, 0.217g, 0.522mmol) and 1,1'-dimethyltriethylamine (0.562g, 0.760 mL, 4.35 mmol, Sigma-Aldrich Corporation) in DMA (4 mL) was added bromotripyrrolidinophosphonium hexafluorophosphate (0.203 g, 0.435 mmol, Sigma-Aldrich Corporation) and the resulting mixture was Heated at ℃ for 1 hour. Bring the reaction to room temperature and add water, saturated NaHCO 3 and extracted with EtOAc (3x). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated. The residue was then chromatographed on silica gel using 0-40% 3:1 EtOAc / EtOH in heptane, resulting in 6-((2,4-dimethoxybenzyl)amino)-N-isobutyl-N-((5- (Trifluoromethyl)pyridin-2-yl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide was obtained as a pale yellow oil. m / z(ESI):594.2(M+H) + .
[0370] Step 2.6-((2,4-dimethoxybenzyl)amino)-N-isobutyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-8,9-dihydro-7H-cyclopenta[c To a solution of ][1,8]naphthyridine-2-carboxamide in DCM (2 mL) was added TFA (14.80 g, 10 mL, 130 mmol, Aldrich) and the resulting mixture was heated at 50 °C for 1 h. Concentrate the reaction to 10% Na 2 C.O. 3 and extracted with DCM. The combined organics were concentrated and chromatographed on silica gel using 0-60% 3:1 EtOAc / EtOH in heptane to give 6-amino-N-isobutyl-N-((5-(trifluoromethyl)pyridine-2- yl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide (607, 0.035 g, 0.079 mmol, yield 18.15%) was obtained as a white solid. m / z(ESI):444.2(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 8.98(s,1H),8.62-8.74(m,1H),8.13-8.27(m,1H),7.86-8.11(m,1H),7.48(brs,1H) ),6.58-7.06(m,2H),4.62-5.04(m,3H),2.90-3.23(m,2H),2.82(brd,J=5.2Hz,2H),2.10-2.28(m,2H), 1.83-2.12(m,1H),0.65-1.01(m,7H).
[0371] The compounds in Table 20 were prepared in a similar manner as described above for Examples 606 and 607.
[0372] [Table 110]
[0373] [Table 111]
[0374] [Table 112]
[0375] [Table 113]
[0376] [Table 114]
[0377] [Table 115]
[0378] [Table 116]
[0379] [Table 117]
[0380] [Table 118]
[0381] [Table 119]
[0382] [Table 120]
[0383] [Table 121]
[0384] Examples 646 and 647: (R) or (S)-4-amino-N-((6-methoxypyridazin-3-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-2 ,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide. [ka]
[0385] Step 1.N-((6-methoxypyridazin-3-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine (125, 0.150g, 0.612mmol), 4-((2,4 -dimethoxybenzyl)amino)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxylic hydrochloride (249, 0.330g, 0.795mmol) and 1,1'-dimethyltriethylamine (0.790g, 1.068mL) , 6.12 mmol, Sigma-Aldrich Corporation) in DMF (5 mL) was added bromotripyrrolidinophosphonium hexafluorophosphate (0.285 g, 0.612 mmol, Sigma-Aldrich Corporation) and the resulting mixture was incubated at 50°C. heated for 45 minutes. Bring the reaction to room temperature and add water, saturated NaHCO 3 and extracted with EtOAc (3x). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated. The residue was then chromatographed on silica gel using 0-50% 3:1 EtOAc / EtOH in heptane to give 4-((2,4-dimethoxybenzyl)amino)-N-((6-methoxypyridazine-3 -yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide was obtained as a pale yellow solid. m / z(ESI):606.2(M+H) + .
[0386] Step 2.4-((2,4-dimethoxybenzyl)amino)-N-((6-methoxypyridazin-3-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-2,3- To a solution of dihydro-1H-cyclopenta[c]quinoline-8-carboxamide in DCM (2 mL) was added TFA (1.5 mL, 19.5 mmol, Aldrich) and the resulting mixture was heated at 50 °C for 1 h. Concentrate the reaction to 10% Na 2 C.O. 3 and extracted with DCM. The combined organics were concentrated and chromatographed on silica gel using 0-50% 3:1 EtOAc / EtOH in heptane to give 4-amino-N-((6-methoxypyridazin-3-yl)methyl)-N-(1 -(Pyrimidin-2-yl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide (0.067 g, 0.147 mmol, yield 24.05%) was obtained as a pale yellow solid.
[0387] Step 3. Add racemic sample to 50% liquid CO 2 and purified by preparative SFC using a Chiral Technologies AD column (250x21 mm, 5 mm) containing 50% MeOH and 0.2% TEA at a flow rate of 50 mL / min. More potent (IC in HCT116 MTAP null cell viability assay) 50 Assign the enantiomer to (R)- (measured by 50 (determined by ) was assigned the enantiomer (S)-. The first eluting peak is (R)-4-amino-N-((6-methoxypyridazin-3-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-2,3- Dihydro-1H-cyclopenta[c]quinoline-8-carboxamide (646, 0.016 g, 0.035 mmol) was isolated as a light brown solid. The second eluting peak is (S)-4-amino-N-((6-methoxypyridazin-3-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-2,3- Dihydro-1H-cyclopenta[c]quinoline-8-carboxamide (647, 0.015 g, 0.033 mmol) was isolated as a pale yellow solid. m / z(ESI):456(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ ppm 8.80(d,J=5.0Hz,2H),7.71(brd,J=1.9Hz,1H),7.47-7.62(m,3H),7.42(t,J= 4.9Hz,1H),7.14(d,J=9.1Hz,1H),6.44(brs,2H),5.33-5.51(m,1H),4.94(brd,J=16.0Hz,1H),4.52-4.72( m,1H),4.00(s,3H),2.89-3.16(m,2H),2.75-2.86(m,2H),2.16(brt,J=7.6Hz,2H),1.60(d,J=7.0Hz ,3H).
[0388] The compounds in Table 21 were prepared in a similar manner as described above for Examples 646 and 647.
[0389] [Table 122]
[0390] [Table 123]
[0391] Example 652: 4-Amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,3-dihydrofuro[3,4-c][1 ,7] Naphthyridine-8-carboxamide. [ka]
[0392] Step 1. To a stirred solution of 4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxylic acid (217, 0.500 g, 2.163 mmol) in dichloromethane (5.00 mL) was added HCl (dioxane (4M, 1.622 mL, 6.49 mmol) was added and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was then concentrated, co-distilled with toluene (3x50mL) and dried. This crude material was dissolved in dichloromethane (5.00 mL) and cooled to 0°C. Oxalyl chloride (1.136 mL, 12.98 mmol) and DMF (0.033 mL, 0.433 mmol) were added dropwise at the same temperature and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure under a nitrogen atmosphere and the resulting crude material was triturated with heptane (3x5 mL) and dried under a nitrogen atmosphere to give 4-amino-1,3-dihydrofuro[3,4- c][1,7]naphthyridine-8-carbonyl chloride hydrochloride (0.500 g, 1.748 mmol, 81% yield) was obtained as a yellow solid.
[0393] Step 2.1-Cyclopropyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine (3, 0.050g, 0.217mmol), tetrahydrofuran (2mL) and diisopropylethylamine (0.112g, 0.151mL, 4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carbonyl chloride hydrochloride (0.065 g, 0.228 mmol) was added to a mixture of 0.869 mmol, Aldrich). The mixture was stirred at room temperature until complete, then concentrated in vacuo. The crude product was purified by silica gel chromatography (0-100% EtOAc / EtOH in heptane (3 / 1)). 4-Amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine -8-Carboxamide (652, 49.5 mg, 0.112 mmol, 51.4% yield) was isolated as an off-white solid. m / z(ESI):444(M+H) + . 1 H NMR (400MHz, methanol-d4) δ ppm 8.75-8.97(m,2H),8.02-8.16(m,1H),7.82(brs,1H),7.59-7.78(m,1H),5.31-5.49(m ,2H),5.04-5.19(m,4H),3.44-3.54(m,2H),1.06-1.31(m,1H),0.37-0.55(m,2H),0.04-0.31(m,2H). 19 F NMR(377MHz, methanol-d4)δ ppm -63.86(m,3F).
[0394] The compounds in Table 22 were prepared in a similar manner as described above for Example 652.
[0395] [Table 124]
[0396] [Table 125]
[0397] [Table 126]
[0398] [Table 127]
[0399] [Table 128]
[0400] [Table 129]
[0401] [Table 130]
[0402] [Table 131]
[0403] [Table 132]
[0404] [Table 133]
[0405] [Table 134]
[0406] [Table 135]
[0407] [Table 136]
[0408] [Table 137]
[0409] [Table 138]
[0410] [Table 139]
[0411] [Table 140]
[0412] [Table 141]
[0413] [Table 142]
[0414] [Table 143]
[0415] [Table 144]
[0416] [Table 145]
[0417] [Table 146]
[0418] [Table 147]
[0419] [Table 148]
[0420] [Table 149]
[0421] [Table 150]
[0422] [Table 151]
[0423] [Table 152]
[0424] [Table 153]
[0425] [Table 154]
[0426] [Table 155]
[0427] [Table 156]
[0428] [Table 157]
[0429] [Table 158]
[0430] [Table 159]
[0431] [Table 160]
[0432] [Table 161]
[0433] [Table 162]
[0434] [Table 163]
[0435] [Table 164]
[0436] [Table 165]
[0437] [Table 166]
[0438] [Table 167]
[0439] [Table 168]
[0440] [Table 169]
[0441] [Table 170]
[0442] [Table 171]
[0443] [Table 172]
[0444] [Table 173]
[0445] [Table 174]
[0446] [Table 175]
[0447] Example 819: (S)-4-Amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[3,4 -c][1,7]naphthyridine-8-carboxamide. [ka]
[0448] 6-(((1-fluoropropan-2-yl)amino)methyl)nicotinonitrile (102, 80 mg, 0.41 mmol) and N-ethyl-N-isopropylpropan-2-amine (107 mg, 0.145 mL, 0.828 mmol) 4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carbonyl chloride (acid 217 (119 mg, 0.476 mmol) was added as a solid all at once. The resulting mixture was stirred at 0°C for 1 hour. The crude mixture was loaded directly onto a silica gel precolumn (25 g) and subjected to combiflash column chromatography on a 12-g ISCO Gold column eluting with MeOH (containing 0.5% ammonium hydroxide) / DCM (0–18%, 15 min). 4-Amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[3,4-c][1, 7] Naphthyridine-8-carboxamide (100 mg, 0.246 mmol, yield 59.4%) was obtained as a white solid.
[0449] Racemic product was added to 80% liquid CO 2 and purified by preparative SFC using a Chiral Technologies OJ column (250x21 mm, 5 mm) containing 20% MeOH and 0.2% TEA at a flow rate of 80 mL / min. Stereochemistry was assigned arbitrarily. The first eluting peak contains (S)-4-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuran. [3,4-c][1,7]naphthyridine-8-carboxamide (48.6 mg, 0.120 mmol, 28.9% yield) was assigned as an off-white solid. The first eluting peak was optionally (S)-4-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(1-fluoropropan-2-yl)-1,3-dihydrofuronate. [3,4-c][1,7]naphthyridine-8-carboxamide and optionally the second eluting peak with (R)-4-amino-N-((5-cyanopyridin-2-yl)methyl )-N-(1-fluoropropan-2-yl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide (43.881 mg, 0.108 mmol, yield 26.1%) and obtained as an off-white solid. m / z(ESI):407.2(M+H) + . 1 H NMR(DMSO-d6,500MHz)δ8.6-9.1(m,2H),8.1-8.3(m,1H),7.5-7.8(m,2H),6.9-7.2(m,2H),5.2-5.4 (m,2H),4.3-5.1(m,7H),3.2-3.3(m,1H),1.20(brd,3H,J=6.4Hz). 1 H NMR (methanol-d4 and some CDCl3,400MHz) δ8.7-9.0(m,2H),7.9-8.1(m,1H),7.6-7.8(m,2H),5.3-5.5(m,2H) ,5.15(brs,2H),4.8-5.1(m,2H),4.7-4.8(m,1H),4.3-4.6(m,2H),1.2-1.4(m,3H). 19 F NMR (methanol-d4,376MHz)δ-227.9--221.0(m,1F).
[0450] The compounds in Table 23 were prepared in a similar manner as described above for Examples 819 and 820.
[0451] [Table 176]
[0452] [Table 177]
[0453] [Table 178]
[0454] [Table 179]
[0455] [Table 180]
[0456] [Table 181]
[0457] [Table 182]
[0458] [Table 183]
[0459] [Table 184]
[0460] [Table 185]
[0461] [Table 186]
[0462] [Table 187]
[0463] [Table 188]
[0464] [Table 189]
[0465] [Table 190]
[0466] [Table 191]
[0467] Example 882: 4-Amino-N-(1-methyl-1H-pyrazol-4-yl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][ 1,7]Naphthyridine-8-carboxamide 2,2,2-trifluoroacetate. [ka]
[0468] 1-Methyl-N-( Pyridine (930 mg, 1000 μL, 11.75 mmol, Sigma-Aldrich Corporation) was added to the stirred suspension. The mixture was heated in an oil bath at 60°C for 6 hours. The resulting residue was partitioned between 50 mL of EtOAc and 5 mL of 1N NaOH. Concentrate the organic layer and analyze the residue by reverse-phase HPLC (10% to 80% CH in water containing 0.1% TFA). 3CN) to give 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4- c][1,7]naphthyridine-8-carboxamide 2,2,2-trifluoroacetate (882, 100 mg, 0.172 mmol, 43.8% yield) was obtained as a brown solid. m / z(ESI):469.0(M+H) + . 1 H NMR(methanol-d 4 ,400MHz)δ8.88(s,1H),7.88(s,1H),7.68(m,2H),7.60(m,2H),7.40(s,1H),7.12(s,1H),5.47(m ,2H),5.1-5.2(m,4H),3.65(s,3H). 19 F NMR(methanol-d 4 ,376MHz)δ-64.04(s,3F),-77.30(s,3F).
[0469] The compounds in Table 24 were prepared in a similar manner as described above for Example 882.
[0470] [Table 192]
[0471] Example 887: 5-Amino-N-[(1R)-1-pyrimidin-2-ylethyl]-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-2,4-dihydro-1H -Pyrano[3,4-c]quinoline-9-carboxamide. [ka]
[0472] Step 1. (R)-1-(pyrimidin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1-amine (112, 0.123g, 0.436mmol) and triethylamine (0.240 g, 0.334 mL, 2.376 mmol, Sigma-Aldrich Corporation) as crude 5-((4-methoxybenzyl)amino)-1,4-dihydro-2H-pyrano[3, 4-c]quinoline-9-carbonyl chloride (0.152 g, 0.396 mmol, from acid 258) was added to the stirred mixture. The reaction mixture was stirred at room temperature for 15 minutes. The reaction mixture was diluted with EtOAc (75 mL) and saturated NH 4 Washed with Cl aqueous solution (50 mL). Separate the organic layer and wash with brine (50 mL), MgSO 4 Dry over water, filter, and concentrate in vacuo to give the crude (R)-5-((4-methoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)-N-(( 5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4-dihydro-2H-pyrano[3,4-c]quinoline-9-carboxamide was obtained as a brown oil in 100% yield. Assuming that, it was used directly in the next step. m / z(ESI):629.1(M+H) + .
[0473] Step 2. Crude (R)-5-((4-methoxybenzyl)amino)-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridine-2- yl)methyl)-1,4-dihydro-2H-pyrano[3,4-c]quinoline-9-carboxamide (249 mg, 0.396 mmol) in trifluoroacetic acid (1530 mg, 1 mL, 13.42 mmol, Sigma-Aldrich Corporation). mixed with. The reaction mixture was stirred at 60 °C for 24 h, then concentrated and added H as the mobile phase. 2 0.1%NH in O 4 Purified on an XBridge column (19x100mm, 5μm) using OH (A) and ACN (B). (R)-5-Amino-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-1,4-dihydro-2H -Pyrano[3,4-c]quinoline-9-carboxamide 2,2,2-trifluoroacetate (80 mg, 0.129 mmol, 32.5% yield) was isolated as a brown solid. m / z(ESI):509.2[M+H] + .
[0474] Example 888: 4-Amino-N-[(1R)-1-pyrimidin-2-ylethyl]-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]-2,3-dihydrofuro[3 ,2-c]quinoline-8-carboxamide [ka]
[0475] Example 888 was prepared in a manner similar to that described above for Example 887. m / z(ESI):495.0(M+H) +
[0476] Example 889: 2-Amino-N-(cyclobutylmethyl)-3-methyl-N-[[5-(trifluoromethyl)-2-pyridyl]methyl]quinoline-6-carboxamide [ka]
[0477] Step 1. A solution of isobutylamine (1 eq., 100 mM in dry DMSO) and a solution of 5-(trifluoromethyl)picolinaldehyde (1 eq., 100 mM in dry DMSO) was added to equal volumes of dry THF and dry MeOH (25 mM final concentration) as well as MS 3A. The mixture was shaken at room temperature. SiliaBond® cyanoborohydride (2.5 eq.) was then added and the reaction mixture was shaken at room temperature. Filter the reaction mixture and remove the filter cake with CH 3 Rinse with CN. The combined washings and filtrate were concentrated under reduced pressure to yield 2-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)propan-1-amine.
[0478] Step 2. 4-Amino-3,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxylic acid (170, 1 eq. in dry DMSO, 100 mM), HOAt (1 eq. in dry DMSO, 100mM) and solutions of EDC and DIPEA (100mM and 200mM, respectively, in dry DMF) were added sequentially to the crude mixture of amines. The reaction was then shaken overnight at room temperature and then concentrated under reduced pressure to yield the crude product, which was purified by HPLC to yield the final product 4-amino-N-isobutyl-3,3-dimethyl- N-[[5-(trifluoromethyl)-2-pyridine]methyl]-1H-furo[3,4-c]quinoline-8-carboxamide was obtained with 99% purity by UV. m / z(ESI):473.2(M+H) + .
[0479] The compounds in Table 25 were prepared in a similar manner as described above for Example 889.
[0480] [Table 193]
[0481] [Table 194]
[0482] [Table 195]
[0483] [Table 196]
[0484] [Table 197]
[0485] [Table 198]
[0486] [Table 199]
[0487] [Table 200]
[0488] [Table 201]
[0489] [Table 202]
[0490] [Table 203]
[0491] [Table 204]
[0492] [Table 205]
[0493] Example 936: 4-Amino-N-(1-(3-cyano-5-(trifluoromethyl)pyridin-2-yl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4, 3-c]quinoline-8-carboxamide [ka]
[0494] Step 1. In a 50 mL round bottom flask, add 1-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)-N-methylethane-1-amine (0.090 mL) in tetrahydrofuran (1.590 mL) and dichloromethane (1.590 mL). g, 0.318 mmol) and n,n-diisopropylethylamine (0.123 g, 0.167 mL, 0.954 mmol, Sigma-Aldrich Corporation) were added. The reaction mixture was cooled to 0 °C and then 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl chloride hydrochloride (0.110 g, 0.350 mmol) was reacted. Added slowly to the mixture. The entire reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo. The crude material was absorbed onto a silica gel plug and CH 2 Cl 2 gradient of 0-8% MeOH in medium, then CH 2 Cl 2 Purification by chromatography on a silica gel column eluting isocratically with 8% MeOH in medium yields 4-amino-N-(1-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)ethyl)-7- Fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide (0.040 g, 0.076 mmol, 23.95% yield) was obtained as an off-white solid. m / z(ESI):525.0(M+H) + .
[0495] Step 2. In a resealable reaction vessel, add 4-amino-N-(1-(3-bromo-5-(trifluoromethyl)pyridine-) in 1,4-dioxane (0.190 mL) and water (0.190 mL). 2-yl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide (0.040g, 0.076mmol), potassium ferrocyanide trihydrate (0.257g, 0.609 mmol, Toronto Research Chemicals) and potassium acetate (0.022 g, 0.228 mmol, Sigma-Aldrich Corporation). The reaction mixture was flushed with argon (gas) for 5 minutes and then methanesulfonato (2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl) (2'- Amino-1,1'-biphenyl-2-yl)palladium(ii) (XPhos Pd G3) (0.012 g, 0.015 mmol, Strem Chemicals, Inc.) was added to the mixture and the vial was sealed. The mixture was stirred and heated at 100°C for 2 hours. The reaction mixture was concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and CH 2 Cl 2 Purification by chromatography on a silica gel column eluting with a gradient of 0-8% MeOH in medium yields 4-amino-N-(1-(3-cyano-5-(trifluoromethyl)pyridin-2-yl)ethyl)-7 -Fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide (0.020 g, 0.042 mmol, 55.7% yield) was obtained as an off-white solid. m / z(ESI):472.1(M+H) + .
[0496] HCT116 proliferation activity HCT116 MTAP null cells and WT cells were seeded in RPMI1640 medium + 10% fetal calf serum in 96-well tissue culture plates. Place plate at 37°C and 5% CO 2 and incubated overnight. Cells were then treated with 8 or 9 serial dilutions of compounds using a maximum concentration of 1 μM or 10 μM, 1:3 serial dilution steps, and a DMSO only control. Cells were incubated in the presence of drug for 6 days. Effects on cell viability were measured with the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) according to the manufacturer's recommendations. Assay plates were read on the EnVision™ Multilabel Reader using an ultra-sensitive luminescence module. I C 50 Using GraphPad Prism v5.01 using a symmetric sigmoidal dose-response least squares fit to a hillslope set to -1 (top constraint set to 100%) or using a 4-parameter logistic model. Calculated using Gene Data Screener, which fits a dose-response curve.
[0497] Alternatively, compounds could be assayed in a 384-well plate format:
[0498] Compounds were pre-spotted into 384-well plates using 22-point serial dilutions of compounds using a maximum concentration of 10 or 50 μM, 1:2 serial dilution steps, and a DMSO only control. HCT116MTAP null cells and WT cells were then plated as described above and after 6 days the effect on cell viability was measured using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Assay plates were read as above and IC was determined using GeneData Screener using a 4-parameter logistic model. 50 Values were calculated and dose response curves were fitted. Reported IC 50 represents the value at which the curve passes through 50% of the control.
[0499] [Table 206]
[0500] [Table 207]
[0501] [Table 208]
[0502] [Table 209]
[0503] [Table 210]
[0504] [Table 211]
[0505] [Table 212]
[0506] [Table 213]
[0507] [Table 214]
[0508] [Table 215]
[0509] [Table 216]
[0510] All publications and patent applications cited in this specification are cited herein as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. It is incorporated herein by reference for all purposes as if fully set forth in its entirety. While the above invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, in light of the teachings of the invention, without departing from the spirit or scope of the appended claims, It will be readily apparent to those skilled in the art that certain changes and modifications may be made thereto.
Claims
1. Compounds of Formula I 【Chemistry 1】 A tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing, wherein: R is a tricyclic ring independently selected from formulas IA and IB; 【Chemistry 2】 During the ceremony, 【Chemistry 3】 is a single bond or a double bond, X 1 , X 2 , X 6 and X 7 is, in each occurrence, N or C; X 1 and X 2 Both cannot be N at the same time, and X 1 when is C, it may be substituted with halo; X 3 , X 4 and X 5 is independently selected from optionally substituted C, O, N and S, said substituents being independently selected from C 1~3 Alkyl, C 1~3 alkyl(OH), wherein alkyl is optionally substituted with halo; R 3 is in each case H or C 1~3 independently selected from alkyl, Ar 1 is a 6-membered, optionally substituted aryl or heteroaryl independently selected from: 【Chemistry 4】 The substituents are independently selected from the group consisting of C 1~3 Alkyl, -OC 1~3 selected from alkyl or halo; R 1 is, at each occurrence, independently H, halo, optionally substituted C 1~3 alkyl, said substituents being selected from halo, -CN, optionally substituted -O-C 1~3 alkyl, wherein the substituents are selected from halo; 1~3 Alkyl (C 1~3 alkyl may be substituted with halo and morpholinyl; R 2 is, in each occurrence, independently, an optionally substituted C 1~8 Alkyl (wherein the substituents are halo, hydroxy, amino, -O-C 1~3 alkyl or -CN; hydroxy, amino or optionally substituted C 1~6 an optionally substituted 5- or 6-membered ring or heterocycle with alkyl, the substituents being selected from halo; 1~6 Alkyl-O-C 1~3 alkyl, wherein the substituents are selected from halo; 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl; C 1~3 alkyl-heterocyclyl, wherein the heterocyclyl is selected from optionally substituted 3,4-dihydro-2H-pyrano[2,3-c]pyridinyl, pyradazinyl, triazolyl, pyrimidinyl, tetrahydrofuranyl, 1H-pyrrolo[2,3-b]pyridinyl, cyclohexyl, and the substituents are 1~3 alkyl, —CN and halo), or optionally substituted C 1~6 Alkyl-O-C 1~3 alkyl (wherein the substituents are selected from halo), optionally substituted phenyl (wherein the substituents are selected from halo or C 1~3 alkyl), a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
2. R 1 2. The compound of claim 1, wherein: is a tricyclic ring of formula IA, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
3. R 1 2. The compound of claim 1, wherein: is a tricyclic ring of formula IB, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
4. X 1 and X 2 and R are both C, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
5. X 1 is unsubstituted or substituted with halo, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
6. X 2 is C, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
7. X 2 is N, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
8. 5. The compound of claim 4, wherein R is a tricyclic ring of formula IA1, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing. 【Chemistry 5】
9. 5. The compound of claim 4, wherein R is a tricyclic ring of formula IA2, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing. 【Chemistry 6】
10. X 3 is C, unsubstituted or substituted with methyl, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
11. R 3 is H, or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt of any of the foregoing.
12. R 3 is methyl, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
13. R 2 is optionally substituted C 1~8 9. The compound of claim 8, wherein R is an alkyl group, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
14. R 2 is optionally substituted methyl, ethyl, isopropyl, or cycloC 1~6 9. The compound of claim 8, wherein R is an alkyl group, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
15. Ar 1 but, 【Chemistry 7】 15. The compound of claim 14, wherein:
16. Ar 1 but, 【Chemistry 8】 15. The compound of claim 14, wherein:
17. R 1 is halo, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
18. R 1 is optionally substituted C 1~3 16. The compound of claim 15, wherein: R is an alkyl or -CN; a tautomer thereof; a stereoisomer thereof; or a pharma- ceutically acceptable salt of any of the foregoing.
19. R 1 is halo, optionally substituted C 1~3 4. The compound of claim 3, wherein: R is -R, ...
20. A compound selected from the following, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing: 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-bromo-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(2,2-dimethylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2,2-dimethylpropyl)-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-3,3-dimethyl-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2,2-dimethylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-chloro-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-chloro-N-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-7-chloro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((1-methylcyclopropyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((6-cyclopropyl-3-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((6-cyclopropyl-3-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; Methyl 4-(6-((((4-amino-1,3-dihydrofuro[3,4-c]quinolin-8-yl)carbonyl)(methyl)amino)methyl)-3-pyridinyl)-1-piperazinecarboxylate; (3S)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-chloro-2-pyridinyl)methyl)-3-methyl-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 5-amino-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 4-amino-N-((5-(3,6-dihydro-2H-pyran-4-yl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; Methyl 6-((((4-amino-1,3-dihydrofuro[3,4-c]quinolin-8-yl)carbonyl)(methyl)amino)methyl)-3',6'-dihydro[3,4'-bipyridine]-1'(2'H)-carboxylate; 5-oxo-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-5,6-dihydropyrazolo[1,5-c]quinazoline-9-carboxamide; 4-amino-1,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-7-fluoro-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(1,3-dimethoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((8R)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((8S)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((8R)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((8S)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridin-8-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(4-(3-oxetanyl)benzyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(4-(3-oxetanyl)benzyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(4-morpholinyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-bromo-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-chloro-5-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(1-methyl-1H-1,2,4-triazol-3-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-cyclopropyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-7-fluoro-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((5-cyclopropyl-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-chloro-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((2R)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((2S)-1-methoxy-2-propanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(tetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 6-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,7]naphthyridine-2-carboxamide; 6-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-8,9-dihydro-7H-cyclopenta[c][1,7]naphthyridine-2-carboxamide; 4-amino-3-methyl-N-(1-methylcyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyrazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-methoxy-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,7-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,3-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-fluoro-2-pyridinyl)methyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-7-fluoro-N,3-dimethyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-cyclopropyl-3-pyridazinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((6-cyclopropyl-3-pyridazinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,3,7-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N,1,7-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-7-fluoro-3-methyl-N-(2-propanyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-(3-fluoro-4-(trifluoromethyl)benzyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((6-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((6-(4-(trifluoromethyl)phenyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(4'-(trifluoromethyl)[biphenyl]-4-yl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(6-(4-(trifluoromethyl)phenyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(4'-(pentafluoro-lambda-6-sulfanyl)[biphenyl]-4-yl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-(5-chloro-2-pyridinyl)-2,2-difluoroethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-7-fluoro-1,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-1-methyl-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyclopropyl-2-pyridinyl)methyl)-N-ethyl-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-(4-(trifluoromethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-1,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(pentafluoroethyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-1-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-7-fluoro-1-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-methyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-hydroxy-4-(pentafluoro-lambda-6-sulfanyl)benzyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-(hydroxymethyl)-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-(hydroxymethyl)-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-2-cyano-1-cyclopropylethyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-2-cyano-1-cyclopropylethyl)-N-((5-cyano-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((3S,4S)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-6-methyl-2-pyridinyl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1,7-trimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-(fluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-bromo-2-pyridinyl)methyl)-N,3-dimethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N,1-dimethyl-N-((1S)-1-(4-(trifluoromethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 6-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-3-methyl-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 6-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 6-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 6-amino-N-((5-chloro-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 6-amino-N-((1R)-1-(3-fluoro-2-pyridinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-8,9-dihydro-7H-cyclopenta[c][1,8]naphthyridine-2-carboxamide; 6-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2-phenanthridinecarboxamide; 6-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2-phenanthridinecarboxamide; 5-amino-N-(2-pyrimidinylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-N-((2S)-1-methoxy-2-propanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)[1,2]oxazolo[4,5-c]quinoline-8-carboxamide; 4-amino-N-((3-fluoro-2-pyridinyl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-(2-pyrimidinylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)thieno[2,3-c]quinoline-8-carboxamide; 5-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c]quinoline-9-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-cyclopropyl-2-methoxyethyl)-N-((6-(4-morpholinyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(1-methoxy-2-methyl-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(1-methoxy-2-methyl-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((6-methoxy-3-pyridazinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-2,3-dihydro-1H-cyclopenta[c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)thieno[2,3-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1S)-1-cyclopropyl-2-methoxyethyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 6-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-7,8,9,10-tetrahydro-2-phenanthridinecarboxamide; 4-amino-7-chloro-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-bromo-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(3,3-difluorocyclobutyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(1-methyl-1H-1,2,4-triazol-3-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((1S)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-((1R)-1-(1-methyl-1H-1,2,4-triazol-3-yl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(3,3-difluorocyclobutyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-methylpropyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-(2-methylpropyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-chloro-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-bromo-6-methyl-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((5-(trifluoromethoxy)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-chloro-5-cyano-2-pyridinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-((2R)-1-methoxy-2-propanyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(cyclopropylmethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-chloro-5-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-chloro-6-methoxy-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2R)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((2S)-1-fluoro-2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(bicyclo[1.1.1]pentan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-cyclopropyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-(difluoromethyl)-2-pyridinyl)methyl)-N-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-methylcyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((6-(trifluoromethyl)-3-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((6-bromo-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2,2,2-trifluoroethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(3-oxetanyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,3-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N,3-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((5-chloro-2-pyridinyl)methyl)-N-(2-propanyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((6-(difluoromethoxy)-3-pyridazinyl)methyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((2R)-1-methoxy-2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-cyclopropyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(6-chloro-3-pyridinyl)ethyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(cyclopropylmethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclobutyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-cyclopropyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-ethyl-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((S)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-N-((1R)-1-(2-pyrimidinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(1-methyl-1H-pyrazol-4-yl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-7-fluoro-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)benzo[c][2,6]naphthyridine-9-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c]quinoline-9-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrido[4,3-c][1,7]naphthyridine-9-carboxamide; 4-amino-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-(2-(4-(trifluoromethyl)phenyl)-2-propanyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrimido[4,5-c][1,7]naphthyridine-9-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((R)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-((S)-cyclopropyl(5-(trifluoromethyl)-2-pyridinyl)methyl)-N-methyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-7-fluoro-3-methyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-N-((6-ethoxy-3-pyridazinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((R)-cyclopropyl(6-(trifluoromethyl)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-methyl-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((5-fluoro-2-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((2,6-difluoro-3-pyridinyl)methyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(5-(difluoromethyl)-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R)-1-(5-(difluoromethyl)-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyrazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((2-fluoro-6-(trifluoromethyl)-3-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((R)-cyclopropyl(6-(trifluoromethyl)-3-pyridazinyl)methyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,3-dimethyl-N-((1R)-1-(4-(pentafluoroethyl)phenyl)ethyl)-3H-pyrazolo[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(4-(pentafluoroethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(4-(pentafluoroethyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N,1-dimethyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-ethyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-1-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclobutyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclobutyl-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-1-methyl-N-(2,2,2-trifluoroethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-7-fluoro-1-methyl-N-(1,3-oxazol-4-ylmethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-1-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((2-methoxy-6-(trifluoromethyl)-3-pyridinyl)methyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-N-((3-fluoro-5-(trifluoromethyl)-2-pyridinyl)methyl)-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-7-(trifluoromethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-7-(trifluoromethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-7-(trifluoromethyl)-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-cyclopropylethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-cyclopropylethyl)-7-fluoro-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-7-fluoro-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(cyclopropylmethyl)-7-fluoro-3-methyl-N-((6-(2,2,2-trifluoroethoxy)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-ethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-3-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3S)-4-amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N-cyclobutyl-3-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyrimidinyl)ethyl)-N-(2-(trifluoromethoxy)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(4-cyanophenyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(4-cyanophenyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1S)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R)-1-(5-cyano-2-pyridinyl)ethyl)-N-ethyl-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(2-propanyl)-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(2-propanyl)-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-methyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)propyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((1S)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(3,5-difluoro-2-pyridinyl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1S)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4-c][1,7]naphthyridine-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1S)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-methoxy-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,3-dimethyl-3H-pyrazolo[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-methoxy-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,3-dimethyl-N-((1R)-1-(4-(pentafluoro-lambda-6-sulfanyl)phenyl)ethyl)-3H-pyrazolo[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1S)-1-(4-(pentafluoro-lambda-6-sulfanyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(4-(pentafluoro-lambda-6-sulfanyl)phenyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-1-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-N-((1R)-1-(5-pyrimidinyl)propyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-1-methyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-N-((1S)-1-(5-pyrimidinyl)propyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-N-((1S)-1-(5-fluoro-2-pyridinyl)ethyl)-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((1S)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-7-(trifluoromethyl)-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-1-methyl-N-((1S)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-cyclopropyl-1-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-(4-(trifluoromethyl)benzyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(3-fluorophenyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,7]naphthyridine-8-carboxamide; 4-amino-N-(1-methyl-1H-pyrazol-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c][1,8]naphthyridine-8-carboxamide; 5-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,4-dihydro-2H-pyrano[3,4-c]quinoline-9-carboxamide; 4-amino-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-2,3-dihydrofuro[3,2-c]quinoline-8-carboxamide; 4-amino-3,3-dimethyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((3-fluoro-2-pyridinyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((3-fluoro-2-pyridinyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-((1S)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-((trans-4-hydroxycyclohexyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-cyanocyclopentyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-cyanocyclopentyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-[1,1'-bi(cyclopropyl)]-2-yl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-spiro[2.5]octan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-aminocyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2R)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,2S)-2-ethoxycyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S)-2,2-dimethylcyclopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S)-spiro[2.4]heptan-1-yl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R,2R)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1S,2S)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R,2R)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1S,2S)-2-(trifluoromethyl)cyclopropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1R)-1-(2-pyrimidinyl)ethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((5-cyano-2-pyridinyl)methyl)-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1-cyanocyclopropyl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-N-((5-cyano-2-pyridinyl)methyl)-3-methyl-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-(5,6-dihydro-2H-pyran-3-ylmethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1-cyanocyclopropyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1-cyanocyclopropyl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2-amino-1,3-thiazol-5-yl)methyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(2-methylpropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S,3R)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S,3S)-3-hydroxy-2-butanyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1R,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((1S,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1R,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,3R)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((1S,3S)-3-hydroxycyclohexyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(2-(cis-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-(2-(trans-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-(2-(cis-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-(2-(trans-3-hydroxycyclobutyl)ethyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S)-2-hydroxypropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S)-3-hydroxy-2-methylpropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((2R)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((2R)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3R)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-((3S)-tetrahydro-3-furanylmethyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2R)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-((2S)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2R)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-((2S)-2-cyanopropyl)-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-N-ethyl-3-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3R)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; (3S)-4-amino-3-methyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,3,3-trimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-ethyl-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-3,3-dimethyl-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-3,3-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; and 4-amino-N-((1R)-1-(3-cyano-5-(trifluoromethyl)-2-pyridinyl)ethyl)-7-fluoro-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide.
21. A compound selected from the following, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing: (3R)-4-amino-N-ethyl-7-fluoro-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-((1R)-1-(3-fluoro-5-(trifluoromethyl)-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N,1-dimethyl-N-(4-(pentafluoro-lambda-6-sulfanyl)benzyl)-1H-pyrazolo[4,3-c][1,7]naphthyridine-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-7-fluoro-N,3-dimethyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 5-amino-N-(2-propanyl)-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)pyrido[4,3-c][1,7]naphthyridine-9-carboxamide; 4-amino-N-ethyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-chloro-N-((1R)-1-(5-fluoro-2-pyridinyl)ethyl)-N,1-dimethyl-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclobutyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-ethyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((6-(trifluoromethyl)-3-pyridazinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((1R)-1-(5-(trifluoromethyl)-2-pyridinyl)ethyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; (3R)-4-amino-N-ethyl-3-methyl-N-((1R)-1-(6-(trifluoromethyl)-3-pyridazinyl)ethyl)-1,3-dihydrofuro[3,4-c]quinoline-8-carboxamide; 4-amino-N-cyclopropyl-7-fluoro-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide; 4-amino-7-fluoro-N,1-dimethyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide and 4-Amino-N-ethyl-1-methyl-N-((5-(trifluoromethyl)-2-pyridinyl)methyl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide.
22. 22. A pharmaceutical composition for treating cancer comprising an effective amount of a compound according to any one of claims 1, 20 or 21, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
23. 23. The pharmaceutical composition of claim 22, wherein the cancer is selected from ovarian cancer, lung cancer, lymphocytic cancer, glioblastoma, colon cancer, melanoma, gastric cancer, pancreatic cancer or bladder cancer.
24. 22. A pharmaceutical composition comprising a compound according to any one of claims 1, 20 or 21, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing, and at least one pharma- ceutically acceptable excipient.
